: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription

Articles published in Breast Cancer Res Treat
Retrieve available abstracts of 844 articles:
HTML format

Single Articles

October 2026

SUTEJITSIRI L, Suami H, Nielsen PMF, Phillips ARJ, et al
A dermal backflow atlas of lymphatic dysfunction in breast cancer-related lymphedema with machine learning-based stage prediction.
Breast Cancer Res Treat. 2026;219:28.
PubMed Abstract available

HARRELL M, Kutuk T, Gokun Y, Upadhyay R, et al
Brain-only metastatic breast cancer as a distinct clinical entity: evidence from national and institutional cohorts with implications for radiation therapy.
Breast Cancer Res Treat. 2026;219:29.
PubMed Abstract available

September 2026

PINHEIRO LC, Zeng C, Dorzhieva D, Joseph L, et al
Implementation and evaluation of the Routine Assessment and Integration of Screening for Employment (RAISE) program in adults with metastatic breast cancer.
Breast Cancer Res Treat. 2026;219:27.
PubMed Abstract available

MAHESWARAN S, Dedeoglu AS, Niemierko A, Abelman RO, et al
Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability.
Breast Cancer Res Treat. 2026;219:26.
PubMed Abstract available

OTTOSEN C, Kragelund E, Pedersen MA, Nguyen VQ, et al
Circulating tumour DNA and its clinical relevance in predicting progression-free survival and overall survival in patients with advanced breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2026;219:23.
PubMed Abstract available

KOUMPRENTZIOTIS IA, Cawley A, Ewig E, Gerard AO, et al
Dermatologic adverse events associated with Sacituzumab Govitecan: an international retrospective study from the EADV Task Force "Dermatology for Cancer Patients" and pharmacovigilance analysis.
Breast Cancer Res Treat. 2026;219:24.
PubMed Abstract available

RAVAL P, Ding Q, Singh P, Alrohaibani A, et al
HER2 status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy in patients with HER2-positive breast cancer.
Breast Cancer Res Treat. 2026;219:25.
PubMed Abstract available

AMIN LB, Kirkwood MK, Levit LA, Balogh EP, et al
Geographic access to triple negative breast cancer clinical trials: are trials located near patients?
Breast Cancer Res Treat. 2026;219:22.
PubMed Abstract available

HUYNH PY, Tran BV, Ngo VT, Tran TT, et al
Recovery of ovarian function after chemotherapy in premenopausal women with breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2026;219:20.
PubMed Abstract available

VENARDI A, Shojaeian F, Diaz S, Schuster CR, et al
Ki-67 expression and rates of pathologic complete response in T1cN0M0 triple-negative breast cancer: a national cancer database analysis.
Breast Cancer Res Treat. 2026;219:21.
PubMed Abstract available

O'SHAUGHNESSY J, Rehnquist MK, Sadetsky N, Verret W, et al
A retrospective, observational cohort study of treatment patterns and outcomes among patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States following endocrine therapy.
Breast Cancer Res Treat. 2026;219:19.
PubMed Abstract available

HLAVIN C, Balogun Z, Lavage DR, Cowher MS, et al
Equivalent survival in targeted axillary dissection compared to axillary lymph node dissection in patients with node positive breast cancer receiving neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2026;219:18.
PubMed Abstract available

LI X, Lampson K, Liou KT, Li Y, et al
Association between cumulative symptom burden and cognitive impairment among breast cancer survivors: a cross-sectional study.
Breast Cancer Res Treat. 2026;219:13.
PubMed Abstract available

SANJARI MOGHADDAM A, Deng Z, Sereika SM, Habib M, et al
Metastatic phenotype and post-metastatic survival across HER2-0, HER2-low, and HER2-positive breast cancer.
Breast Cancer Res Treat. 2026;219:11.
PubMed Abstract available

SCHOCHTER F, Friedl TWP, Schaffler H, Meier-Stiegen F, et al
Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer - results from the phase II DETECT IVb trial.
Breast Cancer Res Treat. 2026;219:12.
PubMed Abstract available

EISSA IR, Wang Y, Tanabe KK
Integrin alpha2 (CD49b) blockade remodels the tumor immune microenvironment and enhances anti-PD-L1 therapy in 4T1 breast cancer model.
Breast Cancer Res Treat. 2026;219:16.
PubMed Abstract available

REAGAN AM, Rutherford CR, Prathibha S, Levy BE, et al
Trends in contralateral prophylactic mastectomy and genetic testing in the era of new society guidelines.
Breast Cancer Res Treat. 2026;219:14.
PubMed Abstract available

LEE B, Santos B, McArthur H, LeVee A, et al
Contemporary therapy for small node-negative triple-negative breast cancer: a retrospective cohort study.
Breast Cancer Res Treat. 2026;219:15.
PubMed Abstract available

MEISEL J, Pham T, Chen C, Kris A, et al
Real-world estrogen receptor alpha 1 (ESR1) testing patterns and results for ER+/HER2- metastatic breast cancer in the United States, 2018-2024.
Breast Cancer Res Treat. 2026;219:8.
PubMed Abstract available

MEISEL JL, Chen C, Kris A, Ru M, et al
Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024.
Breast Cancer Res Treat. 2026;219:9.
PubMed Abstract available

KROLL MR, Schroeder MC, Neuner JM, Viyyuri BR, et al
Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes.
Breast Cancer Res Treat. 2026;219:7.
PubMed Abstract available

LIU J, Ding L, Wang J, Chen T, et al
Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study.
Breast Cancer Res Treat. 2026;219:10.
PubMed Abstract available

CHEN Q, Campbell I, Elwood M, Cavadino A, et al
Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study.
Breast Cancer Res Treat. 2026;219:6.
PubMed Abstract available

PODANY EL, Foffano L, Gerratana L, Medford AJ, et al
Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival.
Breast Cancer Res Treat. 2026;219:5.
PubMed Abstract available

August 2026

TIAN Z, Li H, Deng Y, Yao H, et al
Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study.
Breast Cancer Res Treat. 2026;219:3.
PubMed Abstract available

SAMPLE JW, Johnson S, Hoskin TL, Redaelli M, et al
Body mass index-associated gut microbial taxa and functional pathways in women with benign and malignant breast disease.
Breast Cancer Res Treat. 2026;219:4.
PubMed Abstract available

IJI R, Oba T, Miyazawa R, Kitazawa A, et al
Low pectoralis major muscle mass predicts the risk of post-surgical bleeding after mastectomy in patients with breast cancer.
Breast Cancer Res Treat. 2026;219:2.
PubMed Abstract available

SANTEN RJ, Demers LM
History of the early development of aromatase inhibitors for treatment of breast cancer.
Breast Cancer Res Treat. 2026;219:1.
PubMed Abstract available

HAN K, Zhao C
Comment on "Effects of a sensorimotor-based, movement quality-focused intervention on functional mobility in breast cancer survivors: a multicenter randomized controlled trial".
Breast Cancer Res Treat. 2026;218:47.
PubMed Abstract available

JOHNSON HM, Dong W, Shen Y, Irish W, et al
Validation of a novel prognostic staging system for breast cancer incorporating age at diagnosis.
Breast Cancer Res Treat. 2026;218:44.
PubMed Abstract available

KOLLATOS C, Pantiora E, Jazrawi A, Warnberg F, et al
Factors associated with discordance between pathological and radiological tumor size and risk of re-excision in breast-conserving surgery: a post-hoc analysis within a randomized trial.
Breast Cancer Res Treat. 2026;218:46.
PubMed Abstract available

BENDER U, Ronan K, Aljuhani A, Savill J, et al
The impact of menopausal status on the efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: a systematic review and meta-analysis of phase III clinical trials.
Breast Cancer Res Treat. 2026;218:43.
PubMed Abstract available

YANG TWW, Rose AK, Matheson J, Elder K, et al
Fewer breast cancers during post-treatment surveillance among patients initially staged using contrast-based imaging.
Breast Cancer Res Treat. 2026;218:45.
PubMed Abstract available

LYNCE F, Ru M, Luo L, Miranda M, et al
Real-world clinical outcomes of patients with early-stage TNBC and BRCAm who were treated with adjuvant capecitabine in the United States.
Breast Cancer Res Treat. 2026;218:41.
PubMed Abstract available

SHERN TP, Chamberlain V, Holt LR, Gadd MA, et al
When immunotherapy hurts: neoadjuvant PD-1 inhibitors increase opioid use after mastectomy with reconstruction.
Breast Cancer Res Treat. 2026;218:40.
PubMed Abstract available

GUYON C, Guffroy F, Sabah J, Mossino Diaz L, et al
Breast skin ulceration in de novo metastatic breast cancer: incidence, predictors, and patterns of occurrence.
Breast Cancer Res Treat. 2026;218:42.
PubMed Abstract available

KHAJEH M, Shahram MA
The emerging role of artificial intelligence in preoperative prediction of surgical margin status in breast cancer surgery.
Breast Cancer Res Treat. 2026;218:38.
PubMed

LIU J, Liu L, Yague E, Yang Q, et al
Retraction Note: GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation.
Breast Cancer Res Treat. 2026;218:39.
PubMed

MARGOLIS S, Guirguis AN, Lee C, Smith S, et al
Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?
Breast Cancer Res Treat. 2026;218:35.
PubMed Abstract available

BITSIE KR, Pearson TA, Kwan ML, Yaghjyan L, et al
Self-reported racial and ethnic discrimination in patient-provider interactions and the initiation of adjuvant therapies for breast cancer in the pathways study.
Breast Cancer Res Treat. 2026;218:36.
PubMed Abstract available

KAWASHIMA K, Elsaedy EA, Oshi M, Yamada A, et al
Association of tumor Schwann cells with epithelial-mesenchymal transition and immune-suppressive microenvironment in triple-negative breast cancer.
Breast Cancer Res Treat. 2026;218:37.
PubMed Abstract available

PINHEIRO LC, An A, Landry CA, Tonorezos E, et al
Interstitial lung disease in metastatic breast cancer: a landscape review using SEER-Medicare.
Breast Cancer Res Treat. 2026;218:34.
PubMed Abstract available

VOORTHUIS RAB, Opdam M, Ter Hoeve ND, Silva MD, et al
Invasive lobular breast cancer in young patients without adjuvant systemic treatment: 15-year survival outcomes.
Breast Cancer Res Treat. 2026;218:31.
PubMed Abstract available

SUN W, Li H, Zhao X, Hu S, et al
Optimising screening intervals and BI-RADS management pathways in ultrasound-based breast cancer screening: real-world evidence from Shenzhen (2018-2023).
Breast Cancer Res Treat. 2026;218:33.
PubMed Abstract available

FOULAD D, Tsai J, Luo I, Xu A, et al
Locoregional recurrence and mortality after breast cancer surgery in patients aged 85 and older.
Breast Cancer Res Treat. 2026;218:32.
PubMed Abstract available

TRAINA TA, Serra E, Bedard J, Levesque-Leroux M, et al
First-line treatment patterns and real-world survival outcomes in PD-L1-negative locally recurrent inoperable or metastatic triple-negative breast cancer in the United States.
Breast Cancer Res Treat. 2026;218:30.
PubMed Abstract available

ALI M
Methodological considerations on the predictive value of tumor-infiltrating lymphocytes for pathological complete response in early triple-negative breast cancer.
Breast Cancer Res Treat. 2026;218:28.
PubMed

DOSUNMU GT, Omoleye O, Huo D, Giurcanu M, et al
Birth cohort differences in reproductive and lifestyle breast cancer risk factors among women in the Nigerian breast cancer study.
Breast Cancer Res Treat. 2026;218:29.
PubMed Abstract available

July 2026

LIU B, Wu T, Ding S, Liu X, et al
Machine learning and cox model-based prediction of CDK4/6 inhibitor outcomes in HR+/HER2 - metastatic breast cancer: a multicenter real-world study.
Breast Cancer Res Treat. 2026;218:27.
PubMed Abstract available

NIRAVATH P, Rimawi M, Sun K, Mai H, et al
VEMORA: Vaginal Estrogen versus non-hormonal MOisturizer in women Receiving Aromatase inhibitors: a randomized, controlled trial.
Breast Cancer Res Treat. 2026;218:25.
PubMed Abstract available

TESCH ME, Graham N, Snow C, Stever CE, et al
Association between self-reported breast cancer knowledge and clinical trial participation in patients with triple-negative breast cancer.
Breast Cancer Res Treat. 2026;218:26.
PubMed Abstract available

ANUSZKIEWICZ K, Ekman M, Graczyk M, Drozd M, et al
Correction: Correlation between the drainage time in dynamic indocyanine green lymphography (ICG) and axillary lymph nodes metastatic involvement in breast cancer patients-a prospective study.
Breast Cancer Res Treat. 2026;218:23.
PubMed

ZAYHOWSKI K, Blumen K, Mittendorf KF, Pratt R, et al
Healthcare professional perspectives on hereditary breast cancer risk assessment prior to gender-affirming mastectomy.
Breast Cancer Res Treat. 2026;218:22.
PubMed Abstract available

BOLDRINI C, Bottalico M, Lia FL, Longo V, et al
Assisted Reproductive Technologies (ART) and breast cancer risk: hormonal treatments under the spotlight.
Breast Cancer Res Treat. 2026;218:24.
PubMed Abstract available

WATANABE C, Kashiwagi S, Nishikawa M, Kochi A, et al
Clinical and imaging factors associated with prolonged ablation time in radiofrequency ablation for early-stage breast cancer.
Breast Cancer Res Treat. 2026;218:21.
PubMed Abstract available

LEENHARDT F, Jacot W, Lellouche L, Guiu S, et al
Antacid co-treatment and pregnane X receptor genetic polymorphisms are survival determinants in patients treated with palbociclib.
Breast Cancer Res Treat. 2026;218:20.
PubMed Abstract available

IMANISHI S, Tanaka N, Takeuchi C, Kittaka N, et al
Age-dependent relative and absolute benefit of radiotherapy after breast-conserving surgery: a population-based analysis using SEER data.
Breast Cancer Res Treat. 2026;218:19.
PubMed Abstract available

MAYER EL, Collin SM, Hillman S, Berrocal-Almanza LC, et al
Real-world treatment patterns and outcomes in hormone receptor-positive, HER2-low metastatic breast cancer, 2018-2023: a retrospective, observational, US cohort study.
Breast Cancer Res Treat. 2026;218:15.
PubMed Abstract available

2026 RISE UP for Breast Cancer and Women's Health Conference.
Breast Cancer Res Treat. 2026;217.
PubMed

KRASNOW NA, Salans M, Jayaraj M, Kuwahara K, et al
Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study.
Breast Cancer Res Treat. 2026;218:16.
PubMed Abstract available

KOCO L, Sanderink WBG, Prokop M, Mann RM, et al
Factors influencing discussion duration in breast cancer multidisciplinary team meetings: insights for streamlining care.
Breast Cancer Res Treat. 2026;218:17.
PubMed Abstract available

NISHIMURA M, Kogawa T, Sugiyama K, Ozaki Y, et al
Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B).
Breast Cancer Res Treat. 2026;218:18.
PubMed Abstract available

GOH SSN, Zhou X, Ng QX, Kulkarni D, et al
Extended applications of chest wall perforator flaps in breast surgery: case series and systematic literature review.
Breast Cancer Res Treat. 2026;218:14.
PubMed Abstract available

TERAN S, Illia M, Quevedo MC, Moreno ML, et al
Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitors.
Breast Cancer Res Treat. 2026;218:12.
PubMed Abstract available

FOO CY, Sehrawat O, Puri A, Haque W, et al
Clinicopathologic features, treatment patterns and survival outcomes of acinic cell carcinoma of the breast: a national cancer database analysis.
Breast Cancer Res Treat. 2026;218:13.
PubMed Abstract available

FEDELE P, Rizzo A, Landriscina M, Stucci LS, et al
Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study.
Breast Cancer Res Treat. 2026;218:8.
PubMed Abstract available

COMEAUX JG, Gutierrez N, Ricker CN, Nie Q, et al
Breast cancer screening adherence after multigene panel testing among women with pathogenic variants in moderate-risk genes or with empirically increased breast cancer risk.
Breast Cancer Res Treat. 2026;218:6.
PubMed Abstract available

MARTINS-BRANCO D, Lobo-Martins S, Aftimos P, Pereira B, et al
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.
Breast Cancer Res Treat. 2026;218:7.
PubMed Abstract available

LIU C, Warburton R, Pao JS, Dingee CK, et al
Age-stratified difference in patient-reported health-related quality of life following breast cancer surgery.
Breast Cancer Res Treat. 2026;218:11.
PubMed Abstract available

BYEMERWA J, Neish D, Forgah L, Deveaux A, et al
Association of tumor-infiltrating lymphocytes and proinflammatory biomarkers with breast cancer molecular subtypes: analysis of the MEND study.
Breast Cancer Res Treat. 2026;218:10.
PubMed Abstract available

AMRITT A, Dagar A, Ghosh A, Maiti A, et al
Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer.
Breast Cancer Res Treat. 2026;218:9.
PubMed Abstract available

LUNDORFF CMB, Njor SH, Madsen SL, Jorgensen SF, et al
Socioeconomic variation in adherence to follow-up after an abnormal screening mammogram in the Danish breast cancer screening program.
Breast Cancer Res Treat. 2026;218:5.
PubMed Abstract available

HUANG S, Westvold SJ, Soulos PR, Lewin JM, et al
Tumor characteristics associated with tomosynthesis versus digital mammography in older women with screen-detected breast cancer.
Breast Cancer Res Treat. 2026;218:4.
PubMed Abstract available

ZHANG X, Barrios A, Higgins L, Markowski T, et al
mRNA and protein expression of fetal insulin receptor in breast cancer cell lines and tissues.
Breast Cancer Res Treat. 2026;218:2.
PubMed Abstract available

MASUDA N, Saji S, Kojima Y, Kitada M, et al
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.
Breast Cancer Res Treat. 2026;218:3.
PubMed Abstract available

RAFII S, Al-Shamsi HO, Brufsky A
SERENA-6 and the regulatory limits of radiologic progression in modern oncology.
Breast Cancer Res Treat. 2026;218:1.
PubMed Abstract available

June 2026

JAYASWAL RP, Rana AK, Badyal RK
Comments on: Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.
Breast Cancer Res Treat. 2026;217:65.
PubMed Abstract available

JAYASWAL RP, Thapliyal S, Badyal RK
Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy.
Breast Cancer Res Treat. 2026;217:64.
PubMed Abstract available

AKALIN C, Zaim G, Demir M
Discrimination, spectrum, and clinical utility: ICG lymphography drainage time in axillary staging.
Breast Cancer Res Treat. 2026;217:63.
PubMed Abstract available

ALBERT R, Thomas J, Sadeghi N, Reddy SM, et al
Tumor infiltrating lymphocytes (TILs) as a predictive marker of pathological complete response (pCR) in a diverse patient population with early triple negative breast cancer (TNBC) treated with neoadjuvant real-world KEYNOTE-522 regimen.
Breast Cancer Res Treat. 2026;217:60.
PubMed Abstract available

AHMED S, Mannala S, Mondal P, Mahmood W, et al
Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study.
Breast Cancer Res Treat. 2026;217:62.
PubMed Abstract available

PLOTKE RL, Kanaya MR, Popok PJ, Webster SN, et al
Subjective socioeconomic status moderates the relationship between objective neighborhood disadvantage and quality of life in middle- and older-aged women with breast cancer.
Breast Cancer Res Treat. 2026;217:61.
PubMed Abstract available

DABOUR MS, Shaaban A, Duprez DA, Zordoky BN, et al
Is endothelial dysfunction induced by aromatase inhibitors reversible after treatment?
Breast Cancer Res Treat. 2026;217:55.
PubMed Abstract available

ZHENG S, Sullivan P, Vadehra K, Kim J, et al
Receptor discordance between primary tumors and nodal metastases and correlation with the 21-gene recurrence score in early-stage, estrogen receptor-positive, node-positive breast cancer.
Breast Cancer Res Treat. 2026;217:57.
PubMed Abstract available

ETAN T, Cohen L, Bar Y, Leshem Y, et al
Efficacy and toxicity of neoadjuvant chemotherapy versus chemo-immunotherapy in triple-negative breast cancer patients with and without germline BRCA mutations.
Breast Cancer Res Treat. 2026;217:54.
PubMed Abstract available

YAMAGUCHI Y, Hoshino M, Shimoi T, Tamura H, et al
Clinical implications of discordance in HER2 reassessment from HercepTest to 4B5 in metastatic breast cancer.
Breast Cancer Res Treat. 2026;217:59.
PubMed Abstract available

LEONARD LD, Cohen E, Perry R, Sun J, et al
Surgeon interpretation of margin status utilizing intraoperative 3D tomosynthesis during breast-conserving surgery.
Breast Cancer Res Treat. 2026;217:58.
PubMed Abstract available

OZAKI Y, Yoshida K, Ichikawa T, Kitagawa M, et al
Extracellular vesicles in nipple discharge for breast cancer screening.
Breast Cancer Res Treat. 2026;217:53.
PubMed Abstract available

GIVANT M, Fanning JE, Chen A, Lefevre A, et al
Rediscovering the Ciucci pathway: in-vivo evidence of a palmar lymphatic channel.
Breast Cancer Res Treat. 2026;217:52.
PubMed Abstract available

FENG X, Deng Z, McCullough MS, May BJ, et al
Correction: The impact of cardiovascular risk factors on cancer progression: a prospective study in female breast cancer survivors.
Breast Cancer Res Treat. 2026;217:51.
PubMed

HUNDAL J, Cheema A, Abushamma A, Arora K, et al
Impact of cardiometabolic health on treatment outcomes in early-stage triple-negative breast cancer receiving chemoimmunotherapy.
Breast Cancer Res Treat. 2026;217:50.
PubMed Abstract available

DE LIZ CD, Reis PCA, Blanchard-Cavagis ER, Diniz IC, et al
Three-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2026;217:48.
PubMed Abstract available

TALEB I, Witmeyer S, Huck C, Fournier M, et al
Adenoid cystic carcinoma of the breast: a case series of 26 patients.
Breast Cancer Res Treat. 2026;217:49.
PubMed Abstract available

WILSON JM, Rosenberg SM, Crowell KA, Lynch T, et al
Age-related differences in psychological distress and persistent postsurgical pain after surgery for management of non-invasive breast lesions.
Breast Cancer Res Treat. 2026;217:47.
PubMed Abstract available

DELGADO CASANOVA LB, Dhamne S, Resetkova E, Guirguis MS, et al
Risk of malignancy after diagnosis of radial sclerosing lesion without atypia.
Breast Cancer Res Treat. 2026;217:46.
PubMed Abstract available

VUOTI S, Saari M, Lahti J, Narasimha K, et al
Association of baseline tumor-infiltrating lymphocytes and cell-cycle regulation markers on prognosis and mortality in patients with advanced breast cancer according to tumor characteristics and treatment type: an observational study.
Breast Cancer Res Treat. 2026;217:41.
PubMed Abstract available

BARJIJ I, Naciri S, Lkhoyaali S, Kharmoum S, et al
Post-neoadjuvant and peri-operative ctDNA-defined minimal residual disease in triple-negative breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2026;217:45.
PubMed Abstract available

XIA K, Tang N, Li D, Wang L, et al
Retrospective study on regional nodal irradiation after omission of axillary lymph node dissection in sentinel lymph node-positive breast cancer: a propensity score matching analysis.
Breast Cancer Res Treat. 2026;217:43.
PubMed Abstract available

GONG CL, Chavez-MacGregor M, Xu X, Park L, et al
The value of innovation in breast cancer treatment: real option value of olaparib for first-line treatment of gBRCA-mutated HER2 negative metastatic breast cancer.
Breast Cancer Res Treat. 2026;217:42.
PubMed Abstract available

BAYRAKDARIAN S, Hircock C, Wong HCY, Zhang L, et al
Long-term patient-reported outcomes in a randomized controlled trial of Mepitel Film versus standard of care for the prevention of acute breast radiation dermatitis.
Breast Cancer Res Treat. 2026;217:44.
PubMed Abstract available

LEE KL, Yam C, Zhao L, Bassett RL, et al
Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trial.
Breast Cancer Res Treat. 2026;217:39.
PubMed Abstract available

BYEMERWA J, Neish D, Olunuga E, Osazuwa-Peters O, et al
Association of cumulative lifetime estrogen exposure and reproductive factors with breast cancer molecular subtype among Nigerian women in the MEND study.
Breast Cancer Res Treat. 2026;217:40.
PubMed Abstract available

May 2026

LEVEE A, Santos B, Wong M, Ruel N, et al
Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study.
Breast Cancer Res Treat. 2026;217:38.
PubMed Abstract available

VASIGH M, Ruth K, Bleicher RJ, Lyons W, et al
Impact of axillary surgery on survival in de novo metastatic breast cancer with primary tumor resection.
Breast Cancer Res Treat. 2026;217:56.
PubMed Abstract available

GABA AG, Cao L, Renfrew RJ
The applicability of the 21-gene assay to inform chemotherapy benefit in lymph node positive hormone receptor positive male breast cancer.
Breast Cancer Res Treat. 2026;217:36.
PubMed Abstract available

STICKLAND A, Tao X, Kidwell K, Henry NL, et al
Change in practice patterns over time for endocrine therapy and radiation therapy in women with breast cancer age 65 and older.
Breast Cancer Res Treat. 2026;217:37.
PubMed Abstract available

KONDO S, Kida K, Suzuki M, Kajiura Y, et al
Impact of BRCA1/2 pathogenic variants on ipsilateral breast tumor recurrence and prognosis following breast-conserving surgery.
Breast Cancer Res Treat. 2026;217:35.
PubMed Abstract available

SLOTMAN E, de Munck L, Jager A, Honkoop AH, et al
Characteristics, treatment and survival in de novo and metachronous metastatic breast cancer: a nationwide comparative analysis.
Breast Cancer Res Treat. 2026;217:33.
PubMed Abstract available

JIN Y, Li H, Yang Z, Luo S, et al
Exploring the potential of postmastectomy radiotherapy in cN + and ypN0 breast cancer patients following neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2026;217:32.
PubMed Abstract available

OLSSON M, Janeva S, Martikainen J, Tzikas AK, et al
Retrospective study of comparable survival after neoadjuvant versus adjuvant chemotherapy in cT1-2N0M0 triple-negative breast cancer.
Breast Cancer Res Treat. 2026;217:34.
PubMed Abstract available

LIU Q, Wang R, Jiang S, Yuan J, et al
Comparative efficacy of prevention strategies for oral mucositis in breast cancer patients: a network meta-analysis.
Breast Cancer Res Treat. 2026;217:31.
PubMed Abstract available

FA'AK F, Haan J, Chmielewski-Stivers N, Menicucci A, et al
Whole transcriptome analysis reveals MammaPrint and BluePrint-associated gene expression patterns with early lymph node metastasis in early-stage breast cancer.
Breast Cancer Res Treat. 2026;217:30.
PubMed Abstract available

MATUSZ-FISHER A, Livasy CA, Donahue EE, Hadzikadic-Gusic L, et al
Racial differences in pathologic complete response rate and clinical outcomes following neoadjuvant chemotherapy for breast cancer.
Breast Cancer Res Treat. 2026;217:29.
PubMed Abstract available

RAVANI LV, Wander SA, Kok M, McCann K, et al
Long-term outcomes in triple-negative breast cancer after a pathologic complete response: does the type of neoadjuvant therapy matter?
Breast Cancer Res Treat. 2026;217:28.
PubMed Abstract available

April 2026

SCHUSTER CR, Aslami ZV, Taccheri C, Azizi A, et al
Preoperative breast cancer screening before chest masculinization surgery.
Breast Cancer Res Treat. 2026;217:27.
PubMed Abstract available

PATHMARAJAH T, Gokun Y, Williams N, Sizemore GM, et al
Radiation treatment patterns for breast cancer brain metastases: an NCDB analysis.
Breast Cancer Res Treat. 2026;217:26.
PubMed Abstract available

VERHEUL EM, Doornkamp F, Petrov I, Siesling S, et al
External validation of PREDICT Breast v3.1 for overall survival in international cohorts, including young and invasive lobular subgroups.
Breast Cancer Res Treat. 2026;217:14.
PubMed Abstract available

RODRIGUES LLC, de Holanda Juca Silveira L, de Almeida LFC, de Freitas BG, et al
Oral selective estrogen receptor degraders in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2026;217:16.
PubMed Abstract available

TAM G, Waddell D, Freeman JQ, Chen N, et al
Sacituzumab-induced severe or febrile neutropenia and G-CSF utilization and cost for advanced HER2-negative breast cancer: a single-center retrospective analysis.
Breast Cancer Res Treat. 2026;217:22.
PubMed Abstract available

MILLER PC, Sharma U, Tao J, Sun J, et al
In vivo exposure to CXCL12-high CAFs and chronic CXCL12 stimulation in vitro is sufficient to enhance metastasis of ER-positive breast cancer.
Breast Cancer Res Treat. 2026;217:21.
PubMed Abstract available

YI H, Zhong Y, Xing D, Wang Y, et al
Black and White disparity in U.S. female breast cancer mortality: a nationwide analysis, 1999-2023.
Breast Cancer Res Treat. 2026;217:15.
PubMed Abstract available

RAJPUT S, Vierkant RA, Olson KN, Larson NL, et al
Factors associated with and patterns of alcohol intake in late survivorship for breast cancer survivors.
Breast Cancer Res Treat. 2026;217:13.
PubMed Abstract available

WANG W, Liu M, Li X
Single-cell RNA sequencing and Mendelian randomization identify context-dependent LIPA-associated classical monocyte states in sepsis and breast cancer.
Breast Cancer Res Treat. 2026;217:18.
PubMed Abstract available

WANG DK, Steele JA, Opalenik SR, Balko JM, et al
Topoisomerase I inhibitor antibody-drug conjugates in breast cancer: the relevance of the DNA damage response to resistance, response, and combination treatment strategies.
Breast Cancer Res Treat. 2026;217:17.
PubMed Abstract available

JOHNSON HM, Tasoulis MK, Kuerer HM
Eliminating breast cancer surgery in exceptional responders: selective omission - not blind omission.
Breast Cancer Res Treat. 2026;217:24.
PubMed

KAROLINA A, Marcin E, Magdalena G, Mateusz D, et al
Correlation between the drainage time in dynamic indocyanine green lymphography (ICG) and axillary lymph nodes metastatic involvement in breast cancer patients-a prospective study.
Breast Cancer Res Treat. 2026;217:19.
PubMed Abstract available

MASLANA KE, Burns RD, Bai Y, Playdon MC, et al
The association of an exercise and rehabilitation clinical workflow algorithm on sedentary behavior and performance status from time of breast cancer diagnosis and throughout care.
Breast Cancer Res Treat. 2026;217:23.
PubMed Abstract available

KO G, Zhang E, Yee E, Hallet J, et al
Provider level facilitators and barriers towards neoadjuvant chemotherapy for triple negative and HER2 + breast cancer: a survey of Ontario surgeons.
Breast Cancer Res Treat. 2026;217:20.
PubMed Abstract available

LESHEM Y, Golomb I, Zubkov A, Bar Y, et al
Neoadjuvant twelve weekly paclitaxel-carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer.
Breast Cancer Res Treat. 2026;217:12.
PubMed Abstract available

FADELU TA, Odai-Afotey A, Martin A, Skeffington M, et al
The LIFT UP study: feasibility of systematically identifying and addressing resource needs in those with metastatic breast cancer.
Breast Cancer Res Treat. 2026;217:11.
PubMed Abstract available

HORNER M, Tretschock LM, John N, Ziegler P, et al
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.
Breast Cancer Res Treat. 2026;217:9.
PubMed Abstract available

LOPEZ JCV, Ho A, Hughes KS, Bardia A, et al
Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to delineate characteristics of this site of recurrence.
Breast Cancer Res Treat. 2026;217:8.
PubMed Abstract available

MOLNAR AO, McArthur E, Bota SE, Stirling K, et al
Kidney function changes associated with trastuzumab use in women with breast cancer: a retrospective cohort study.
Breast Cancer Res Treat. 2026;217:10.
PubMed Abstract available

March 2026

DECKER KM, Feely A, Pitz M, Hebbard P, et al
The impact of the COVID-19 pandemic on breast cancer screening, treatment, and overall survival.
Breast Cancer Res Treat. 2026;217:7.
PubMed Abstract available

KUPIS W, Klosowska D, Harhala M, Sekula M, et al
The use of endpoints in phase 3 randomized controlled trials in metastatic breast cancer.
Breast Cancer Res Treat. 2026;217:6.
PubMed Abstract available

RUGO HS, Pluard TJ, Sharma P, Melisko M, et al
OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.
Breast Cancer Res Treat. 2026;217:5.
PubMed Abstract available

TAVARES GM, Ramalho SOB, da Silva LR, Telles GD, et al
Adjuvant capecitabine in women with triple-negative breast cancer with residual disease after carboplatin-containing neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2026;217:4.
PubMed Abstract available

MITSUEDA R, Sagara Y, Niikura N, Ohno S, et al
Real-world treatment patterns and outcomes in older patients with metastatic breast cancer: a multi-institutional retrospective cohort study.
Breast Cancer Res Treat. 2026;217:3.
PubMed Abstract available

CHIDDARWAR T, Blaes A, Kuntz K
Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.
Breast Cancer Res Treat. 2026;217:2.
PubMed Abstract available

AMNIOUEL S, Jafri MS
Development and validation of a highly accurate multigene gene expression biomarker to predict chemotherapy response in primary triple-negative breast cancer.
Breast Cancer Res Treat. 2026;217:1.
PubMed Abstract available

YANG EJ, Kim HS, Jeon HR, Suh MR, et al
Effects of a sensorimotor-based, movement quality-focused intervention on functional mobility in breast cancer survivors: a multicenter randomized controlled trial.
Breast Cancer Res Treat. 2026;216:37.
PubMed Abstract available

HAWKINS LA, Rumano RP, Smith SS, Beverly-Hery CM, et al
Telehealth utilization during the COVID-19 pandemic: comparing breast cancer survivors to non-cancer patients and implications for current practice.
Breast Cancer Res Treat. 2026;216:38.
PubMed Abstract available

ZHU Y, Hadidchi R, Nguyen HQ, Hariharan S, et al
Automated calculation of background parenchymal enhancement as a biomarker of treatment responses and recurrence-free survival in breast cancer.
Breast Cancer Res Treat. 2026;216:35.
PubMed Abstract available

MORRAR D, Ross D, Razavi P, Brogi E, et al
Rb expression in metastatic ER-positive breast cancer: implications for precision oncology.
Breast Cancer Res Treat. 2026;216:36.
PubMed Abstract available

DE MOURA LEITE L, de Almeida GR, Tavares MC, Cesca MG, et al
Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer.
Breast Cancer Res Treat. 2026;216:34.
PubMed Abstract available

BAXTER SM, McShane CM, McIntosh SA, Bennett D, et al
House value as an individual socioeconomic indicator for breast cancer survival and late-stage diagnosis: a population-based cohort study from Northern Ireland.
Breast Cancer Res Treat. 2026;216:33.
PubMed Abstract available

DOYLE C, Lohmann AE, Iqbal N, Henning JW, et al
Correction to: A Canadian real?world, multi?center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy +/- targeted therapy in HR + HER2?negat
Breast Cancer Res Treat. 2026;216:32.
PubMed

MASUDA N, Yasojima H, Bando H, Yamanaka T, et al
Long-term outcomes of eribulin?based neoadjuvant chemotherapy for triple?negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.
Breast Cancer Res Treat. 2026;216:31.
PubMed Abstract available

ANDRADE MO, Bonadio RC, Ipina A, Testa L, et al
Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.
Breast Cancer Res Treat. 2026;216:27.
PubMed Abstract available

CASTELO BB, Brito LGO, Torresan RZ, Filho CC, et al
Omission of axillary surgery in early breast cancer with negative lymph nodes: a systematic review and meta-analysis of randomized clinical trials.
Breast Cancer Res Treat. 2026;216:30.
PubMed Abstract available

JING F, Jiang L, Cao Y, Tian M, et al
ESR1 polymorphisms were associated with aromatase inhibitors induced musculoskeletal symptoms in breast cancer patients.
Breast Cancer Res Treat. 2026;216:28.
PubMed Abstract available

MANIKYA S, Vadhithala V, Kumar R, Nainwal P, et al
Comment on: "Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors".
Breast Cancer Res Treat. 2026;216:29.
PubMed

GUIRAO GARCIA ME, Marin Rodriguez P, Servet Perez de Lema CM, Blaya Boluda N, et al
Unlocking the predictive value of post-neoadjuvant immune biomarkers in breast cancer: neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII).
Breast Cancer Res Treat. 2026;216:26.
PubMed Abstract available

SONG PN, Mansur A, Gallegos CA, Ghanate P, et al
Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer.
Breast Cancer Res Treat. 2026;216:25.
PubMed Abstract available

BRUFSKY AM, Finn RS, Metzger O, Goncalves R, et al
Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care.
Breast Cancer Res Treat. 2026;216:22.
PubMed Abstract available

GAYFIELD S, Ma J, Waleski M, Kim J, et al
Comparing infectious risk of Trastuzumab-deruxtecan to Trastuzumab-emtansine in patients with breast cancer.
Breast Cancer Res Treat. 2026;216:23.
PubMed Abstract available

GIORDANO A, Graham N, Aizer AA, Tayob N, et al
A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis.
Breast Cancer Res Treat. 2026;216:24.
PubMed Abstract available

February 2026

TOLOSA P, Garcia-Fructuoso I, Pascual T, Martinez-Saez O, et al
Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.
Breast Cancer Res Treat. 2026;216:21.
PubMed Abstract available

DROZD C, Curtit E, Jacquinot Q, Roux P, et al
Effect of a supervised intermittent exercise program on insomnia in breast cancer patients undergoing chemotherapy.
Breast Cancer Res Treat. 2026;216:20.
PubMed Abstract available

TAGHIAN AJ, Aggarwal M, Shui AM, O'Donnell K, et al
Baseline and early postoperative bioimpedance spectroscopy and perometry measurements in patients treated for breast cancer: insights from a prospective screening program.
Breast Cancer Res Treat. 2026;216:19.
PubMed Abstract available

SISCA L, Polito MG, Silletta M, La Cesa A, et al
Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2026;216:16.
PubMed Abstract available

HENRY NL, Monkman LK, Griffith K, Scheu K, et al
Ovarian function suppression decision-making and uptake in premenopausal women with breast cancer: a mixed methods analysis.
Breast Cancer Res Treat. 2026;216:17.
PubMed Abstract available

STERPI M, Dreyfus N, Lo Y, Fineberg S, et al
Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study.
Breast Cancer Res Treat. 2026;216:18.
PubMed Abstract available

HUBER E, Gupta GP, Morse R, Abdou Y, et al
Investigating initial patterns of progression on first-line treatment in patients with de novo metastatic breast cancer.
Breast Cancer Res Treat. 2026;216:15.
PubMed Abstract available

VASIGH M, Williams AD, Hasler JS, Aggon A, et al
The role of regional nodal irradiation in clinically node-positive breast cancer patients who undergo neoadjuvant chemotherapy and breast-conserving surgery.
Breast Cancer Res Treat. 2026;216:14.
PubMed Abstract available

SHINN E, Zahrieh D, DeMichele A, Zdenkowski N, et al
Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.
Breast Cancer Res Treat. 2026;216:12.
PubMed

TSE SSW, Wong HCY, Charbonneau F, Cao JQ, et al
Cost-effectiveness analysis of Mepitel Film for prevention of acute radiation dermatitis in breast cancer: a Canadian healthcare perspective.
Breast Cancer Res Treat. 2026;216:10.
PubMed Abstract available

SOYANO MULLER AE, Goodridge DN, Mo Q, Whiting J, et al
Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer.
Breast Cancer Res Treat. 2026;216:11.
PubMed Abstract available

WANG J, Bayard S, Assel M, Kim M, et al
Remote symptom monitoring with clinical alerts following lumpectomy: do alerts predict 30-day re-operation or re-admission rates?
Breast Cancer Res Treat. 2026;216:9.
PubMed Abstract available

BHARANI AN, Prateeksha A, Samanvay HP
Letter to editor on the article by K.?H. Yoon et al., titled Impact of obesity on breast cancer recurrence by menopausal status and subtype.
Breast Cancer Res Treat. 2026;216:7.
PubMed

BROWN NL, Howell SJ, Papantoniou D, Eriksson O, et al
Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors.
Breast Cancer Res Treat. 2026;216:6.
PubMed Abstract available

KLUGMAN MF, Aboumrad M, Chen R, Marshall CH, et al
Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancer.
Breast Cancer Res Treat. 2026;216:5.
PubMed Abstract available

MARTIN E, Chichua M, Chiodi CK, Zyumbileva P, et al
ATTITUDE - Addressing attrition in longitudinal cancer cohorts: an in-depth qualitative analysis of experiences and perspectives on participation in longitudinal studies among breast cancer survivors.
Breast Cancer Res Treat. 2026;216:4.
PubMed Abstract available

KAJA E, Grupinska J, Budzyn M, Ciomborowska-Basheer J, et al
Disease- and chemotherapy-associated salivary microbiome changes in breast cancer patients.
Breast Cancer Res Treat. 2026;216:2.
PubMed Abstract available

PARSONS K, Yin H, Yu OHY, Khosrow-Khavar F, et al
The association between pre-existing type 2 diabetes on cancer-related and all-cause mortality among women with breast cancer.
Breast Cancer Res Treat. 2026;216:3.
PubMed Abstract available

ZHANG Y, Peng J, Ma T, Liu X, et al
TMEM205 promotes M2-like macrophage polarization and advances the progression of triple-negative breast cancer.
Breast Cancer Res Treat. 2026;216:1.
PubMed Abstract available

LEBLANC A, Beltran-Bless AA, Pond GR, El Emam K, et al
Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudy.
Breast Cancer Res Treat. 2026;215:74.
PubMed Abstract available

LEE TH, Lee H, Jang JY, Park W, et al
Refined risk stratification in residual triple-negative breast cancer after neoadjuvant therapy using residual cancer burden class and lymphovascular invasion.
Breast Cancer Res Treat. 2026;215:76.
PubMed Abstract available

GARG G, Bharath S, Krishna A, Sethi S, et al
Diagnostic accuracy of tumor bed biopsy for predicting pathological complete response in breast cancer patients achieving clinical complete response after neoadjuvant chemotherapy: a meta-analysis.
Breast Cancer Res Treat. 2026;215:75.
PubMed Abstract available

TIELS LM, Walstra CJEF, Voogd AC, van der Sangen MJC, et al
Postoperative complications after salvage mastectomy and repeat breast-conserving surgery in patients with IBTR after previous breast-conserving surgery: a multicenter, retrospective cohort study.
Breast Cancer Res Treat. 2026;215:71.
PubMed Abstract available

REUL-HIRCHE HM, Dunn MR, Plinsinga ML, Laakso EL, et al
The relationship between impaired upper-body function, quality of life and breast cancer-related lymphoedema: results from a prospective, population-based cohort study.
Breast Cancer Res Treat. 2026;215:73.
PubMed Abstract available

JACQUINOT Q, Ennequin G, Falcoz A, Sawyer D, et al
Exercise training decreases Neuregulin-1 concentrations in HER2-positive breast cancer patients undergoing adjuvant trastuzumab: the CARDAPAC study.
Breast Cancer Res Treat. 2026;215:69.
PubMed Abstract available

AMBURN T, Parvin-Nejad FP, Sevilimedu V, Zou H, et al
Oncologic safety of prophylactic nipple-sparing mastectomy: Outcomes of 1,255 cases exceeding a 6-year median follow-up.
Breast Cancer Res Treat. 2026;215:72.
PubMed Abstract available

CHUN S, Lee HR, Jung JH, Kim SH, et al
Association of low muscle mass and obesity with mortality and cardiovascular outcomes in breast cancer: a population-based study.
Breast Cancer Res Treat. 2026;215:70.
PubMed Abstract available

CHEN Y, Wang R, Wu L, Li J, et al
Fertility preservation in breast cancer patients: a systematic review and summary of current evidence and recommendations.
Breast Cancer Res Treat. 2026;215:68.
PubMed Abstract available

January 2026

ROJAS DP, Frassoni S, Maisonneuve P, Intra M, et al
A nomogram for predicting in-breast tumor recurrence risk in breast cancer patients treated with partial breast irradiation using intraoperative electron radiation therapy.
Breast Cancer Res Treat. 2026;215:67.
PubMed Abstract available

RICCERI F, Favaro E, Catalano A, Gilcrease GW, et al
Risk of myocardial infarction and stroke after breast cancer: an analysis of a population of 1.3 million women from North-West Italy.
Breast Cancer Res Treat. 2026;215:66.
PubMed Abstract available

LEGGAT-BARR K, Lewis T, Tice JA, Tsopurashvili E, et al
Breast cancer risk level and prediction of tumor aggressiveness in the Athena Breast Health Network.
Breast Cancer Res Treat. 2026;215:65.
PubMed Abstract available

LAMMERS EMJ, Beens-van Dijk J, Nijdam A, Menezes R, et al
Dual-modality breast cancer screening compared to MRI or mammography alone among female Hodgkin lymphoma survivors who received chest radiotherapy.
Breast Cancer Res Treat. 2026;215:64.
PubMed Abstract available

LAVIGNE O, Poumeaud F, Reverdy T, Huynh VT, et al
Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study.
Breast Cancer Res Treat. 2026;215:63.
PubMed Abstract available

FUMAROLA C, Caffarra C, La Monica S, Galetti M, et al
Correction: Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Breast Cancer Res Treat. 2026;215:62.
PubMed

WANG Q, Van Alsten SC, Ji X, Salim E, et al
Molecular and socioeconomic characteristics of inflammatory breast cancer in the Carolina Breast Cancer Study.
Breast Cancer Res Treat. 2026;215:61.
PubMed Abstract available

PEDERSINI R, Moretti L, Lagana M, Schivardi G, et al
Fracture risk in metastatic breast cancer patients treated with CDK 4/6 inhibitors and endocrine therapy.
Breast Cancer Res Treat. 2026;215:58.
PubMed Abstract available

STABELLINI N, Kaur J, Owusu C, Moftakhar B, et al
Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort study.
Breast Cancer Res Treat. 2026;215:59.
PubMed Abstract available

ALONSO-ROMERO JL, Martinez-Garcia J, Carrillo-Vicente R, Aramburo AF, et al
Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer.
Breast Cancer Res Treat. 2026;215:60.
PubMed Abstract available

BLUM M, Koch SM, Mousavi M, Vorburger D, et al
Trends in postmastectomy radiotherapy for early and locally advanced breast cancer in Switzerland: a population-based cross-sectional and longitudinal analysis.
Breast Cancer Res Treat. 2026;215:57.
PubMed Abstract available

LEITZELAR BN, Willis AR, Price SN, Tooze JA, et al
Updated systematic review and meta-analysis: taking the next step in physical activity behavioral interventions for post-treatment breast cancer survivors.
Breast Cancer Res Treat. 2026;215:56.
PubMed Abstract available

CHEN EL, Heiling H, Li T, Bellon JR, et al
Outcomes of patients with de novo oligometastatic breast cancer treated with curative intent at a single institution.
Breast Cancer Res Treat. 2026;215:55.
PubMed Abstract available

HJORTH S, Vandraas KF, Trewin-Nybraten CB, Botteri E, et al
Anti-HER2 treatment in everyday practice: how we treat older women with breast cancer differently.
Breast Cancer Res Treat. 2026;215:54.
PubMed Abstract available

LIU S, Du B, Zhang M, Zhai D, et al
Prognosis and endocrine therapy efficacy in early breast cancer with estrogen receptor low expression.
Breast Cancer Res Treat. 2026;215:51.
PubMed Abstract available

TAHANEY WM, Lanier A, Qian J, Moyer CL, et al
Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells.
Breast Cancer Res Treat. 2026;215:49.
PubMed Abstract available

LIU J, Chu F, Yao L, Sun J, et al
Risk of second non-breast primary cancer in Chinese breast cancer patients with germline BRCA1/2 pathogenic variants.
Breast Cancer Res Treat. 2026;215:50.
PubMed Abstract available

ARTIGNAN J, Capmas P, Panjo H, Bejarano-Quisoboni D, et al
Changes in compliance with cardiovascular medication after a breast cancer diagnosis: a latent class trajectory analysis using French nationwide data.
Breast Cancer Res Treat. 2026;215:52.
PubMed Abstract available

GLATT T, Leggat-Barr K, Seth N, Heditsian D, et al
RISE UP for breast cancer 2024: conference highlights & takeaways.
Breast Cancer Res Treat. 2026;215:53.
PubMed Abstract available

December 2025

CARSON EK, Dhillon HM, Vardy JL, Brown C, et al
The impact of breast cancer treatment on sleep disturbance: a systematic review.
Breast Cancer Res Treat. 2025;215:48.
PubMed Abstract available

OLOMU MUO, Scherer C, Wood E, Escobar K, et al
Assessing barriers to genomic testing in breast cancer among diverse patients: a qualitative community-engaged research study.
Breast Cancer Res Treat. 2025;215:47.
PubMed Abstract available

DUNN MR, Van Alsten SC, Emerson MA, Reeder-Hayes K, et al
Tumor biology and access to care and metastatic breast cancer outcomes.
Breast Cancer Res Treat. 2025;215:46.
PubMed Abstract available

DE PLACIDO P, Troll E, Niman SM, Ryan S, et al
Assessing the accuracy of inflammatory breast cancer self-reported diagnoses through the metastatic breast cancer project from the count me in initiative database.
Breast Cancer Res Treat. 2025;215:45.
PubMed Abstract available

WOPAT H, Patel R, Provenzano D, Rao YJ, et al
Body composition, chemotherapy dosing and hematologic toxicity among Black and non-Black women being treated for breast cancer.
Breast Cancer Res Treat. 2025;215:44.
PubMed Abstract available

SCHUPP E, Gokun Y, Eckstein J, Stover DG, et al
Trimodal therapy is associated with higher overall survival than chemotherapy only in patients with metastatic inflammatory breast cancer.
Breast Cancer Res Treat. 2025;215:43.
PubMed Abstract available

CHENG H, Gong J, Yu L, Feng X, et al
Compression sleeves for prevention and treatment of breast cancer-related lymphedema: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2025;215:41.
PubMed Abstract available

WOOSTER M, DeStephano D, Beauchemin M, Wang S, et al
Disparities in delays and outcomes in patients with HER2-positive breast cancer.
Breast Cancer Res Treat. 2025;215:37.
PubMed Abstract available

YEN TWF, Canales B, McGinley EL, Tarima S, et al
The association of contemporary mortgage lending bias and receipt of guideline-concordant systemic treatment among older women with breast cancer.
Breast Cancer Res Treat. 2025;215:40.
PubMed Abstract available

FERRI GM, Martinez CB, Acevedo J, Bhatt S, et al
Exploring the effect of Duffy status on patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors.
Breast Cancer Res Treat. 2025;215:36.
PubMed Abstract available

SADIA K, Talia T, Hussain I, Chaudhry M, et al
Efficacy and safety of abemaciclib plus endocrine therapy versus endocrine therapy alone in HR + and HER2-negative breast cancer; a systematic review and meta-analysis.
Breast Cancer Res Treat. 2025;215:39.
PubMed Abstract available

YANG Z, Qing M, Zhang Y, Wu J, et al
Risk factors for postoperative bleeding following breast cancer surgery: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2025;215:38.
PubMed Abstract available

GREENBERG MR, Noveihed A, George M
Overview of ocular toxicities associated with breast cancer therapies.
Breast Cancer Res Treat. 2025;215:33.
PubMed Abstract available

PAGE K, Martinson LJ, Hastings RK, Acheampong E, et al
Assessing endocrine resistance: monitoring circulating ESR1 mutations in Irosustat-treated ER positive breast cancer.
Breast Cancer Res Treat. 2025;215:34.
PubMed Abstract available

ZUBROWSKA J, Pieniazek M, Polakiewicz-Gilowska A, Malejcikova M, et al
Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study.
Breast Cancer Res Treat. 2025;215:35.
PubMed Abstract available

WIEDER V, Engel J, Eichstadt K, Kaufhold S, et al
Prospective validation of the prognostic and predictive impact of uPA/PAI-1 in early breast cancer.
Breast Cancer Res Treat. 2025;215:31.
PubMed Abstract available

ASHOK KUMAR P, Ghelani G, Koorapati G, Paulraj S, et al
The impact of adjuvant chemotherapy on overall survival in premenopausal (age
Breast Cancer Res Treat. 2025;215:32.
PubMed Abstract available

RADWAN E, Memoli V, Seguin L, Mancini J, et al
Side effects and adherence trajectories of adjuvant endocrine therapy in breast cancer patients: results from the VICAN2 study.
Breast Cancer Res Treat. 2025;215:30.
PubMed Abstract available

JARA P, Ariant M, Jimenez R, Bringas M, et al
Antitumor activity of the combination of vinorelbine and gemcitabine in patients with HR + /HER2- advanced breast cancer after CDK4/6 inhibitor.
Breast Cancer Res Treat. 2025;215:28.
PubMed Abstract available

KAKANI P, Ro V, McGuinness JE, Michel A, et al
Factors associated with receipt of surveillance breast MRI among racially and ethnically diverse women with operable breast cancer.
Breast Cancer Res Treat. 2025;215:27.
PubMed Abstract available

LAPERCHE-SANTOS D, Assad-Suzuki D, Resende H, Moura FC, et al
Impact of public vs. private insurance coverage on quality of life of women with early-stage estrogen receptor-positive breast cancer.
Breast Cancer Res Treat. 2025;215:26.
PubMed Abstract available

DEDEEPYA SD, Goel V, Desai NN
Comment on "Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis".
Breast Cancer Res Treat. 2025;215:29.
PubMed Abstract available

OGU JC, Ozcan BB, Dogan BE, Xi Y, et al
Patient perspectives on artificial intelligence in mammography interpretation: a comparative survey study of safety-net and academic hospital settings.
Breast Cancer Res Treat. 2025;215:25.
PubMed Abstract available

PATHAK N, Kimmel A, Berner-Wygoda Y, Almuthri SA, et al
Using the cancer aging and research group- breast cancer (CARG-BC) predictive model in older adults (OA) with early breast cancer: an external validation study.
Breast Cancer Res Treat. 2025;215:24.
PubMed Abstract available

HERMANN N, Faermann R, Grinin K, Sklair-Levy M, et al
Identifying patients most likely to benefit from routine post-operative mammogram after breast-conserving surgery.
Breast Cancer Res Treat. 2025;214:347-353.
PubMed Abstract available

YANG W, Alongi A, Ma Z, Styblo TM, et al
Long-term follow-up confirms patients with high-risk breast lesions can be successfully managed at a multidisciplinary conferences.
Breast Cancer Res Treat. 2025;214:409-418.
PubMed Abstract available

WILLERT CB, Mellemkjaer L, Tolver A, Gerdes AA, et al
Time trends, uptake, and oncological effects of risk-reducing surgeries in 3067 Danish BRCA1/2 carriers: a population-based study with matched controls.
Breast Cancer Res Treat. 2025;214:355-366.
PubMed Abstract available

PALMQUIST E, Kiernan R, Sevilimedu V, Le T, et al
Breast surgical site infections in patients undergoing lumpectomy with and without closure of defect.
Breast Cancer Res Treat. 2025;214:339-346.
PubMed Abstract available

November 2025

ZELIZER S, Gallagher GB, Gonen M, Dang C, et al
Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer.
Breast Cancer Res Treat. 2025;215:19.
PubMed Abstract available

KAUR M, Quirarte A, Vertido A, Torosian T, et al
Impact of concurrent lobular carcinoma in situ on recurrence outcomes in patients with classic and pleomorphic invasive lobular carcinoma of the breast.
Breast Cancer Res Treat. 2025;215:20.
PubMed Abstract available

GHASEMI F, Arima J, Takabe K
High PARP1 expression is associated with proliferative tumor biology in breast cancer.
Breast Cancer Res Treat. 2025;215:21.
PubMed Abstract available

REAM M, Taub CJ, Rosenbaum AR, Olguin EO, et al
Promoting Resilience in Stress Management (PRISM) for women with breast cancer: a qualitative analysis of patient impressions and recommendations.
Breast Cancer Res Treat. 2025;215:22.
PubMed Abstract available

BERNIK S, Balija TM, Kim D, Cuadros A, et al
Breast cancer patients treated at a New York City academic health system during the COVID-19 pandemic in 2021 had delayed presentations and more advanced disease than pre-pandemic cases.
Breast Cancer Res Treat. 2025;215:23.
PubMed Abstract available

DOLEVICZENYI L, Frivaldszky L, Rancz A, Fedorcsak DL, et al
The significance of perioperative glucocorticoids in the prevention of seroma formation after mastectomies: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2025;215:13.
PubMed Abstract available

MALHOTRA S, Choi DX, Sevilimedu V, Greenup RA, et al
Association between hospital volume and survival in patients with locally advanced breast cancer.
Breast Cancer Res Treat. 2025;215:15.
PubMed Abstract available

ZHAO Z, Lei H, Wang B, Guo L, et al
Mesothelin-expressing triple-negative breast cancer: a highly invasive and immunosuppressive subtype.
Breast Cancer Res Treat. 2025;215:18.
PubMed Abstract available

ABABNEH HS, Naoum GE, Niemierko A, Ly A, et al
Analysis of factors associated with loco-regional failure in breast cancer patients following neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2025;215:17.
PubMed Abstract available

IWAI C, Konishi T, Miyawaki A, Okada A, et al
Cardiovascular adverse events associated with denosumab versus zoledronic acid in patients with breast cancer: a propensity score overlap weighted analysis.
Breast Cancer Res Treat. 2025;215:16.
PubMed Abstract available

CANDELL L, Foulad D, Wapnir I, Tsai J, et al
Breast cancer diagnosis at age 85 and older.
Breast Cancer Res Treat. 2025;215:14.
PubMed Abstract available

NYQVIST-STRENG J, Chamalidou C, Kovacs A, Parris TZ, et al
Worse survival despite indolent features for triple-negative invasive lobular carcinoma: a Swedish nationwide registry-based study.
Breast Cancer Res Treat. 2025;215:12.
PubMed Abstract available

XU Q, Li X, Deng X, Li M, et al
Impact of lymph node status on the prognosis of female breast cancer patients who underwent immediate reconstruction after total mastectomy: a multi-institutional retrospective cohort study.
Breast Cancer Res Treat. 2025;215:8.
PubMed Abstract available

FREEMAN JQ, Schechter K, Nguyen LC, Omoleye OJ, et al
Racial and ethnic disparities and socioeconomic determinants of male breast cancer mortality in the United States.
Breast Cancer Res Treat. 2025;215:9.
PubMed Abstract available

COLLIN SM, Lam C, Sredni ST, Haji-Noor ZM, et al
HER2 testing results, practices, and preferences among pathologists and oncologists in the US community setting: a mixed-methods study.
Breast Cancer Res Treat. 2025;215:2.
PubMed Abstract available

LIN J, Lipkowitz S, Hu H, Nealeigh M, et al
Chronic inflammatory diseases and survival among breast cancer patients in the U.S. military health system.
Breast Cancer Res Treat. 2025;215:4.
PubMed Abstract available

POST KE, Dunderdale L, Datta S, Varella L, et al
Improving adjuvant endocrine therapy initiation among patients with breast cancer: a nurse-led, culturally sensitive pilot study.
Breast Cancer Res Treat. 2025;215:7.
PubMed Abstract available

DALTON JC, Nierenberg TC, Leonard A, Liang J, et al
Risk prediction models for malignancy upgrade in high-risk breast lesions: a qualitative systematic review.
Breast Cancer Res Treat. 2025;215:3.
PubMed Abstract available

HAMMER PM, Enamandram S, Ikeda DM, Lam MM, et al
Mammary small cell neuroendocrine carcinomas that showed excellent pathologic response following etoposide-based neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2025;215:10.
PubMed Abstract available

OLIVEIRA LJC, Mano MS, Barrios C, Dienstmann R, et al
The promise of ctDNA-based, molecularly-driven early switch therapy from PADA-1 to SERENA-6.
Breast Cancer Res Treat. 2025;215:5.
PubMed Abstract available

HASSAN AM, Hajj JP, Lewis JP, Fisher CS, et al
Socioeconomic and ethnic disparities in breast cancer-related lymphedema and quality-of-life after immediate lymphatic reconstruction.
Breast Cancer Res Treat. 2025;215:1.
PubMed Abstract available

SCHRUP S, Maimone S, Villalba M, Vierkant RA, et al
High-resolution microCT to assess breast microcalcification morphometry by histologic lesion subtype and radiologic classification.
Breast Cancer Res Treat. 2025;214:49-58.
PubMed Abstract available

SHANTHAKUMAR D, Chalau V, Shi Y, Ranjitkar R, et al
Diffuse reflectance and fluorescence spectroscopy for breast conserving surgery.
Breast Cancer Res Treat. 2025;214:25-36.
PubMed Abstract available

October 2025

YOON KH, Yoon Y, Jeong S, Kang J, et al
Impact of obesity on breast cancer recurrence by menopausal status and subtype: a retrospective cohort study.
Breast Cancer Res Treat. 2025 Oct 21. doi: 10.1007/s10549-025-07823.
PubMed Abstract available

AMITANI M, Oba T, Kitazawa A, Iji R, et al
Prognostic significance of baseline skeletal muscle index and its dynamics in patients with metastatic breast cancer undergoing eribulin treatment.
Breast Cancer Res Treat. 2025 Oct 15. doi: 10.1007/s10549-025-07827.
PubMed Abstract available

SHI L, Kolor K, Chen Z, Moonesinghe R, et al
BRCA testing utilization among commercially insured women with breast or ovarian cancer.
Breast Cancer Res Treat. 2025;213:291-298.
PubMed Abstract available

STRINGER-REASOR EM, Saha P, Kocherginsky M, Lastra R, et al
Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer.
Breast Cancer Res Treat. 2025;213:347-354.
PubMed Abstract available

CHOI S, Park B, Lee EG, Lee S, et al
Prediction of upstaging in DCIS: the dominant role of pathological over imaging risk factors.
Breast Cancer Res Treat. 2025;213:325-334.
PubMed Abstract available

MAMTANI A, Sevilimedu V, Barrio AV, Morrow M, et al
Axillary dissection is avoidable in most cT1N0 triple-negative & HER2+ breast cancers treated with upfront surgery.
Breast Cancer Res Treat. 2025;213:355-363.
PubMed Abstract available

KOVACS A, Klint L, Linderholm B, Parris TZ, et al
Changes in HER2low and HER2-ultralow status in 47 advanced breast carcinoma core biopsies, matching surgical specimens, and their distant metastases assessed by conventional light microscopy, digital pathology, and artificial intelligence.
Breast Cancer Res Treat. 2025;213:397-408.
PubMed Abstract available

September 2025

PIENIAZEK M, Polakiewicz-Gilowska A, Las-Jankowska M, Wronowicz J, et al
Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis.
Breast Cancer Res Treat. 2025 Sep 27. doi: 10.1007/s10549-025-07825.
PubMed Abstract available

HUANG Z, Liu Y, Li S, Li Y, et al
Correction: IHC4 and COMBINE scores for enhanced prognostic stratification in HR+/HER2- breast cancer patients after neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2025 Sep 25. doi: 10.1007/s10549-025-07824.
PubMed

ZAGO A, Leveque E, Augustynen A, Leheurteur M, et al
Correction: Analysis of the impact of the COVID-19 pandemic on the stage at diagnosis in breast cancer patients at a French comprehensive cancer centre, through two different methods: a preliminary study.
Breast Cancer Res Treat. 2025 Sep 23. doi: 10.1007/s10549-025-07813.
PubMed

JI L, Chen X, Lyu H, Song G, et al
Pathological complete response and survival outcomes in single hormone receptor-positive/HER2-negative breast cancer after neoadjuvant chemotherapy and its intrinsic biological features and immune landscape.
Breast Cancer Res Treat. 2025 Sep 17. doi: 10.1007/s10549-025-07822.
PubMed Abstract available

GRACIANO N, Lopez L, Rodriguez CA, Montoya K, et al
Survival impact of adjuvant capecitabine in triple-negative breast cancer Latin American patients with residual disease: a real-world study.
Breast Cancer Res Treat. 2025 Sep 16. doi: 10.1007/s10549-025-07814.
PubMed Abstract available

DINGER TL, Volders JH, Kuijer A, Kelder JC, et al
Evaluating clinical response to primary endocrine therapy in elderly breast cancer patients in routine practice.
Breast Cancer Res Treat. 2025 Sep 12. doi: 10.1007/s10549-025-07809.
PubMed Abstract available

ELIAS N, Karak FE, Damaj N, Hajj A, et al
Effects of intermittent discontinuation cyclin-dependent kinase inhibitors on metastatic breast cancer during Lebanon's economic crisis.
Breast Cancer Res Treat. 2025 Sep 11. doi: 10.1007/s10549-025-07794.
PubMed Abstract available

NEZIREVIC S, Anders C, Dent S, Bansal R, et al
Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer.
Breast Cancer Res Treat. 2025 Sep 11. doi: 10.1007/s10549-025-07818.
PubMed Abstract available

FIELDER AM, Kim S, Ruterbusch JJ, Martin C, et al
Prescription and self-reported use of endocrine therapy among black hormone receptor-positive breast cancer survivors in the Detroit Research on Cancer Survivors cohort.
Breast Cancer Res Treat. 2025 Sep 9. doi: 10.1007/s10549-025-07816.
PubMed Abstract available

TARUNO K, Den H, Takeuchi M, Inuzuka M, et al
Clinicopathologic features and contralateral breast cancer risk in BRCA1/2 pathogenic variant carriers: a multicenter registry study of Japanese women.
Breast Cancer Res Treat. 2025 Sep 6. doi: 10.1007/s10549-025-07815.
PubMed Abstract available

SIREK A, Sirek T, Nowakowski R, Borawski P, et al
Correction to: Subtype-specific dysregulation of biogenic amine-related genes and miRNAs in breast cancer: identification of DRD2, HRH2, and HRH4 as potential therapeutic targets in TNBC and HER2 + subtypes.
Breast Cancer Res Treat. 2025 Sep 5. doi: 10.1007/s10549-025-07807.
PubMed

LEE JJ, Jettinghoff W, Arbour G, Zepeda A, et al
Natural language processing for local, regional, and distant breast cancer relapse identification in pathology reports.
Breast Cancer Res Treat. 2025 Sep 2. doi: 10.1007/s10549-025-07801.
PubMed Abstract available

ZHAN H, Chan NNN, Khaimova R, Aung TN, et al
Quantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS.
Breast Cancer Res Treat. 2025;213:273-279.
PubMed Abstract available

MIDDLETON LP, Perkins GH, Whitman GJ, Mouabbi JA, et al
Immediate and ipsilateral recurrence rates and treatment recommendations for patients with pleomorphic and florid lobular carcinoma in situ.
Breast Cancer Res Treat. 2025;213:225-235.
PubMed Abstract available

LIN HK, Dai J, Pusztai L
Integrating large-scale in vitro functional genomic screen and multi-omics data to identify novel breast cancer targets.
Breast Cancer Res Treat. 2025 Sep 1. doi: 10.1007/s10549-025-07817.
PubMed Abstract available

August 2025

SANLI AN, Turan B, Tekcan Sanli DE, Karaca I, et al
Neoadjuvant response stratification based on complete, partial, and no response in HR-positive/HER2-positive breast cancer.
Breast Cancer Res Treat. 2025 Aug 28. doi: 10.1007/s10549-025-07812.
PubMed Abstract available

WEI J, Aller A, Zhu S, Habel LA, et al
Beyond the 5-year mark: adherence to and continuation of extended adjuvant endocrine therapy in non-metastatic breast cancer patients.
Breast Cancer Res Treat. 2025 Aug 27. doi: 10.1007/s10549-025-07811.
PubMed Abstract available

LIU Z, Liu Z, Wang M, Liu Y, et al
Transcriptomic and microenvironment characteristics of triple-negative breast cancer under three different neoadjuvant treatment regimens.
Breast Cancer Res Treat. 2025 Aug 27. doi: 10.1007/s10549-025-07810.
PubMed Abstract available

NOLAN L, Huan H, McDonnell W, Walsh S, et al
The impact of mammographic breast density on locoregional recurrence in breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2025 Aug 25. doi: 10.1007/s10549-025-07804.
PubMed Abstract available

BELTRAN-BLESS AA, Saunders D, Clemons L, Machado I, et al
Patient perceptions around the use of clinico-pathologic and genomic tools in the management of early breast cancer.
Breast Cancer Res Treat. 2025 Aug 21. doi: 10.1007/s10549-025-07797.
PubMed Abstract available

PATEL R, Fukui J, Klein P, Moshier E, et al
Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer.
Breast Cancer Res Treat. 2025 Aug 16. doi: 10.1007/s10549-025-07802.
PubMed Abstract available

COHN JG, Locke SC, Herring KW, Dent SF, et al
Palliative care use and end-of-life care quality in HR+/HER2- metastatic breast cancer.
Breast Cancer Res Treat. 2025 Aug 16. doi: 10.1007/s10549-025-07805.
PubMed Abstract available

UMUTONI V, Sun Y, Freeman JQ, Zhao F, et al
Quality of life during the COVID-19 pandemic and survival outcomes among breast cancer survivors.
Breast Cancer Res Treat. 2025 Aug 15. doi: 10.1007/s10549-025-07808.
PubMed Abstract available

MATA DGMM, Sutradhar R, Castelo M, Hahn E, et al
Omission of anthracyclines from neoadjuvant chemotherapy for breast cancer: a population-based analysis.
Breast Cancer Res Treat. 2025 Aug 13. doi: 10.1007/s10549-025-07778.
PubMed Abstract available

BAKHUIS CFJ, Prekovic S, Suelmann BBM, Verloop J, et al
Worse prognosis for breast cancer diagnosed in advanced pregnancy and shortly postpartum: an update of the Dutch pregnancy-associated breast cancer cohort.
Breast Cancer Res Treat. 2025 Aug 12. doi: 10.1007/s10549-025-07806.
PubMed Abstract available

GONZALO-ENCABO P, Giobbie-Hurder A, Sears DD, Mayer EL, et al
Combined intermittent fasting and exercise intervention in patients with metastatic, hormone receptor-positive breast cancer (FastER): a pilot study.
Breast Cancer Res Treat. 2025 Aug 12. doi: 10.1007/s10549-025-07803.
PubMed Abstract available

BEHLAM I, Sudershan A, Priya I, Sudershan S, et al
Association between ESR1 polymorphisms (XbaI & PvuII) and breast cancer risk: a comprehensive meta-analysis of case-control studies.
Breast Cancer Res Treat. 2025 Aug 8. doi: 10.1007/s10549-025-07800.
PubMed Abstract available

OIKONOMIDOU O, Beresford MJ, Galve-Calvo E, Woeckel A, et al
Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2- advanced breast cancer in Europe.
Breast Cancer Res Treat. 2025 Aug 6. doi: 10.1007/s10549-025-07707.
PubMed Abstract available

WANG MJ, Rastegar A, Kung TA
Readability analysis of breast cancer resources shared on X-implications for patient education and the potential of AI.
Breast Cancer Res Treat. 2025 Aug 6. doi: 10.1007/s10549-025-07799.
PubMed Abstract available

BELTRAN-BLESS AA, de Lima Machada I, Clemons L, Pond GR, et al
Do regularly scheduled visits result in earlier detection of curable breast cancer recurrences?
Breast Cancer Res Treat. 2025 Aug 5. doi: 10.1007/s10549-025-07793.
PubMed Abstract available

VACHARANUKRAUH P, Miller KJ, Alif SM, Grace F, et al
Pharmacological interventions for anthracycline-induced cardiotoxicity in breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Breast Cancer Res Treat. 2025 Aug 5. doi: 10.1007/s10549-025-07791.
PubMed Abstract available

LLOYD K, Newman LA, Glass C, Ogayo ER, et al
Assessing racial disparities in disease outcomes of patients with high-risk, triple-negative breast cancer and residual disease after neoadjuvant therapy: a post-hoc analysis of the ECOG-ACRIN 1131 clinical trial.
Breast Cancer Res Treat. 2025 Aug 4. doi: 10.1007/s10549-025-07798.
PubMed Abstract available

IWASE T, Sridhar N, Kai M, Dong W, et al
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study.
Breast Cancer Res Treat. 2025 Aug 2. doi: 10.1007/s10549-025-07795.
PubMed Abstract available

PHADKE S, Miller KD, Shah A, Danciu OC, et al
Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers.
Breast Cancer Res Treat. 2025;212:521-530.
PubMed Abstract available

ADAMS EJ, Zheng V, Cooper R, Warwar S, et al
Barriers to recruitment in a pre-surgical trial for ductal carcinoma in situ: an exploratory qualitative study of at-risk women, survivors, and providers.
Breast Cancer Res Treat. 2025;213:33-42.
PubMed Abstract available

DUAN C, Du J, Zhu L, Niu M, et al
The DCIS-IBC guide board on predicting postoperative upgrading in breast ductal carcinoma in situ: clinical insights from a multicenter study.
Breast Cancer Res Treat. 2025;213:101-114.
PubMed Abstract available

WILLIAMS T, Fine K, Duckworth E, Adam T, et al
Patient decision aids in breast surgery and breast reconstruction reduce decisional conflict: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2025;213:1-14.
PubMed Abstract available

KAUR M, Quirarte A, Shui AM, Vertido A, et al
Socioeconomic status impacts tumor biology, treatment, and outcomes in over 200,000 patients with invasive lobular carcinoma of the breast: an analysis of the National Cancer Database.
Breast Cancer Res Treat. 2025;213:161-169.
PubMed Abstract available

CHAPMAN JW, Bayani J, SenGupta S, Bartlett JMS, et al
Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole.
Breast Cancer Res Treat. 2025;213:51-61.
PubMed Abstract available

July 2025

KLEBANER D, Park N, Stone K, Riaz F, et al
Impact of timing and breastfeeding on postpartum breast cancer diagnostic patterns and outcomes.
Breast Cancer Res Treat. 2025 Jul 30. doi: 10.1007/s10549-025-07796.
PubMed Abstract available

GIUFFRE GM, Carbognin L, Masone Iacobucci G, Gistro M, et al
Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective study.
Breast Cancer Res Treat. 2025 Jul 29. doi: 10.1007/s10549-025-07788.
PubMed Abstract available

XUE M, Zhang N, Dong X, Tian Q, et al
The feasibility and safety of fasting-mimicking diet in breast cancer patients with chemotherapy in China.
Breast Cancer Res Treat. 2025 Jul 25. doi: 10.1007/s10549-025-07756.
PubMed Abstract available

Correction: 2024 RISE UP for breast cancer abstract collection.
Breast Cancer Res Treat. 2025 Jul 24. doi: 10.1007/s10549-025-07782.
PubMed

MADORSKY FELDMAN D, Sklair-Levy M, Laitman Y, Faermann R, et al
Breast biopsies and breast cancer risk in Israeli BRCA germline pathogenic variant carriers.
Breast Cancer Res Treat. 2025 Jul 22. doi: 10.1007/s10549-025-07787.
PubMed Abstract available

THOMAS MB, Ghaffar SA, Kadri H, Quinn CM, et al
Multi-level factors drive use of sentinel lymph node biopsy in older women with early-stage breast cancer.
Breast Cancer Res Treat. 2025 Jul 22. doi: 10.1007/s10549-025-07789.
PubMed Abstract available

GABRIELSEN E, Wilsgaard T, Frydenberg H, Lofterod T, et al
Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study.
Breast Cancer Res Treat. 2025 Jul 22. doi: 10.1007/s10549-025-07786.
PubMed Abstract available

ALKASSIS S, Suresh Y, Lipsyc-Sharf M, Zhang S, et al
Circulating tumor DNA detection of local recurrence in a patient with early stage triple-negative breast cancer.
Breast Cancer Res Treat. 2025 Jul 21. doi: 10.1007/s10549-025-07773.
PubMed Abstract available

BAE SY, Kim CW, Chin J, Lee JA, et al
Clinical subtypes and prognosis of invasive breast cancer with Paget's disease: a SEER study.
Breast Cancer Res Treat. 2025 Jul 18. doi: 10.1007/s10549-025-07784.
PubMed Abstract available

JIA H, Liu C, Lu Y, He X, et al
Body-mind exercise for cancer-related cognitive impairment in breast cancer patients: a network meta-analysis.
Breast Cancer Res Treat. 2025 Jul 17. doi: 10.1007/s10549-025-07774.
PubMed Abstract available

TSE SSW, Hircock C, Karam I, Soliman H, et al
Repeat lumpectomy and external beam radiation therapy for ipsilateral breast cancer recurrence: a systematic review.
Breast Cancer Res Treat. 2025 Jul 16. doi: 10.1007/s10549-025-07779.
PubMed Abstract available

KING A, Ortiz C, Goswami R, Kaufmann TL, et al
Time and location of specialty palliative care for women dying with metastatic breast cancer.
Breast Cancer Res Treat. 2025 Jul 15. doi: 10.1007/s10549-025-07780.
PubMed Abstract available

CHAUBAL R, Talker E, Chitra J, Kadam R, et al
Genomic landscape of hormone therapy-resistant HR-positive, HER2-negative breast cancer.
Breast Cancer Res Treat. 2025 Jul 12. doi: 10.1007/s10549-025-07759.
PubMed Abstract available

BREMS-ESKILDSEN AS, Kenholm J, Brixen AT, Ronlev JD, et al
A direct comparison of classical oral Navelbine vs metronomic Navelbine in metastatic breast cancer: results from the Danish Breast Cancer Group's (DBCG) NAME-trial.
Breast Cancer Res Treat. 2025 Jul 11. doi: 10.1007/s10549-025-07777.
PubMed Abstract available

KIM YY, Lee G, Jeon Y, Gong G, et al
SOD2 expression in patients with triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and prognosis.
Breast Cancer Res Treat. 2025 Jul 9. doi: 10.1007/s10549-025-07775.
PubMed Abstract available

BLANCO E, Acevedo J, Perez L, Herrera M, et al
Arsenic in drinking water and breast cancer: a case-control study from a high exposure area in Northern Chile.
Breast Cancer Res Treat. 2025 Jul 8. doi: 10.1007/s10549-025-07765.
PubMed Abstract available

MAHESWARAN S, Medford AJ, Stryjewski TP, Thai JN, et al
A 40-year-old woman with early-stage triple-negative breast cancer and a retinal lesion.
Breast Cancer Res Treat. 2025 Jul 7. doi: 10.1007/s10549-025-07770.
PubMed Abstract available

BHIMANI J, Wang P, Gallagher GB, O'Connell K, et al
Patient characteristics associated with conventional schedule vs. dose dense chemotherapy in women with stage I-IIIA breast cancer.
Breast Cancer Res Treat. 2025 Jul 6. doi: 10.1007/s10549-025-07764.
PubMed Abstract available

BAXTER SM, McShane CM, McIntosh SA, Bennett D, et al
Stage at diagnosis and breast cancer-specific mortality in breast cancer patients treated with antidepressants, anxiolytics, and antipsychotics: a population-based cohort study from Northern Ireland.
Breast Cancer Res Treat. 2025 Jul 5. doi: 10.1007/s10549-025-07766.
PubMed Abstract available

MEZZANOTTE-SHARPE J, Hsu CY, Choi D, Sheffield H, et al
Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers.
Breast Cancer Res Treat. 2025 Jul 4. doi: 10.1007/s10549-025-07758.
PubMed Abstract available

CHRISTENSEN RAG, Anderson GM, Kim SJ, Aminoleslami A, et al
Adherence to breast screening guidelines and breast cancer mortality: a population cohort study.
Breast Cancer Res Treat. 2025 Jul 3. doi: 10.1007/s10549-025-07754.
PubMed Abstract available

BETTARIGA F, Taaffe DR, Crespo-Garcia C, Clay TD, et al
A single bout of resistance or high-intensity interval training increases anti-cancer myokines and suppresses cancer cell growth in vitro in survivors of breast cancer.
Breast Cancer Res Treat. 2025 Jul 3. doi: 10.1007/s10549-025-07772.
PubMed Abstract available

RING A, Sutherland S, Harper-Wynne C, Owen J, et al
A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2-positive unresectable LA/MBC: final results of the ESTHER study.
Breast Cancer Res Treat. 2025;212:113-121.
PubMed Abstract available

NIERENBERG TC, Thomas SM, Halliday I, Botty van den Bruele A, et al
Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database study.
Breast Cancer Res Treat. 2025;212:161-172.
PubMed Abstract available

COSAR R, Sut N
Our response to the letter to the editor for the article "Comparison of survival between unilateral and bilateral breast cancers using propensity score matching: a retrospective single-center analysis".
Breast Cancer Res Treat. 2025;212:185-186.
PubMed Abstract available

JASPER JM, Vora H, Kantor O, McGrath M, et al
Management of ipsilateral breast tumor recurrence after prior breast conservation therapy.
Breast Cancer Res Treat. 2025;212:361-369.
PubMed Abstract available

AKTAS A, Gurleyik MG, Akkus D, Ucur Z, et al
Invasive lobular breast carcinoma variants; clinicopathological features and patient outcomes.
Breast Cancer Res Treat. 2025;212:347-359.
PubMed Abstract available

YAO J, Zhou W, Jia X, Zhu Y, et al
Machine learning prediction of pathological complete response to neoadjuvant chemotherapy with peritumoral breast tumor ultrasound radiomics: compare with intratumoral radiomics and clinicopathologic predictors.
Breast Cancer Res Treat. 2025;212:325-336.
PubMed Abstract available

YI ZL, Yang BB, Zhang JN, Zhao MJ, et al
Radiation recall dermatitis induced by abemaciclib with successful rechallenge: a case series and literature review.
Breast Cancer Res Treat. 2025;212:189-193.
PubMed Abstract available

June 2025

KOLBOW M, Luo Q, Cerrato Grande A, Marmor S, et al
The use of indocyanine green and technetium-99 for dual-tracer sentinel lymph node biopsy in breast cancer.
Breast Cancer Res Treat. 2025 Jun 27. doi: 10.1007/s10549-025-07767.
PubMed Abstract available

ALESSANDRA Z, Emilie L, Aline A, Marianne L, et al
Analysis of the impact of the COVID-19 pandemic on the stage at diagnosis in breast cancer patients at a French comprehensive cancer centre, through two different methods: a preliminary study.
Breast Cancer Res Treat. 2025 Jun 27. doi: 10.1007/s10549-025-07762.
PubMed Abstract available

ABRAHAO R, Ruddy KJ, Laurent CA, Chubak J, et al
Trastuzumab therapy and new-onset hypertension in adolescents and young adults with breast cancer.
Breast Cancer Res Treat. 2025 Jun 27. doi: 10.1007/s10549-025-07760.
PubMed Abstract available

FANNING JE, Chen A, Thomson S, Tillotson E, et al
The deltopectoral lymph node: a potential protective biomarker for breast cancer-related lymphedema.
Breast Cancer Res Treat. 2025 Jun 25. doi: 10.1007/s10549-025-07748.
PubMed Abstract available

ALHARBI M, Krishnan J, Roy AM, Patel A, et al
Area deprivation index and breast cancer outcomes among patients in Western New York.
Breast Cancer Res Treat. 2025 Jun 22. doi: 10.1007/s10549-025-07733.
PubMed Abstract available

BRAUN M, Hamann M, Hanusch C, Andrulat A, et al
Correction: Evaluating the impact of histological vs. nuclear grading on CPS + EG Score for HR + /HER2-early breast cancer.
Breast Cancer Res Treat. 2025 Jun 19. doi: 10.1007/s10549-025-07755.
PubMed

FRANKS J, Azuero A, Kenzik K, Jahan N, et al
Effect of pretreatment lab abnormalities on the time-to-treatment discontinuation and overall survival of metastatic breast cancer patients receiving CDK 4/6i, PI3Ki, and/or mTORi.
Breast Cancer Res Treat. 2025 Jun 18. doi: 10.1007/s10549-025-07751.
PubMed Abstract available

KERLIKOWSKE K, Abraham L, Sprague BL, Sattayapiwat O, et al
Mammographic calcifications association with risk of advanced breast cancer.
Breast Cancer Res Treat. 2025 Jun 17. doi: 10.1007/s10549-025-07753.
PubMed Abstract available

ROCQUE GB, Olguin EO, Shuey JM, Padalkar T, et al
Promoting resilience in stress management (PRISM) for patients with early stage breast cancer: a pilot feasibility study.
Breast Cancer Res Treat. 2025 Jun 16. doi: 10.1007/s10549-025-07741.
PubMed Abstract available

LIUTTI VT, do Vale DL, de Souza BL, Manea RRF, et al
Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2025 Jun 13. doi: 10.1007/s10549-025-07746.
PubMed Abstract available

HANNOUN-LEVI JM, Strnad V, Polgar C
Local treatment of ipsilateral breast cancer recurrence: a sensitive decision-making process.
Breast Cancer Res Treat. 2025 Jun 12. doi: 10.1007/s10549-025-07761.
PubMed

SHIN E, Cha YJ, Kim HM, Koo JS, et al
PD-L1 22C3 CPS in paired primary breast cancer and lung metastasis.
Breast Cancer Res Treat. 2025 Jun 11. doi: 10.1007/s10549-025-07757.
PubMed Abstract available

STENMARK TULLBERG A, Thurfjell V, Kovacs A, Micke P, et al
Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights from the randomized SweBCG91RT trial.
Breast Cancer Res Treat. 2025 Jun 9. doi: 10.1007/s10549-025-07744.
PubMed Abstract available

ULENE SR, Wang S, Cook JR, McAuley F, et al
Continuous glucose monitoring to characterize hyperglycemia during chemotherapy for early stage breast cancer.
Breast Cancer Res Treat. 2025 Jun 4. doi: 10.1007/s10549-025-07745.
PubMed Abstract available

LEE KT, Hu B, Martinez Tyson D, Geiss C, et al
A mixed-methods study characterizing experiences of medical oncologists' use of gonadotropin-releasing hormone agonists for treatment of breast cancer.
Breast Cancer Res Treat. 2025 Jun 3. doi: 10.1007/s10549-025-07734.
PubMed Abstract available

COHEN LN, Rogers CC, Lloren JIC, Kamaraju S, et al
National trends in neoadjuvant systemic therapy utilization in patients with early-stage HER2-positive breast cancer from 2016-2021: The impact of the KATHERINE trial.
Breast Cancer Res Treat. 2025 Jun 3. doi: 10.1007/s10549-025-07750.
PubMed Abstract available

WING SE, Liu Y, Zheng F, Hamm NC, et al
Insurer and patient costs for repeat breast surgery after initial lumpectomy for breast cancer.
Breast Cancer Res Treat. 2025 Jun 3. doi: 10.1007/s10549-025-07735.
PubMed Abstract available

DING K, Chen L, Levine KM, Sikora MJ, et al
FGFR4 in endocrine resistance: overexpression and estrogen regulation without direct causative role.
Breast Cancer Res Treat. 2025;211:501-515.
PubMed Abstract available

HAN R, Brogi E, Thompson D, El-Tamer M, et al
Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience.
Breast Cancer Res Treat. 2025;211:449-454.
PubMed Abstract available

BOTTY VAN DEN BRUELE A, Ren Y, Thomas SM, Ntowe KW, et al
High risk surveillance MRI may not be necessary in BRCA1/2 mutation carriers over 70 years old.
Breast Cancer Res Treat. 2025;211:421-429.
PubMed Abstract available

COLCIAGO RR, Ferrario F, Chissotti C, Rossano G, et al
Long-term outcomes of volume de-escalation for breast nodal irradiation.
Breast Cancer Res Treat. 2025;211:375-384.
PubMed Abstract available

DUGGIRALA N, Zhang S, Master A, Rao R, et al
Biology, care, and outcomes of gestational breast cancers: a review.
Breast Cancer Res Treat. 2025;211:547-559.
PubMed Abstract available

NEWMAN AM, Daly AE, Anderman KJ, Dang PA, et al
Timing of radiofrequency identification tag placement: can early placement save time and patient experience?
Breast Cancer Res Treat. 2025;211:669-674.
PubMed Abstract available

ZHANG C, Liu J, Gu T, Meng X, et al
Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: mechanism and safety evaluation.
Breast Cancer Res Treat. 2025;211:637-648.
PubMed Abstract available

BUZATTO IPC, Recife SA, Miguel L, Bonini RM, et al
Machine learning can reliably predict malignancy of breast lesions based on clinical and ultrasonographic features.
Breast Cancer Res Treat. 2025;211:581-593.
PubMed Abstract available

WEHBE A, Katlin F, Sharma E, Hans M, et al
Breast imaging recommendations for young females (age < 40 years) with >/= 20% lifetime breast cancer risk: practice patterns at a specialized clinic.
Breast Cancer Res Treat. 2025 Jun 1. doi: 10.1007/s10549-025-07738.
PubMed Abstract available

May 2025

MUSTAFA NM, Mustafa MT, Abushanab AK, Alakhras HM, et al
Efficacy and safety of entinostat plus exemestane in hormone receptor-positive breast cancer: a systematic review meta-analysis of randomized controlled trials.
Breast Cancer Res Treat. 2025 May 31. doi: 10.1007/s10549-025-07737.
PubMed Abstract available

BADER G, Quintanilha JCF, Veney D, Graf RP, et al
Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study.
Breast Cancer Res Treat. 2025 May 30. doi: 10.1007/s10549-025-07740.
PubMed Abstract available

MEDFORD AJ, Velimirovic M, Gefen Y, Niemierko A, et al
Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes.
Breast Cancer Res Treat. 2025 May 29. doi: 10.1007/s10549-025-07710.
PubMed Abstract available

GEMMILL JAL, Thompson P, Batiste R, Vacchi-Suzzi C, et al
Metastatic breast cancer through the Oncotype DX Breast Recurrence Score(R): insights from a small cohort study.
Breast Cancer Res Treat. 2025 May 28. doi: 10.1007/s10549-025-07736.
PubMed Abstract available

SPRIET J, Miled AB, Mailliez A, Bonnier S, et al
Breast magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy and immunotherapy in early triple-negative breast cancer patients: prediction of pathological response and performance of ultrafast sequences.
Breast Cancer Res Treat. 2025 May 28. doi: 10.1007/s10549-025-07650.
PubMed Abstract available

FREITAS AJA, Causin RL, Calfa S, Santana IVV, et al
Exploring the Nottingham classification: assessing gene expression profiles in breast cancer patients and their association with outcomes.
Breast Cancer Res Treat. 2025 May 28. doi: 10.1007/s10549-025-07718.
PubMed Abstract available

SIREK A, Sirek T, Nowakowski R, Borawski P, et al
Subtype-specific dysregulation of biogenic amine-related genes and miRNAs in breast cancer: identification of DRD2, HRH2, and HRH4 as potential therapeutic targets in TNBC and HER2+ subtypes.
Breast Cancer Res Treat. 2025 May 27. doi: 10.1007/s10549-025-07732.
PubMed Abstract available

KOSTOV AM, Jensen MB, Ejlertsen B, Thomassen M, et al
Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study.
Breast Cancer Res Treat. 2025 May 23. doi: 10.1007/s10549-025-07726.
PubMed Abstract available

GRACIANO N, Lopez L, Rodriguez CA, Montoya K, et al
Effect of chemotherapy timing in triple-negative breast cancer: a real-world evidence study.
Breast Cancer Res Treat. 2025 May 21. doi: 10.1007/s10549-025-07716.
PubMed Abstract available

WADDEN E, Yogeswaran V, Ray RM, Vasbinder A, et al
Social determinants of cardiovascular disease in women with and without breast cancer.
Breast Cancer Res Treat. 2025 May 21. doi: 10.1007/s10549-025-07731.
PubMed Abstract available

LORENTZEN EH, Chen YJ, Jones AL, Kantor O, et al
Omission of multimodal therapy in older adults with high-risk breast cancer.
Breast Cancer Res Treat. 2025 May 20. doi: 10.1007/s10549-025-07728.
PubMed Abstract available

ARIF S, Muhammad N, Ang BH, Naeemi H, et al
Predicting the likelihood of carrying BRCA1 or BRCA2 pathogenic variants in high-risk Pakistani breast cancer patients.
Breast Cancer Res Treat. 2025 May 20. doi: 10.1007/s10549-025-07724.
PubMed Abstract available

PEREZ-MORENO E, Ortega-Hernandez V, Zavala VA, Gamboa J, et al
Suppression of breast cancer metastatic behavior by microRNAs targeting EMT transcription factors. A relevant participation of miR-196a-5p and miR-22-3p in ZEB1 expression.
Breast Cancer Res Treat. 2025 May 18. doi: 10.1007/s10549-025-07723.
PubMed Abstract available

ARRATO NA, Soo MS, Wren AA, Stalls JM, et al
Impact of loving-kindness meditation intervention vs. music intervention during biopsy on adherence to recommended breast cancer screening.
Breast Cancer Res Treat. 2025 May 16. doi: 10.1007/s10549-025-07721.
PubMed Abstract available

HADIDCHI R, Duong KS, Hou J, Maldjian T, et al
COVID-19 pandemic interruption of breast cancer screening is linked to clinical upstaging at presentation: the roles of demographics, socioeconomic status and unmet social needs.
Breast Cancer Res Treat. 2025 May 15. doi: 10.1007/s10549-025-07713.
PubMed Abstract available

BECK AS, Earley M, Troxell M, Tsai J, et al
Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer.
Breast Cancer Res Treat. 2025 May 15. doi: 10.1007/s10549-025-07722.
PubMed Abstract available

AJJAWI I, Rios A, Wei W, Park TS, et al
Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer.
Breast Cancer Res Treat. 2025 May 15. doi: 10.1007/s10549-025-07725.
PubMed Abstract available

WOOLPERT KM, Ahern TP, Baurley JW, Maliniak ML, et al
Genetic variants in tamoxifen metabolism and early treatment discontinuation among premenopausal breast cancer patients.
Breast Cancer Res Treat. 2025 May 14. doi: 10.1007/s10549-025-07719.
PubMed Abstract available

WOOSTER M, Chen L, Accordino MK, Sathe C, et al
Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer.
Breast Cancer Res Treat. 2025 May 13. doi: 10.1007/s10549-025-07714.
PubMed Abstract available

IWAI C, Miyawaki A, Konishi T, Okada A, et al
Ocular adverse events of perioperative adjuvant docetaxel vs paclitaxel for breast cancer: propensity-score overlap-weighted analysis.
Breast Cancer Res Treat. 2025 May 13. doi: 10.1007/s10549-025-07720.
PubMed Abstract available

RADWAN RM, Schuster ALR, Hertz DL, Lustberg MB, et al
Tolerance for chemotherapy-induced peripheral neuropathy among women with metastatic breast cancer: a discrete-choice experiment.
Breast Cancer Res Treat. 2025 May 13. doi: 10.1007/s10549-025-07715.
PubMed Abstract available

HEGER PW, Hotz D, Kalder M, Kostev K, et al
Association between Extract Rheum rhaponticum 731 (ERr 731) prescription and subsequent breast cancer.
Breast Cancer Res Treat. 2025 May 13. doi: 10.1007/s10549-025-07711.
PubMed Abstract available

KOOIJMAN MML, Hage JJ, Scholten AN, van Duijnhoven FH, et al
Advantages of immediate implant-based breast reconstruction over delayed breast reconstruction in women treated with postmastectomy radiotherapy for breast cancer.
Breast Cancer Res Treat. 2025 May 12. doi: 10.1007/s10549-025-07690.
PubMed Abstract available

JANKOWSKI C, Houvenaeghel G, Renaudeau C, Leveque J, et al
How can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?
Breast Cancer Res Treat. 2025 May 6. doi: 10.1007/s10549-025-07642.
PubMed Abstract available

GULTEKIN SC, Karadibak D, Cakir AB, Guc ZG, et al
Self-administered versus lymphedema therapist-administered complex decongestive therapy protocol in breast cancer-related lymphedema: a non-inferiority randomized controlled trial with three-month follow-up.
Breast Cancer Res Treat. 2025 May 6. doi: 10.1007/s10549-025-07709.
PubMed Abstract available

2024 RISE UP for breast cancer abstract collection.
Breast Cancer Res Treat. 2025 May 6. doi: 10.1007/s10549-025-07692.
PubMed

LEE SF, Wong HCY, Robijns J, Ciocon SLB, et al
Chronic skin toxicities in breast cancer survivors: a systematic review and meta-analysis of radiotherapy techniques.
Breast Cancer Res Treat. 2025 May 5. doi: 10.1007/s10549-025-07700.
PubMed Abstract available

WOCKEL A, Park-Simon TW, Korfel A, Raab K, et al
Correction: Preferences of patients with high-risk HR+/HER2- breast cancer for adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study from Germany.
Breast Cancer Res Treat. 2025;211:273-275.
PubMed

OZEN A, Halici M
Letter to the editor regarding the article "Comparison of survival between unilateral and bilateral breast cancers using propensity score matching: a retrospective single-center analysis".
Breast Cancer Res Treat. 2025;211:271-272.
PubMed Abstract available

POELHEKKEN K, Dorrius MD, Dibden A, Duffy SW, et al
The natural history of ductal carcinoma in situ: development, validation, and estimated outcomes of the SimDCIS model.
Breast Cancer Res Treat. 2025;211:223-231.
PubMed Abstract available

SAFGREN SL, Suman VJ, Leon Ferre RA, Kosel ML, et al
The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen.
Breast Cancer Res Treat. 2025;211:261-270.
PubMed Abstract available

HEINDL F, Schiel J, Hack CC, Amann N, et al
Malignant upgrade in lesions of uncertain malignant potential in the breast (B3 lesions) - is open excision always necessary?
Breast Cancer Res Treat. 2025;211:173-183.
PubMed Abstract available

KHUBCHANDANI JA, Kc M, Dey P, Proussaloglou EM, et al
Racial and ethnic disparities in conversion to mastectomy following lumpectomy.
Breast Cancer Res Treat. 2025;211:99-110.
PubMed Abstract available

PADILLA DB, Tsai J, Beck AS, Wapnir IL, et al
Lumpectomy surgery for large ductal carcinoma in situ.
Breast Cancer Res Treat. 2025;211:51-58.
PubMed Abstract available

FRIEDEWALD SM, Sieniek M, Jansen S, Mahvar F, et al
Triaging mammography with artificial intelligence: an implementation study.
Breast Cancer Res Treat. 2025;211:1-10.
PubMed Abstract available

April 2025

MAURER C, Agostinetto E, Ameye L, Lambertini M, et al
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial.
Breast Cancer Res Treat. 2025 Apr 28. doi: 10.1007/s10549-025-07699.
PubMed Abstract available

SANVISENS A, Vidal-Vila A, Puigdemont M, Vinas G, et al
Population-based analysis of breast cancer incidence and mortality: overall and age-specific temporal trends over 40-year period in Girona, Spain.
Breast Cancer Res Treat. 2025 Apr 25. doi: 10.1007/s10549-025-07704.
PubMed Abstract available

VIDULA N, Blouch E, Hesler K, Niemierko A, et al
Brain metastases in patients with metastatic breast cancer and BRCA1/2 mutations in cell-free DNA.
Breast Cancer Res Treat. 2025 Apr 25. doi: 10.1007/s10549-025-07705.
PubMed Abstract available

WILKERSON AD, Obi M, Gentle C, Wei W, et al
First mammogram-detected cancers portend worse survival in young women diagnosed with breast cancer.
Breast Cancer Res Treat. 2025 Apr 25. doi: 10.1007/s10549-025-07703.
PubMed Abstract available

FEST SN, Farland LV, Doody DR, Eliassen AH, et al
Correction: Hormone-associated dietary patterns and premenopausal breast cancer risk.
Breast Cancer Res Treat. 2025 Apr 24. doi: 10.1007/s10549-025-07706.
PubMed

PERDRIX A, Olympios N, Rouvet J, Degremont M, et al
Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy.
Breast Cancer Res Treat. 2025 Apr 22. doi: 10.1007/s10549-025-07702.
PubMed Abstract available

ISIK B, Davey MG, Jaffer AA, Buckley J, et al
Correction: Assessing the clinical utility of pre-operative neutrophil-lymphocyte ratio as a predictor of clinicopathological parameters in patients being treated for primary breast cancer.
Breast Cancer Res Treat. 2025 Apr 18. doi: 10.1007/s10549-025-07698.
PubMed

GHOLAMI S, Saffarfar H, Mehraban MR, Ardabili NS, et al
Targeting breast cancer: the promise of phage-based nanomedicines.
Breast Cancer Res Treat. 2025 Apr 17. doi: 10.1007/s10549-025-07696.
PubMed Abstract available

LAU C, LaBorde K, Fatima B, Alfartosy SS, et al
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer.
Breast Cancer Res Treat. 2025 Apr 16. doi: 10.1007/s10549-025-07701.
PubMed Abstract available

SHIGEMATSU H, Takaya M, Suzuki K, Fujimoto M, et al
Exploring the possibility of omitting axillary surgery in patients with clinical node-positive breast cancer achieving ypT0 after neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2025 Apr 12. doi: 10.1007/s10549-025-07697.
PubMed Abstract available

MCQUEEN SRA, Chin WQ, Cunliffe HE, McDonald FJ, et al
Stable overexpression of the epithelial sodium channel alpha subunit reduces migration and proliferation in breast cancer cells.
Breast Cancer Res Treat. 2025 Apr 12. doi: 10.1007/s10549-025-07667.
PubMed Abstract available

TURKOGLU E, Akdag Topal G, Yildirim S, Kinikoglu O, et al
Comparison of paclitaxel and docetaxel in dual HER2 blockade: efficacy and safety in neoadjuvant treatment of HER2-positive breast cancer.
Breast Cancer Res Treat. 2025 Apr 11. doi: 10.1007/s10549-025-07694.
PubMed Abstract available

CHIEN YN, Lin LY, Lin YC, Hsieh YC, et al
Correction: Taxane/anthracycline combinations reduced incidence of breast cancer recurrence in young women across molecular subtypes: a real-world evidence of Taiwan from 2011 to 2019.
Breast Cancer Res Treat. 2025 Apr 10. doi: 10.1007/s10549-025-07691.
PubMed

DIAO B, Cai Y, Song D, Hu Y, et al
A potential therapeutic molecule target: lncRNA AK023507 inhibits the metastasis of breast cancer by regulating the WNT/DOCK4/beta-catenin axis.
Breast Cancer Res Treat. 2025 Apr 9. doi: 10.1007/s10549-025-07695.
PubMed Abstract available

HIDAKA K, Goto-Yamaguchi L, Sueta A, Tomiguchi M, et al
Identifying gene expression predictive of response to neoadjuvant endocrine therapy in early breast cancer.
Breast Cancer Res Treat. 2025 Apr 9. doi: 10.1007/s10549-025-07693.
PubMed Abstract available

JUNG W, Hubbard RA, Smith AM, Ko K, et al
Risk-guided cardioprotection with carvedilol in patients with breast cancer (CCT guide): a phase 1 randomized clinical trial.
Breast Cancer Res Treat. 2025 Apr 2. doi: 10.1007/s10549-025-07636.
PubMed Abstract available

POTRONY M, Morales-Romero B, Moreno L, Pastor B, et al
Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice.
Breast Cancer Res Treat. 2025;210:507-519.
PubMed Abstract available

MAKINELI S, Vriens MR, van Diest PJ, Witkamp AJ, et al
Intraductal laser ablation during ductoscopy in patients with pathological nipple discharge.
Breast Cancer Res Treat. 2025;210:329-335.
PubMed Abstract available

CHEN Q, Elwood M, Campbell I, Cavadino A, et al
Incidence trends of ductal carcinoma in situ in New Zealand women between 1999 and 2022.
Breast Cancer Res Treat. 2025;210:439-449.
PubMed Abstract available

QIU ZX, Xie LY, Li YZ, Zhang ZC, et al
L-ICG as an optical agent to improve intraoperative margin detection in breast-conserving surgery: a prospective study.
Breast Cancer Res Treat. 2025;210:709-718.
PubMed Abstract available

ERIN N, Tavsan E, Haksever S, Yerlikaya A, et al
Targeting BMP-1 enhances anti-tumoral effects of doxorubicin in metastatic mammary cancer: common and distinct features of TGF-beta inhibition.
Breast Cancer Res Treat. 2025;210:563-574.
PubMed Abstract available

BAHL M, Kshirsagar A, Pohlman S, Lehman CD, et al
Traditional versus modern approaches to screening mammography: a comparison of computer-assisted detection for synthetic 2D mammography versus an artificial intelligence algorithm for digital breast tomosynthesis.
Breast Cancer Res Treat. 2025;210:529-537.
PubMed Abstract available

OZLER T, Cosar R, Sut N, Nurlu D, et al
Comparison of survival between unilateral and bilateral breast cancers using propensity score matching: a retrospective single-center analysis.
Breast Cancer Res Treat. 2025;210:673-686.
PubMed Abstract available

STUTZ K, Mason H, Niakan S, Coulter AP, et al
The impact of surgical technique on the number of sentinel lymph nodes removed and its effect on complication rates.
Breast Cancer Res Treat. 2025;210:605-613.
PubMed Abstract available

BAYRAM A, Bagbudar S, Karanlik H, Cabioglu N, et al
Estrogen receptor positivity in stromal cells of the tumor bed predicts the response to neoadjuvant chemotherapy for breast carcinoma.
Breast Cancer Res Treat. 2025;210:627-633.
PubMed Abstract available

KORPINEN K, Autere TA, Tuominen J, Loyttyniemi E, et al
Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma.
Breast Cancer Res Treat. 2025;210:463-475.
PubMed Abstract available

QI M, Gao S, Zhang Z, Lang R, et al
Secretory breast carcinoma: a multicenter clinicopathologic study of 80 cases with emphasis on prognostic analysis and chemotherapy benefit.
Breast Cancer Res Treat. 2025;210:451-461.
PubMed Abstract available

BERLANGA L, Lotersztein V, Aranda EI, Cerretini R, et al
Contribution of large genomic rearrangements in BRCA1/2 genes and CHEK2 1100delC allele variant to the development of breast/ovarian cancer in Argentinian population.
Breast Cancer Res Treat. 2025;210:385-391.
PubMed Abstract available

SUMAN L, D'Ascoli E, Depretto C, Berenghi A, et al
Diagnostic performance of MRI-guided vacuum-assisted breast biopsy (VABB): an essential but still underused technique.
Breast Cancer Res Treat. 2025;210:417-423.
PubMed Abstract available

AL HASAN SM, Matthew KA, Toriola AT
Education and mammographic breast density.
Breast Cancer Res Treat. 2025;210:377-384.
PubMed Abstract available

TARIQ N, Dani S, Makhija P, Warren MV, et al
Breast hamartomas associated with epithelial atypia and malignancy: are there specific clinical, radiological or pathological features that identify at risk patients?
Breast Cancer Res Treat. 2025;210:393-404.
PubMed Abstract available

YOON KH, Ahn SH, Shin HC, Koh HW, et al
Oncoplastic breast reconstruction with single-port laparoscopically harvested omental flap: insights from a ten-year tertiary center experience.
Breast Cancer Res Treat. 2025;210:355-364.
PubMed Abstract available

ZAMBRANO-O YT, Mejia-Garcia A, Morales PD, Tsao HM, et al
Inference of genetic ancestry from a multi-gene cancer panel in Colombian women with cancer.
Breast Cancer Res Treat. 2025;210:251-259.
PubMed Abstract available

March 2025

FEST SN, Farland LV, Doody DR, Eliassen AH, et al
Hormone-associated dietary patterns and premenopausal breast cancer risk.
Breast Cancer Res Treat. 2025 Mar 30. doi: 10.1007/s10549-025-07689.
PubMed Abstract available

BRAUN M, Hamann M, Hanusch C, Andrulat A, et al
Evaluating the impact of histological vs. nuclear grading on CPS + EG Score for HR + /HER2-early breast cancer.
Breast Cancer Res Treat. 2025 Mar 28. doi: 10.1007/s10549-025-07685.
PubMed Abstract available

NIKSERESHT S, Shewell LK, Day CJ, Jennings MP, et al
Improved breast cancer diagnosis using a CA15-3 capture antibody-lectin sandwich assay.
Breast Cancer Res Treat. 2025 Mar 27. doi: 10.1007/s10549-025-07672.
PubMed Abstract available

ZHANG W, Shi S, Hong Y
Comment on ''patient preferences for CDK4/6 inhibitor treatments in HR + /HER2- early breast cancer: a discrete choice survey study''.
Breast Cancer Res Treat. 2025 Mar 27. doi: 10.1007/s10549-025-07673.
PubMed

SUTTON AL, Zhao J, He J, Tossas KY, et al
Examining factors associated with experiencing cardiac arrhythmias in Black and White breast cancer survivors who received anthracyclines or trastuzumab.
Breast Cancer Res Treat. 2025 Mar 27. doi: 10.1007/s10549-025-07671.
PubMed Abstract available

SHINN E, Zahrieh D, DeMichele A, Zdenkowski N, et al
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.
Breast Cancer Res Treat. 2025 Mar 27. doi: 10.1007/s10549-025-07653.
PubMed Abstract available

MODI S, Zhang S, Byng D, Hunter S, et al
Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: a US real-world cohort study.
Breast Cancer Res Treat. 2025 Mar 25. doi: 10.1007/s10549-025-07649.
PubMed Abstract available

SCHONBERG MA, Wolfson EA, Eliassen AH, Rosner BA, et al
Population attributable risk of a competing-risk model for breast cancer and non-breast cancer death among women >/= 65 years.
Breast Cancer Res Treat. 2025 Mar 25. doi: 10.1007/s10549-025-07683.
PubMed Abstract available

VENKATARAMAN J, Mokbel K
Critical appraisal of a data mining model for predicting nodal response to neoadjuvant treatment in breast cancer.
Breast Cancer Res Treat. 2025 Mar 21. doi: 10.1007/s10549-025-07686.
PubMed

LIU H, Kou F, Hu L, Sun J, et al
Potential candidates for adjuvant olaparib treatment in operable breast cancer patients with germline BRCA1/2 pathogenic variants after neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2025 Mar 19. doi: 10.1007/s10549-025-07687.
PubMed Abstract available

WANG J, Katsaros D, Wang Z, Ma L, et al
Mitochondrial tRNA fragment, mt-tRF-Tyr-GTA-001 (tRF-21-X3OJI8EWB), in breast cancer and its potential clinical implications.
Breast Cancer Res Treat. 2025 Mar 18. doi: 10.1007/s10549-025-07682.
PubMed Abstract available

KRONEN EA, Chervu NL, Ng AP, Lee H, et al
National trends and survival outcomes associated with non-guideline-concordant treatment of inflammatory breast cancer.
Breast Cancer Res Treat. 2025 Mar 18. doi: 10.1007/s10549-025-07669.
PubMed Abstract available

GAO Y, Zhang X, Ding M, Fu Z, et al
Targeting "don't eat me" signal: breast cancer immunotherapy.
Breast Cancer Res Treat. 2025 Mar 18. doi: 10.1007/s10549-025-07659.
PubMed Abstract available

AHN JH, Lee SJ, Yang SH, Kim JY, et al
Clinical treatment score post-5 years and survival benefit from extended endocrine therapy for breast cancer patients under and over 50 years of age.
Breast Cancer Res Treat. 2025 Mar 17. doi: 10.1007/s10549-025-07679.
PubMed Abstract available

XIE LX, Liu Y, Yang YG, Wang JN, et al
Postoperative radiotherapy improves long-term survival in HER2-positive metastatic breast cancer: real-world evidence from the latest SEER database.
Breast Cancer Res Treat. 2025 Mar 14. doi: 10.1007/s10549-025-07665.
PubMed Abstract available

GHORBANI M, Namazi S, Dehghani M, Razi F, et al
Identifying the potential mediators of pathological complete response to neoadjuvant chemotherapy among TACR1 gene polymorphisms: a study on breast cancer patients.
Breast Cancer Res Treat. 2025 Mar 13. doi: 10.1007/s10549-025-07674.
PubMed Abstract available

BASMADJIAN RB, Xu Y, Quan ML, Lupichuk S, et al
Evaluating PREDICT and developing outcome prediction models in early-onset breast cancer using data from Alberta, Canada.
Breast Cancer Res Treat. 2025 Mar 12. doi: 10.1007/s10549-025-07654.
PubMed Abstract available

DE VIS JB, Wang C, Nguyen KV, Sun L, et al
Body composition as a potential biomarker of recurrence risk in patients with triple-negative breast cancer.
Breast Cancer Res Treat. 2025 Mar 11. doi: 10.1007/s10549-025-07675.
PubMed Abstract available

BELLINI A, Keegan THM, Li Q, Jacinto A, et al
The effect of body mass index on breast cancer stage and breast cancer specific survival.
Breast Cancer Res Treat. 2025 Mar 10. doi: 10.1007/s10549-025-07678.
PubMed Abstract available

ZHAN H, Antony VM, Tang H, Theriot J, et al
PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence.
Breast Cancer Res Treat. 2025 Mar 10. doi: 10.1007/s10549-025-07660.
PubMed Abstract available

LI L, Zhang Z, Huang N, Ren J, et al
IGF1R activates FOXP3-beta-catenin signaling to promote breast cancer development.
Breast Cancer Res Treat. 2025 Mar 7. doi: 10.1007/s10549-025-07663.
PubMed Abstract available

NAKAUCHI C, Masunaga N, Kagara N, Oshiro C, et al
Development of a prediction model for ctDNA detection (Cir-Predict) in breast cancer.
Breast Cancer Res Treat. 2025 Mar 7. doi: 10.1007/s10549-025-07647.
PubMed Abstract available

MCCANN KE, Osman N, Cannon J, Brent L, et al
Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study.
Breast Cancer Res Treat. 2025 Mar 6. doi: 10.1007/s10549-025-07656.
PubMed Abstract available

JUNG W, Park SH, Park YM, Song YM, et al
Correction: Weight change and cardiovascular disease incidence in breast cancer survivors: a nationwide cohort study.
Breast Cancer Res Treat. 2025 Mar 6. doi: 10.1007/s10549-025-07655.
PubMed

'T HART D, Marriott R, Stone J
Perceptions of breast cancer risk after breast density notification in a population-based screening program.
Breast Cancer Res Treat. 2025 Mar 6. doi: 10.1007/s10549-025-07662.
PubMed Abstract available

BERNSTEIN-MOLHO R, Haisraely O, Galper S, Abu-Shhada N, et al
The impact of loco-regional treatment on ipsilateral breast cancer recurrence and outcomes in carriers of BRCA1/2 pathogenic variants.
Breast Cancer Res Treat. 2025 Mar 5. doi: 10.1007/s10549-025-07658.
PubMed Abstract available

BRABENDER D, Hossino D, Kim S, Jayich M, et al
Factors associated with locoregional recurrence after neoadjuvant chemotherapy for breast cancer in a safety-net medical center.
Breast Cancer Res Treat. 2025 Mar 4. doi: 10.1007/s10549-025-07668.
PubMed Abstract available

HARDY ABELOOS C, Gurewitz J, Xiao J, Darvishian F, et al
Is the risk of local recurrence higher for microinvasive breast cancer vs. early stage invasive breast cancer?
Breast Cancer Res Treat. 2025 Mar 3. doi: 10.1007/s10549-025-07664.
PubMed Abstract available

February 2025

KIM SH, Park GE, Bertrand KA, Sandler DP, et al
Mammographic density as a predictor of invasive breast cancer and ductal carcinoma in situ in over six million South Korean women.
Breast Cancer Res Treat. 2025 Feb 28. doi: 10.1007/s10549-025-07648.
PubMed Abstract available

SULLIVAN M, Lei X, Karuturi M, Malinowski C, et al
Use of adjuvant capecitabine in older patients with early-stage triple-negative breast cancer.
Breast Cancer Res Treat. 2025 Feb 28. doi: 10.1007/s10549-025-07637.
PubMed Abstract available

TERVASMAKI A, Kumpula TA, Grip M, Koivuluoma S, et al
Population-based study of recurrent DNA damage response gene variants in breast cancer cases.
Breast Cancer Res Treat. 2025 Feb 26. doi: 10.1007/s10549-025-07634.
PubMed Abstract available

CHANDEKAR KR, Satapathy S, Dharmashaktu Y, Ballal S, et al
Somatostatin receptor-targeted theranostics in patients with estrogen receptor-positive metastatic breast cancer-a prospective exploratory study.
Breast Cancer Res Treat. 2025 Feb 26. doi: 10.1007/s10549-025-07651.
PubMed Abstract available

RANDALL ARMEL S, Malcolmson J, Volenik A, Maganti M, et al
Genetic counseling referral rates and genetic testing outcomes in women with young breast cancer: a 20-year Canadian review.
Breast Cancer Res Treat. 2025 Feb 22. doi: 10.1007/s10549-025-07646.
PubMed Abstract available

KIMURA T, Takami T, Piao Y, Wang M, et al
Treatment patterns and clinical outcomes in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer treated with chemotherapy: a large-scale data analysis using the Japanese claims databas
Breast Cancer Res Treat. 2025 Feb 20. doi: 10.1007/s10549-025-07640.
PubMed Abstract available

BANYS-PALUCHOWSKI M, Hartmann S, Basali T, Gasparri ML, et al
Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer-a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial.
Breast Cancer Res Treat. 2025 Feb 20. doi: 10.1007/s10549-025-07635.
PubMed Abstract available

DING X, Wang Q, Kan H, Zhao F, et al
The regulation mechanism of perceived stress on cognitive function of patients with breast cancer undergoing chemotherapy: a multiple mediation analysis.
Breast Cancer Res Treat. 2025 Feb 20. doi: 10.1007/s10549-025-07641.
PubMed Abstract available

WOCKEL A, Park-Simon TW, Korfel A, Raab K, et al
Preferences of patients with high-risk HR + /HER2- breast cancer for adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study from Germany.
Breast Cancer Res Treat. 2025 Feb 20. doi: 10.1007/s10549-025-07622.
PubMed Abstract available

REAM M, Plotke R, Taub CJ, Borowsky PA, et al
Cognitive behavioral stress management effects on cancer-related distress and neuroendocrine signaling in breast cancer: differential effects by neighborhood disadvantage.
Breast Cancer Res Treat. 2025 Feb 18. doi: 10.1007/s10549-025-07631.
PubMed Abstract available

DESAI R, Jain A
Long-term benefits of exercise interventions during chemotherapy in breast cancer: insights from the optitrain trial calling for longitudinal studies.
Breast Cancer Res Treat. 2025 Feb 17. doi: 10.1007/s10549-025-07638.
PubMed

HOLZEL D, Schlesinger-Raab A, Schubert-Fritschle G, Halfter K, et al
Prolonged time to breast cancer surgery and the risk of metastasis: an explorative simulation analysis using epidemiological data from Germany and the USA.
Breast Cancer Res Treat. 2025 Feb 17. doi: 10.1007/s10549-025-07630.
PubMed Abstract available

HUANG Z, Liu Y, Li S, Li Y, et al
IHC4 and COMBINE scores for enhanced prognostic stratification in HR+/HER2- breast cancer patients after neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2025 Feb 15. doi: 10.1007/s10549-025-07645.
PubMed Abstract available

ALBESHAN SM, Almuqbil MM, Elsharkawi MM, Nassri H, et al
Outcomes of the Saudi breast cancer early detection program: a nine-year analysis (2012-2020).
Breast Cancer Res Treat. 2025 Feb 14. doi: 10.1007/s10549-025-07633.
PubMed Abstract available

DAI YW, Wu ZX, Cheng Y, Wu HD, et al
Formosanin C inhibits triple-negative breast cancer progression by suppressing the phosphorylation of STAT3 and the polarization of M2 macrophages.
Breast Cancer Res Treat. 2025 Feb 14. doi: 10.1007/s10549-025-07623.
PubMed Abstract available

SUBELACK J, Morant R, Blum M, Eichenberger A, et al
Risk factors for interval breast cancer: insights from a decade of a mammography screening program.
Breast Cancer Res Treat. 2025 Feb 12. doi: 10.1007/s10549-025-07619.
PubMed Abstract available

FENG X, Deng Z, McCullough MS, May BJ, et al
The impact of cardiovascular risk factors on cancer progression: a prospective study in female breast cancer survivors.
Breast Cancer Res Treat. 2025 Feb 10. doi: 10.1007/s10549-025-07611.
PubMed Abstract available

CHEN N, Matossian M, Saha P, Rampurwala M, et al
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.
Breast Cancer Res Treat. 2025 Feb 10. doi: 10.1007/s10549-025-07626.
PubMed Abstract available

MAYER EL, Smith ML, Guerin A, Latremouille-Viau D, et al
Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2- early breast cancer: a discrete choice survey study.
Breast Cancer Res Treat. 2025 Feb 7. doi: 10.1007/s10549-025-07627.
PubMed Abstract available

JOGENDRAN M, Flemming JA, Djerboua M, Korzeniowski M, et al
The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study.
Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-025-07612.
PubMed Abstract available

COOPER K, Nalbant G, Essat M, Harnan S, et al
Gene expression profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review.
Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-024-07596.
PubMed Abstract available

JANSEN BAM, Bargon CA, Bouman MA, van der Molen DRM, et al
Patient-reported outcomes after immediate and delayed DIEP-flap breast reconstruction in the setting of post-mastectomy radiation therapy-results of the multicenter UMBRELLA breast cancer cohort.
Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-025-07613.
PubMed Abstract available

BONADIO RC, Tavares MC, Balint FC, de Sousa IM, et al
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study.
Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-025-07628.
PubMed Abstract available

PARK E, Peterson L, McKeon S, Fiala MA, et al
Returning to work after breast cancer: a longitudinal analysis of employment and financial hardship.
Breast Cancer Res Treat. 2025 Feb 2. doi: 10.1007/s10549-025-07624.
PubMed Abstract available

HASHEMI MH, Moaiery H, Nikkhoo B, Zamani F, et al
Molecular Dynamics of Breast Cancer Subtypes: The Role of FAM83H-AS1 Long Non-coding RNA in Breast Cancer Metastasis.
Breast Cancer Res Treat. 2025 Feb 1. doi: 10.1007/s10549-024-07603.
PubMed Abstract available

ERGAS IJ, Cheng RK, Roh JM, Kresovich JK, et al
Diet quality and cardiometabolic health in breast cancer survivors: the Pathways Study.
Breast Cancer Res Treat. 2025 Feb 1. doi: 10.1007/s10549-025-07629.
PubMed Abstract available

NEUNER JM, Stolley M, Kamaraju S, Tiegs J, et al
The association of distress and depression screening measures and other electronic health record information with adjuvant endocrine therapy persistence.
Breast Cancer Res Treat. 2025;209:541-552.
PubMed Abstract available

LONG R, Luo Y, Cao M, Cao K, et al
Malignancy risk stratification prediction of BI-RADS 4B calcifications based on contrast-enhanced mammographic features: a multicenter study.
Breast Cancer Res Treat. 2025;210:135-145.
PubMed Abstract available

LEE CW, Shin HJ, Kim HJ, Baek S, et al
Performance of high-resolution diffusion-weighted magnetic resonance imaging for detecting clinically occult early breast cancers: a multi-reader study.
Breast Cancer Res Treat. 2025;210:71-86.
PubMed Abstract available

SAKATANI T, Tsuda H, Yoshida M, Honma N, et al
Current status and challenges in HER2 IHC assessment: scoring survey results in Japan.
Breast Cancer Res Treat. 2025;210:27-36.
PubMed Abstract available

KUO MC, Sims J, Solis OK, Meszoely IM, et al
Disease recurrence in patients undergoing mastectomy for ductal carcinoma in situ.
Breast Cancer Res Treat. 2025;209:675-679.
PubMed Abstract available

CHIKARMANE SA, Gibson A, Chesebro AL, Giess CS, et al
Frequency and outcomes of new or suspicious MRI findings on breast MRI for patients on neoadjuvant therapy.
Breast Cancer Res Treat. 2025;209:521-531.
PubMed Abstract available

January 2025

LIU G, Pan LZ, Chen J, Ma J, et al
Unveiling the role of PANoptosis-related genes in breast cancer: an integrated study by multi-omics analysis and machine learning algorithms.
Breast Cancer Res Treat. 2025 Jan 28. doi: 10.1007/s10549-025-07620.
PubMed Abstract available

STEARNS V, Chen R, Blackford AL, Saylor E, et al
The Johns Hopkins Hope at Hopkins Clinic: supporting the comprehensive needs of individuals with metastatic breast cancer.
Breast Cancer Res Treat. 2025 Jan 27. doi: 10.1007/s10549-024-07591.
PubMed Abstract available

FEFFERMAN ML, Chan K, Cotler J, Thompson DM, et al
Did the COVID-19 consortium recommendations impact the treatment of breast cancer during the COVID-19 pandemic?
Breast Cancer Res Treat. 2025 Jan 26. doi: 10.1007/s10549-025-07617.
PubMed Abstract available

DOYLE C, Lohmann AE, Iqbal N, Henning JW, et al
A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy +/- targeted therapy in HR + HER2-negative advanced br
Breast Cancer Res Treat. 2025 Jan 23. doi: 10.1007/s10549-024-07580.
PubMed Abstract available

KAI C, Tamori H, Ohtsuka T, Nara M, et al
Classifying the molecular subtype of breast cancer using vision transformer and convolutional neural network features.
Breast Cancer Res Treat. 2025 Jan 22. doi: 10.1007/s10549-025-07614.
PubMed Abstract available

WILLIAMSON J, Kelley K, Scholand MB, Crossno C, et al
Efficacy of a novel interstitial lung disease monitoring program in breast cancer patients undergoing treatment with trastuzumab-deruxtecan.
Breast Cancer Res Treat. 2025 Jan 22. doi: 10.1007/s10549-024-07586.
PubMed Abstract available

ISIK B, Davey MG, Jaffer AA, Buckley J, et al
Assessing the clinical utility of pre-operative neutrophil-lymphocyte ratio as a predictor of clinicopathological parameters in patients being treated for primary breast cancer.
Breast Cancer Res Treat. 2025 Jan 20. doi: 10.1007/s10549-025-07615.
PubMed Abstract available

ROHAN TE, Wang Y, Couch F, Feigelson HS, et al
Clinicopathologic characteristics of ductal carcinoma in situ and risk of subsequent invasive breast cancer: a multicenter, population-based cohort study.
Breast Cancer Res Treat. 2025 Jan 20. doi: 10.1007/s10549-024-07599.
PubMed Abstract available

ASHOK KUMAR P, Sampat P, Sandhu M, Kumar VCS, et al
A meta-analysis of the utility of cryotherapy for preventing peripheral neuropathy among breast cancer patients receiving paclitaxel and nab-paclitaxel.
Breast Cancer Res Treat. 2025 Jan 19. doi: 10.1007/s10549-024-07597.
PubMed Abstract available

BASHEY SZ, Kordon A, Ositelu K, Rao A, et al
The role of statins in breast cancer survivors.
Breast Cancer Res Treat. 2025 Jan 16. doi: 10.1007/s10549-024-07605.
PubMed Abstract available

BOGACZ P, Pelc Z, Mlak R, Sedlak K, et al
Sentinel lymph node biopsy in breast cancer: the role of ICG fluorescence after neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2025 Jan 14. doi: 10.1007/s10549-025-07608.
PubMed Abstract available

NYQVIST-STRENG J, Helou M, Helou K, Chamalidou C, et al
The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study.
Breast Cancer Res Treat. 2025 Jan 12. doi: 10.1007/s10549-025-07610.
PubMed Abstract available

MANIRUZZAMAN M, Bhuiyan MRH, Jaman MS, Haque MS, et al
MicroRNA dynamics, PTEN/PI3K/AKT signaling, and their relationship to breast cancer: prospects for pharmaceuticals and natural product application.
Breast Cancer Res Treat. 2025 Jan 10. doi: 10.1007/s10549-024-07600.
PubMed Abstract available

GOKSEN TOSUN N, Kaplan O
Dual targeting of HSP90 and BCL-2 in breast cancer cells using inhibitors BIIB021 and ABT-263.
Breast Cancer Res Treat. 2025 Jan 9. doi: 10.1007/s10549-024-07587.
PubMed Abstract available

SCAFETTA R, Zagami P, Del Re M, Criscitiello C, et al
Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences.
Breast Cancer Res Treat. 2025 Jan 8. doi: 10.1007/s10549-024-07595.
PubMed Abstract available

VICINI E, Galimberti V, Leonardi MC, Kahler-Ribeiro-Fontana S, et al
Shifting from axillary dissection to targeted axillary surgery after neoadjuvant treatment: the evolving management of occult breast cancer in a monoinstitutional series of 114 patients.
Breast Cancer Res Treat. 2025 Jan 8. doi: 10.1007/s10549-024-07604.
PubMed Abstract available

SILVA CR, Vieira DP, de Freitas AZ, Ribeiro MS, et al
Photodynamic therapy as a strategic ally in radiotherapy for triple-negative breast cancer: the importance of treatment order.
Breast Cancer Res Treat. 2025 Jan 8. doi: 10.1007/s10549-024-07607.
PubMed Abstract available

OSLER TS, Schoeman M, Pretorius WJS, Mathew CG, et al
Application of genetic testing criteria for hereditary breast cancer in South Africa.
Breast Cancer Res Treat. 2025 Jan 7. doi: 10.1007/s10549-024-07585.
PubMed Abstract available

SANOBA SA, Thull DL, McAuliffe PF, Steiman JG, et al
Correction: Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy.
Breast Cancer Res Treat. 2025 Jan 7. doi: 10.1007/s10549-024-07573.
PubMed

PILEHVARI A, You W, Kimmick G, Bonilla G, et al
Disparities in treatment delays among metastatic breast cancer patients: insights from nationwide electronic health records, 2011-2022.
Breast Cancer Res Treat. 2025 Jan 7. doi: 10.1007/s10549-024-07593.
PubMed Abstract available

KNOWLTON SE, Wardell AC, Bailey C, Connelly B, et al
Assessment of the functional and health-related needs of patients with metastatic breast cancer prior to initiation of cancer treatment.
Breast Cancer Res Treat. 2025 Jan 6. doi: 10.1007/s10549-024-07590.
PubMed Abstract available

JUNG W, Park SH, Park YM, Song YM, et al
Weight change and cardiovascular disease incidence in breast cancer survivors: a nationwide cohort study.
Breast Cancer Res Treat. 2025 Jan 6. doi: 10.1007/s10549-024-07594.
PubMed Abstract available

XU Y, Cai Q, Li J, Guo W, et al
Frequency of somatic and germline variants of predisposition genes in young Chinese women with breast cancer.
Breast Cancer Res Treat. 2025 Jan 5. doi: 10.1007/s10549-024-07602.
PubMed Abstract available

MARK C, Pujara V, Boyle MK, Yuan Y, et al
Demographic and clinical trends of young breast cancer patients from the national cancer database: disproportionate effect on minority populations.
Breast Cancer Res Treat. 2025 Jan 5. doi: 10.1007/s10549-024-07588.
PubMed Abstract available

AHMED GA, Baron DH, Agrawal A
Oncologic and cosmetic outcomes of oncoplastic breast-conserving surgery after neoadjuvant systemic therapy: systematic review and meta-analysis.
Breast Cancer Res Treat. 2025;209:229-252.
PubMed Abstract available

LI JJX, Ng JKM, Hon NKY, See KW, et al
Effects on lymph node size, staging and primary tumor histology on diagnostic accuracy of axillary lymph node aspirate of breast cancers.
Breast Cancer Res Treat. 2025;209:15-20.
PubMed Abstract available

SAMAHA M, Fellner A, Raque K, Kuritzky A, et al
Magnetic lymphatic tracing for omission of sentinel lymph node biopsies in mastectomy patients: a community cancer center experience.
Breast Cancer Res Treat. 2025;209:161-166.
PubMed Abstract available

SITU J, Walker C, Jayathungage Don TD, Suami H, et al
Discordance between peritumoral and subareolar injections for mapping sentinel lymph nodes in the breast.
Breast Cancer Res Treat. 2025;209:283-290.
PubMed Abstract available

ROSENBERGER LH, Thomas SM, Hieken TJ, Gallagher KK, et al
Germline genetic mutations in a multi-center cohort of 248 phyllodes tumors.
Breast Cancer Res Treat. 2025;209:275-282.
PubMed Abstract available

SHIN E, Kim HM, Koo JS
CD68 positive and/or CD163 positive tumor-associated macrophages and PD-L1 expression in breast phyllodes tumor.
Breast Cancer Res Treat. 2025;209:261-273.
PubMed Abstract available

December 2024

FALTINOVA M, Vehmanen L, Lyytinen H, Savolainen-Peltonen H, et al
Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial.
Breast Cancer Res Treat. 2024 Dec 27. doi: 10.1007/s10549-024-07564.
PubMed Abstract available

MALON D, Molto C, Prasla S, Cuthbert D, et al
Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor.
Breast Cancer Res Treat. 2024 Dec 25. doi: 10.1007/s10549-024-07578.
PubMed Abstract available

LAMONT EB, Stein E, Tarantino P, Tolaney SM, et al
Pooled clinical trial analyses evaluating outcomes of HER2-low vs HER2-0 expression in patients with metastatic breast cancer following chemotherapy.
Breast Cancer Res Treat. 2024 Dec 20. doi: 10.1007/s10549-024-07581.
PubMed Abstract available

LEGGAT-BARR K, Yee D, Duralde E, Hodge C, et al
Correction: A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.
Breast Cancer Res Treat. 2024 Dec 20. doi: 10.1007/s10549-024-07572.
PubMed

YUE M, Zhao J, Wu S, Cai L, et al
Establishment of multiple machine learning prognostic model for gene differences between primary tumors and lymph nodes in luminal breast cancer.
Breast Cancer Res Treat. 2024 Dec 10. doi: 10.1007/s10549-024-07574.
PubMed Abstract available

SIGURJONSDOTTIR G, De Marchi T, Ehinger A, Hartman J, et al
Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort.
Breast Cancer Res Treat. 2024 Dec 10. doi: 10.1007/s10549-024-07561.
PubMed Abstract available

KAPPOS EA, Fabi A, Halbeisen FS, Abu-Ghazaleh A, et al
Vascularized lymph node transfer (VLNT) versus lymphaticovenous anastomosis (LVA) for chronic breast cancer-related lymphedema (BCRL): a retrospective cohort study of effectiveness over time.
Breast Cancer Res Treat. 2024 Dec 10. doi: 10.1007/s10549-024-07567.
PubMed Abstract available

BHATTACHARYA M, Liu B, Kurian AW, Stevens J, et al
Receipt of guideline-concordant care and survival among young adult women with non-metastatic breast cancer.
Breast Cancer Res Treat. 2024 Dec 9. doi: 10.1007/s10549-024-07570.
PubMed Abstract available

WU M, Huang Q, Zhang L, Liu Y, et al
Apo10 and TKTL1 in blood macrophages as potential biomarkers for early diagnosis of operable breast cancer.
Breast Cancer Res Treat. 2024 Dec 7. doi: 10.1007/s10549-024-07569.
PubMed Abstract available

PRASATH V, Boutrid H, Wesolowski R, Abdel-Rasoul M, et al
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.
Breast Cancer Res Treat. 2024 Dec 7. doi: 10.1007/s10549-024-07551.
PubMed Abstract available

DI LEONE A, Filippone A, Maggiore C, Rossi MM, et al
The role of body composition in neurological and hematologic toxicity in a retrospective analysis of 120 breast cancer patients undergoing neoadjuvant chemotherapy: the COMBOTOX study.
Breast Cancer Res Treat. 2024 Dec 4. doi: 10.1007/s10549-024-07553.
PubMed Abstract available

RUGO HS, Campbell M, Yau C, Jo Chien A, et al
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Breast Cancer Res Treat. 2024 Dec 3. doi: 10.1007/s10549-024-07555.
PubMed Abstract available

LEONE JP, Leone J, Hassett MJ, Freedman RA, et al
Incidence, treatment patterns, and mortality for patients with breast cancer during the first year of the COVID-19 pandemic: a population-based study.
Breast Cancer Res Treat. 2024 Dec 2. doi: 10.1007/s10549-024-07562.
PubMed Abstract available

SCHRUP S, Hardway H, Vierkant RA, Winham SJ, et al
Microcalcifications in benign breast biopsies: association with lesion type and risk.
Breast Cancer Res Treat. 2024;208:543-551.
PubMed Abstract available

BOWLES EJA, Ramin C, Vo JB, Feigelson HS, et al
Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018.
Breast Cancer Res Treat. 2024;208:577-587.
PubMed Abstract available

FALADE IO, Switalla KM, Baxter ME, Quirarte A, et al
Variation in surgical treatment by body mass index in patients with invasive lobular carcinoma of the breast.
Breast Cancer Res Treat. 2024;208:569-575.
PubMed Abstract available

BEYPINAR I, Demir H, Yaslikaya S, Koseci T, et al
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study.
Breast Cancer Res Treat. 2024;208:597-604.
PubMed Abstract available

LAITMAN Y, Niskakoski A, Bernstein-Molho R, Koskinen L, et al
Phenotypes of carriers of two mutated alleles in major cancer susceptibility genes.
Breast Cancer Res Treat. 2024;208:589-595.
PubMed Abstract available

KUO AM, Reingold RE, Ketosugbo KF, Pan A, et al
Oral minoxidil for late alopecia in cancer survivors.
Breast Cancer Res Treat. 2024;208:491-499.
PubMed Abstract available

SOLIS O, Addae J, Sweeting R, Meszoely I, et al
Cost containment analysis of superparamagnetic iron oxide (SPIO) injection in patients with ductal carcinoma in situ.
Breast Cancer Res Treat. 2024;208:565-568.
PubMed Abstract available

November 2024

ROZENBLIT M, Qing T, Ye Y, Zhao H, et al
Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history.
Breast Cancer Res Treat. 2024 Nov 27. doi: 10.1007/s10549-024-07560.
PubMed Abstract available

ANAMPA JD, Alvarez Soto A, Bernal AM, Acuna-Villaorduna A, et al
Racial disparities in treatment and outcomes between Hispanic and non-Hispanic black women with triple-negative breast cancer.
Breast Cancer Res Treat. 2024 Nov 26. doi: 10.1007/s10549-024-07565.
PubMed Abstract available

HANF D, Fasching P, Gass P, Matthias W Beckmann, et al
Impact of CCND1 amplification on the prognosis of hormone receptor-positive, HER2-negative breast cancer patients-correlation of clinical and pathological markers.
Breast Cancer Res Treat. 2024 Nov 26. doi: 10.1007/s10549-024-07545.
PubMed Abstract available

ROCQUE GB, Blum JL, Ji Y, Pluard T, et al
Real-world quality-of-life of patients with HR+/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS.
Breast Cancer Res Treat. 2024 Nov 25. doi: 10.1007/s10549-024-07524.
PubMed Abstract available

LACZMANSKA I, Matkowski R, Supplitt S, Karpinski P, et al
Correction: Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status.
Breast Cancer Res Treat. 2024 Nov 23. doi: 10.1007/s10549-024-07544.
PubMed

MATOSSIAN MD, Shiang C, Dolcen DN, Dreyer M, et al
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration.
Breast Cancer Res Treat. 2024 Nov 23. doi: 10.1007/s10549-024-07515.
PubMed Abstract available

LONNING PE, Nikolaienko O, Knappskog S
Letter to the Editor in response to paper "BRCA1 promoter methylation in triple-negative breast cancer......" by K Daster et al.
Breast Cancer Res Treat. 2024 Nov 22. doi: 10.1007/s10549-024-07563.
PubMed

ZHAO H, Shen C, Laureano JJ, Lei X, et al
Real-world neoadjuvant and adjuvant Trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021.
Breast Cancer Res Treat. 2024 Nov 22. doi: 10.1007/s10549-024-07552.
PubMed Abstract available

REFAAT S, Al-Rashidi HE, El Azeem RAA, Nouh WE, et al
The functional TNF-alpha(-308)G > a single-nucleotide polymorphism (rs1800629): association with the predictive indices of breast cancer carcinogenesis.
Breast Cancer Res Treat. 2024 Nov 21. doi: 10.1007/s10549-024-07536.
PubMed Abstract available

ENGEL J, Wieder V, Bauer M, Kaufhold S, et al
Correction: Prognostic and predictive impact of NOTCH1 in early breast cancer.
Breast Cancer Res Treat. 2024 Nov 20. doi: 10.1007/s10549-024-07520.
PubMed

VAIDYA R, Till C, Henry NL, Fisch MJ, et al
Neighborhood socioeconomic deprivation and patient-reported outcomes in symptom management trials for women with breast cancer.
Breast Cancer Res Treat. 2024 Nov 19. doi: 10.1007/s10549-024-07523.
PubMed Abstract available

GOLDVASER H, Yerushalmi R, Mutai R, Kuchuk I, et al
ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes.
Breast Cancer Res Treat. 2024 Nov 19. doi: 10.1007/s10549-024-07549.
PubMed Abstract available

BETTARIGA F, Taaffe DR, Crespo-Garcia C, Clay TD, et al
Effects of resistance training vs high intensity interval training on body composition, muscle strength, cardiorespiratory fitness, and quality of life in survivors of breast cancer: a randomized trial.
Breast Cancer Res Treat. 2024 Nov 18. doi: 10.1007/s10549-024-07559.
PubMed Abstract available

LEE AW, Solis C, Tubman S, Wells N, et al
Factors associated with breast cancer detection method in California women: an analysis of California Health Interview Survey data.
Breast Cancer Res Treat. 2024 Nov 16. doi: 10.1007/s10549-024-07534.
PubMed Abstract available

KO G, Li Q, Liu N, Amir E, et al
Impact of the COVID-19 pandemic on breast cancer surgeries in a Canadian population.
Breast Cancer Res Treat. 2024 Nov 15. doi: 10.1007/s10549-024-07547.
PubMed Abstract available

ONASANYA O, Rosenblatt P, dosReis S, Onukwugha E, et al
Trajectories of antidepressant use after tamoxifen initiation among young and middle-aged women with breast cancer.
Breast Cancer Res Treat. 2024 Nov 15. doi: 10.1007/s10549-024-07554.
PubMed Abstract available

RELLA R, Belli P, Romanucci G, Bufi E, et al
Association between mammographic breast density and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2024 Nov 12. doi: 10.1007/s10549-024-07548.
PubMed Abstract available

LEGGAT-BARR K, Yee D, Duralde E, Hodge C, et al
A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.
Breast Cancer Res Treat. 2024 Nov 12. doi: 10.1007/s10549-024-07522.
PubMed Abstract available

RIZK M, Mokbel K
Enhancing surgical precision: active marker localization at the time of biopsy in breast cancer management.
Breast Cancer Res Treat. 2024 Nov 12. doi: 10.1007/s10549-024-07550.
PubMed

HO KL, Tu Y, Dibble KE, Visvanathan K, et al
The food environment and postdiagnosis weight gain among Black women breast cancer survivors in Maryland.
Breast Cancer Res Treat. 2024 Nov 10. doi: 10.1007/s10549-024-07543.
PubMed Abstract available

KOMATSU N, Chishima T, Watanabe C, Taruno K, et al
Correction: Development of a novel prediction model for carriage of BRCA1/2 pathogenic variant in Japanese patients with breast cancer based on Japanese organization of hereditary breast and ovarian cancer registry data.
Breast Cancer Res Treat. 2024 Nov 9. doi: 10.1007/s10549-024-07521.
PubMed

EE C, Singleton A, Elder E, Davis N, et al
The experience of weight gain during and after breast cancer treatment: a qualitative study.
Breast Cancer Res Treat. 2024 Nov 7. doi: 10.1007/s10549-024-07528.
PubMed Abstract available

ALMEKINDERS CAM, Lin L, Beijnen JH, Sonke GS, et al
Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort.
Breast Cancer Res Treat. 2024 Nov 7. doi: 10.1007/s10549-024-07542.
PubMed Abstract available

PISLAR N, Gasljevic G, Matos E, Pilko G, et al
Predicting nodal response to neoadjuvant treatment in breast cancer with core biopsy biomarkers of tumor microenvironment using data mining.
Breast Cancer Res Treat. 2024 Nov 4. doi: 10.1007/s10549-024-07539.
PubMed Abstract available

VADLAKONDA A, Chervu NL, Porter G, Sakowitz S, et al
Racial disparities in presenting stage and surgical management among octogenarians with breast cancer: a national cancer database analysis.
Breast Cancer Res Treat. 2024 Nov 4. doi: 10.1007/s10549-024-07531.
PubMed Abstract available

XING N, Liu D, Chen L, Wang G, et al
Quantitative analysis of pressure levels in manual lymphatic drainage across stages of breast cancer-related lymphedema: implications for optimized treatment protocols.
Breast Cancer Res Treat. 2024 Nov 4. doi: 10.1007/s10549-024-07540.
PubMed Abstract available

CHIEN YN, Lin LY, Lin YC, Hsieh YC, et al
Taxane/anthracycline combinations reduced incidence of breast cancer recurrence in young women across molecular subtypes: a real-world evidence of Taiwan from 2011 to 2019.
Breast Cancer Res Treat. 2024 Nov 2. doi: 10.1007/s10549-024-07527.
PubMed Abstract available

PASETTO CV, Aguiar FN, Peixoto MB, Doria MT, et al
Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast.
Breast Cancer Res Treat. 2024;208:9-18.
PubMed Abstract available

BORREGO MR, Lu YS, Reyes-Cosmelli F, Park YH, et al
SGLT2 inhibition improves PI3Kalpha inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials.
Breast Cancer Res Treat. 2024;208:111-121.
PubMed Abstract available

BOURGEOIS P
Letter to the BRCT editor.
Breast Cancer Res Treat. 2024;208:201.
PubMed

PEIPINS LA, Dasari S, Viox MH, Rodriguez JL, et al
Information needs persist after genetic counseling and testing for BRCA1/2 and Lynch Syndrome.
Breast Cancer Res Treat. 2024;208:19-27.
PubMed Abstract available

CHEN Q, Campbell I, Elwood M, Cavadino A, et al
Outcomes from low-risk ductal carcinoma in situ: a systematic review and meta-analysis.
Breast Cancer Res Treat. 2024;208:237-251.
PubMed Abstract available

RAMPAL R, Jones SJ, Hartup S, Robertson C, et al
Three and twelve-month analysis of the PROM-Q study: comparison of patient-reported outcome measures using the BREAST-Q questionnaire in pre- vs. sub-pectoral implant-based immediate breast reconstruction.
Breast Cancer Res Treat. 2024;208:275-282.
PubMed Abstract available

KAIDAR-PERSON O, Faermann R, Polikar D, Cohen K, et al
A BRILLIANT-BRCA study: residual breast tissue after mastectomy and reconstruction.
Breast Cancer Res Treat. 2024;208:359-367.
PubMed Abstract available

CHO Y, Park EK, Chang Y, Kwon MR, et al
Concordant and discordant breast density patterns by different approaches for assessing breast density and breast cancer risk.
Breast Cancer Res Treat. 2024 Nov 1. doi: 10.1007/s10549-024-07541.
PubMed Abstract available

October 2024

TERRA L, Boekel NB, Hooning MH, Collee M, et al
Cardiovascular disease risk after breast cancer treatment in patients with a BRCA1/2 pathogenic variant.
Breast Cancer Res Treat. 2024 Oct 31. doi: 10.1007/s10549-024-07516.
PubMed Abstract available

OZA S, Patil S, Sampathkumar Y, Gany F, et al
Trends in exercise initiation and participation among employed breast cancer survivors undergoing curative treatment.
Breast Cancer Res Treat. 2024 Oct 31. doi: 10.1007/s10549-024-07526.
PubMed Abstract available

BOSCOLO BIELO L, Guerini Rocco E, Crimini E, Repetto M, et al
Molecular tumor board in patients with metastatic breast cancer.
Breast Cancer Res Treat. 2024 Oct 30. doi: 10.1007/s10549-024-07535.
PubMed Abstract available

VAZ-GONCALVES L, Protani MM, Saunus JM, Colditz GA, et al
Continental differences in the association between excess body weight and prognosis in triple-negative breast cancer: a meta-analysis.
Breast Cancer Res Treat. 2024 Oct 30. doi: 10.1007/s10549-024-07538.
PubMed Abstract available

GONZALEZ-NUNEZ C, Mohar A, Reynoso-Noveron N, Alvarez-Gomez RM, et al
Clinical characteristics of male patients with breast cancer in the Latino population.
Breast Cancer Res Treat. 2024 Oct 29. doi: 10.1007/s10549-024-07525.
PubMed Abstract available

TAYA M, Merenbakh-Lamin K, Zubkov A, Honig Z, et al
Beyond endocrine resistance: estrogen receptor (ESR1) activating mutations mediate chemotherapy resistance through the JNK/c-Jun MDR1 pathway in breast cancer.
Breast Cancer Res Treat. 2024 Oct 29. doi: 10.1007/s10549-024-07507.
PubMed Abstract available

PHUNG TH, Pham TT, Nguyen HT, Nguyen DT, et al
Clinicopathological characteristics of mucinous breast cancer: a retrospective analysis of a 6-years study from national cancer center in Vietnam.
Breast Cancer Res Treat. 2024 Oct 23. doi: 10.1007/s10549-024-07529.
PubMed Abstract available

JAHANGIRI S, Abdan Z, Soroush A, Houshmand M, et al
Strong association of single nucleotide polymorphisms in BRCA1, ATM, and CHEK2 with breast cancer susceptibility in a sub-population of Iranian women.
Breast Cancer Res Treat. 2024 Oct 22. doi: 10.1007/s10549-024-07503.
PubMed Abstract available

WOLFRAM S, Herriman SA, Lipps DB
Prevalence and mechanisms of subacromial impingement in breast cancer patients after breast-conserving surgery and radiation therapy: a case-cohort study.
Breast Cancer Res Treat. 2024 Oct 21. doi: 10.1007/s10549-024-07514.
PubMed Abstract available

ROSENBERG SM, Zheng Y, Santos K, Riley E, et al
Patient-reported outcomes, and perceptions and knowledge about recurrence in women with hormone receptor-positive breast cancer.
Breast Cancer Res Treat. 2024 Oct 21. doi: 10.1007/s10549-024-07510.
PubMed Abstract available

STEARNS V, ONeill A, Schneider BP, Skaar TC, et al
CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108.
Breast Cancer Res Treat. 2024 Oct 21. doi: 10.1007/s10549-024-07519.
PubMed Abstract available

COTTU P, Cheeseman S, Hall P, Wockel A, et al
Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records.
Breast Cancer Res Treat. 2024 Oct 20. doi: 10.1007/s10549-024-07506.
PubMed Abstract available

GARCIA-MURILLAS I, Cutts RJ, Walsh-Crestani G, Phillips E, et al
Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer.
Breast Cancer Res Treat. 2024 Oct 18. doi: 10.1007/s10549-024-07508.
PubMed Abstract available

TALEC H, Aube C, Guerin-Charbonnel C, Berge P, et al
The use of a clip prior to neoadjuvant chemotherapy for breast cancer with microcalcifications may not always be required.
Breast Cancer Res Treat. 2024 Oct 17. doi: 10.1007/s10549-024-07517.
PubMed Abstract available

ITO M, Amari M, Sato A, Hikichi M, et al
Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy.
Breast Cancer Res Treat. 2024 Oct 17. doi: 10.1007/s10549-024-07509.
PubMed Abstract available

BRUNELLE CL, Serig A
Is axillary web syndrome a risk factor for breast cancer-related lymphedema of the upper extremity? A systematic review and meta-analysis.
Breast Cancer Res Treat. 2024 Oct 16. doi: 10.1007/s10549-024-07518.
PubMed Abstract available

LAI SW
Comment on "Association between prediabetes and breast cancer: a comprehensive meta-analysis".
Breast Cancer Res Treat. 2024 Oct 15. doi: 10.1007/s10549-024-07505.
PubMed

ISHIKAWA E, Watanabe T, Kihara T, Kuroiwa M, et al
The cytokine profile correlates with less tumor-infiltrating lymphocytes in luminal A breast cancer.
Breast Cancer Res Treat. 2024 Oct 14. doi: 10.1007/s10549-024-07492.
PubMed Abstract available

LV Z, Wang TY, Bi Y, Li D, et al
BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses.
Breast Cancer Res Treat. 2024 Oct 14. doi: 10.1007/s10549-024-07504.
PubMed Abstract available

LABELLA M, Lile-King RE, Agala CB, Spanheimer PM, et al
Trends in management and related outcomes for occult primary breast cancer.
Breast Cancer Res Treat. 2024 Oct 13. doi: 10.1007/s10549-024-07500.
PubMed Abstract available

DE AMORIM ISS, Pinheiro D, da Silva Oliveira M, de Sousa Rodrigues MM, et al
APX2009 sensitizes hypoxic breast cancer cells to doxorubicin by increasing its accumulation and caspase-3/7-mediated apoptosis.
Breast Cancer Res Treat. 2024 Oct 13. doi: 10.1007/s10549-024-07512.
PubMed Abstract available

DASTER K, Hench J, Diepenbruck M, Volkmann K, et al
BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors.
Breast Cancer Res Treat. 2024 Oct 11. doi: 10.1007/s10549-024-07502.
PubMed Abstract available

PACHUAU L, Lalremmawia H, Ralte L, Vanlalpeka J, et al
Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe.
Breast Cancer Res Treat. 2024 Oct 9. doi: 10.1007/s10549-024-07501.
PubMed Abstract available

RASHID NS, Lamba N, Catalano PJ, Bi WL, et al
Intracranial outcomes following neurosurgical resection in patients with brain metastases secondary to HER2-positive breast cancer versus other subtypes.
Breast Cancer Res Treat. 2024 Oct 5. doi: 10.1007/s10549-024-07493.
PubMed Abstract available

BITSIE KR, Pearson TA, Kwan ML, Yaghjyan L, et al
Race and ethnicity and self-reported racial/ethnic discrimination in breast cancer patient interactions with providers in the Pathways Study.
Breast Cancer Res Treat. 2024 Oct 5. doi: 10.1007/s10549-024-07499.
PubMed Abstract available

BROWNE IM, McLaughlin RA, Weadick CS, O'Sullivan S, et al
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX(R) testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer.
Breast Cancer Res Treat. 2024 Oct 4. doi: 10.1007/s10549-024-07486.
PubMed Abstract available

KOMATSU N, Chishima T, Watanabe C, Taruno K, et al
Development of a novel prediction model for carriage of BRCA1/2 pathogenic variant in Japanese patients with breast cancer based on Japanese organization of hereditary breast and ovarian cancer registry data.
Breast Cancer Res Treat. 2024 Oct 2. doi: 10.1007/s10549-024-07485.
PubMed Abstract available

KESSLER AJ, Patel R, Gallagher EJ, Sheng T, et al
Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppression.
Breast Cancer Res Treat. 2024;207:529-532.
PubMed Abstract available

TOMITA S, Yoshitake T, Matsunaga N, de Kerckhove M, et al
Patient-reported outcomes and quality of life after breast-conserving surgery, mastectomy, and breast reconstruction assessed using the BREAST-Q questionnaire.
Breast Cancer Res Treat. 2024;207:641-648.
PubMed Abstract available

RAJAN KK, Nijveldt JJ, Verheijen S, Siesling S, et al
Adherence to guideline recommendations for follow-up in patients with DCIS at a large teaching hospital in the Netherlands.
Breast Cancer Res Treat. 2024;207:633-640.
PubMed Abstract available

FARIA JP, Assumpcao JG, de Oliveira Matos L, Soardi FC, et al
Spectrum of germline pathogenic variants in Brazilian hereditary breast/ovarian cancer cases.
Breast Cancer Res Treat. 2024;207:615-624.
PubMed Abstract available

LEONARDIS JM, Momoh AO, Lipps DB
Choosing breast-conserving therapy or mastectomy and subpectoral implant breast reconstruction: implications for pectoralis major function.
Breast Cancer Res Treat. 2024;207:569-578.
PubMed Abstract available

SOLEIMANI T, Euhus D, Sogunro O, Cope L, et al
De-escalating indications for excision when breast core needle biopsy returns fibroepithelial lesion-not further characterized.
Breast Cancer Res Treat. 2024;207:561-568.
PubMed Abstract available

SANTANA VALENCIANO A, Rivas Fidalgo S, Corral Moreno S, Gamero Medina V, et al
Surgical marker navigation system in breast conserving surgery and excision of non-palpable lesions: first Spanish single-center experience.
Breast Cancer Res Treat. 2024;207:533-540.
PubMed Abstract available

MARTINS-BRANCO D, Brandao M, de Azambuja E
Response to letter "re: Surgery of the primary tumor in patients with de novo metastatic breast cancer: A nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)".
Breast Cancer Res Treat. 2024 Oct 1. doi: 10.1007/s10549-024-07498.
PubMed

September 2024

VERRECK EEF, Kuijer A, van Steenhoven JEC, Volders JH, et al
70-Gene signature-guided adjuvant systemic treatment adjustments in early-stage ER+ breast cancer patients: 7-year follow-up of a prospective multicenter cohort study.
Breast Cancer Res Treat. 2024 Sep 30. doi: 10.1007/s10549-024-07496.
PubMed Abstract available

WOJCIK KM, Wilson OWA, Kamil D, Rajagopal PS, et al
Clinical and sociodemographic determinants of older breast cancer survivors' reports of receiving advice about exercise.
Breast Cancer Res Treat. 2024 Sep 30. doi: 10.1007/s10549-024-07460.
PubMed Abstract available

GUNSTER JLB, van Duijnhoven FH, Scholten AN, Smorenburg CH, et al
The efficacy of screening with FDG-PET/CT for distant metastases in breast cancer patients scheduled for neoadjuvant systemic therapy.
Breast Cancer Res Treat. 2024 Sep 26. doi: 10.1007/s10549-024-07478.
PubMed Abstract available

KULIGINA ES, Romanko AA, Jankevic T, Martianov AS, et al
HLA gene polymorphism is a modifier of age-related breast cancer penetrance in carriers of BRCA1 pathogenic alleles.
Breast Cancer Res Treat. 2024 Sep 21. doi: 10.1007/s10549-024-07497.
PubMed Abstract available

JACOB S, Christofferson A, Fisch S, Norwood P, et al
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
Breast Cancer Res Treat. 2024 Sep 21. doi: 10.1007/s10549-024-07481.
PubMed Abstract available

BANSAL R, Adeyelu T, Elliott A, Walker P, et al
Genomic and transcriptomic landscape of HER2-low breast cancer.
Breast Cancer Res Treat. 2024 Sep 20. doi: 10.1007/s10549-024-07495.
PubMed Abstract available

SCHMIDT JA, Hjorth CF, Farkas DK, Damkier P, et al
Genetic variants and social benefit receipt in premenopausal women with breast cancer treated with docetaxel: a Danish population-based cohort study.
Breast Cancer Res Treat. 2024 Sep 20. doi: 10.1007/s10549-024-07474.
PubMed Abstract available

JANSSEN LM, de Vries BBLP, Janse MHA, van der Wall E, et al
Tumor infiltrating lymphocytes and change in tumor load on MRI to assess response and prognosis after neoadjuvant chemotherapy in breast cancer.
Breast Cancer Res Treat. 2024 Sep 16. doi: 10.1007/s10549-024-07484.
PubMed Abstract available

MIRZA L, Steventon L, Roylance R, Hughes C, et al
Regional differences in neo/adjuvant chemotherapy timing in patients with early-stage triple-negative breast cancer in England.
Breast Cancer Res Treat. 2024 Sep 16. doi: 10.1007/s10549-024-07480.
PubMed Abstract available

THAI CHNC, An SJ, Haase CR, Selfridge JM, et al
Differential prognostic value of residual nodal burden in breast cancer subtypes.
Breast Cancer Res Treat. 2024 Sep 15. doi: 10.1007/s10549-024-07494.
PubMed Abstract available

HENNEGHAN AM, Van Dyk KM, Haywood D, Patel M, et al
Characterizing cancer-related cognitive impairments and impact on quality of life in women with metastatic breast cancer.
Breast Cancer Res Treat. 2024 Sep 13. doi: 10.1007/s10549-024-07479.
PubMed Abstract available

ZHU HR, Wei YB, Guo JQ, Liu XF, et al
Double-negative T cells with a distinct transcriptomic profile are abundant in the peripheral blood of patients with breast cancer.
Breast Cancer Res Treat. 2024 Sep 10. doi: 10.1007/s10549-024-07477.
PubMed Abstract available

NELSON RA, Chlebowski RT, Pan K, Rohan TE, et al
Breast Cancer Risk Assessment Tool (BCRAT) and long-term breast cancer mortality in the Women's Health Initiative.
Breast Cancer Res Treat. 2024 Sep 10. doi: 10.1007/s10549-024-07470.
PubMed Abstract available

DUARTE BN, Alem CER, da Silva Cabello AER, Teixeira SRC, et al
Risk-reducing surgeries for breast cancer in Brazilian patients undergoing multigene germline panel: impact of results on decision making.
Breast Cancer Res Treat. 2024 Sep 10. doi: 10.1007/s10549-024-07476.
PubMed Abstract available

SARTOR H, Hagberg O, Hemmingsson O, Lang K, et al
Breast cancer recurrence in relation to mode of detection: implications on personalized surveillance.
Breast Cancer Res Treat. 2024 Sep 10. doi: 10.1007/s10549-024-07475.
PubMed Abstract available

GUO Q, Liu M, Li Y, Sun Q, et al
Overcoming technical hurdles in mobile health: insights from the Fit2ThriveMB breast cancer study.
Breast Cancer Res Treat. 2024 Sep 5. doi: 10.1007/s10549-024-07483.
PubMed

TANG WZ, Deng WX, Liu TH
Letter to the editor: "Frequency of zoledronate administration in early breast cancer".
Breast Cancer Res Treat. 2024 Sep 4. doi: 10.1007/s10549-024-07490.
PubMed

SWEDE H, Ridwan SM, Strandberg J, Salner AL, et al
Baseline sLAG-3 levels in Caucasian and African-American breast cancer patients.
Breast Cancer Res Treat. 2024 Sep 4. doi: 10.1007/s10549-024-07455.
PubMed Abstract available

August 2024

WALYELDEEN AA, Sabet S, Anis SE, Stein T, et al
Correction: FBLN2 is associated with basal cell markers Krt14 and ITGB1 in mouse mammary epithelial cells and has a preferential expression in molecular subtypes of human breast cancer.
Breast Cancer Res Treat. 2024 Aug 29. doi: 10.1007/s10549-024-07472.
PubMed

CONLEY CC, Anderson A, Rodriguez JD, Kang H, et al
Barriers and facilitators to breast cancer screening among high-risk women: a qualitative study.
Breast Cancer Res Treat. 2024 Aug 27. doi: 10.1007/s10549-024-07471.
PubMed Abstract available

BRUFSKY A, Kwan ML, Sandin R, Stergiopoulos S, et al
Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer.
Breast Cancer Res Treat. 2024 Aug 23. doi: 10.1007/s10549-024-07469.
PubMed Abstract available

GUNASEKHARAN V, Lin HK, Marczyk M, Rios-Hoyo A, et al
Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer.
Breast Cancer Res Treat. 2024 Aug 23. doi: 10.1007/s10549-024-07462.
PubMed Abstract available

DU X, Huang X, Feng X, Shui Y, et al
The effects of the-optimal-lymph-flow health IT system application on treatment-related high risk lymphedema in breast cancer patients: a randomized controlled trial.
Breast Cancer Res Treat. 2024 Aug 23. doi: 10.1007/s10549-024-07468.
PubMed Abstract available

SPENCER JV, Liu J, Deyarmin B, Hu H, et al
Cytokine levels in breast cancer are highly dependent on cytomegalovirus (CMV) status.
Breast Cancer Res Treat. 2024 Aug 22. doi: 10.1007/s10549-024-07459.
PubMed Abstract available

WILLIS C, Tan CJ, Chhibber A, Watanabe AH, et al
Patient characteristics and treatment patterns of patients with locally advanced or metastatic HER2-low breast cancer, a single site descriptive study.
Breast Cancer Res Treat. 2024 Aug 22. doi: 10.1007/s10549-024-07458.
PubMed Abstract available

FRANDSEN CLB, Nohr B, Gottschau M, Viuff JH, et al
Polycystic ovary syndrome and risk of breast cancer in premenopausal and postmenopausal women: a nationwide population-based cohort study.
Breast Cancer Res Treat. 2024 Aug 21. doi: 10.1007/s10549-024-07467.
PubMed Abstract available

ENGEL J, Wieder V, Bauer M, Kaufhold S, et al
Prognostic and predictive impact of NOTCH1 in early breast cancer.
Breast Cancer Res Treat. 2024 Aug 17. doi: 10.1007/s10549-024-07444.
PubMed Abstract available

BLANTER J, Baldwin E, Patel R, Sheng T, et al
Patterns in use and tolerance of adjuvant neratinib in patients with hormone receptor (HR)-positive, HER2-positive early-stage breast cancer.
Breast Cancer Res Treat. 2024 Aug 17. doi: 10.1007/s10549-024-07461.
PubMed Abstract available

BHIMANI J, O'Connell K, Persaud S, Blinder V, et al
The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system.
Breast Cancer Res Treat. 2024 Aug 16. doi: 10.1007/s10549-024-07433.
PubMed Abstract available

MELINK Z, Lustberg MB, Schnell PM, Mezzanotte-Sharpe J, et al
Effect of minocycline on changes in affective behaviors, cognitive function, and inflammation in breast cancer survivors undergoing chemotherapy: a pilot randomized controlled trial.
Breast Cancer Res Treat. 2024 Aug 14. doi: 10.1007/s10549-024-07457.
PubMed Abstract available

KAUR M, Rothschild HT, Mukhtar RA
Reply to: "Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)".
Breast Cancer Res Treat. 2024 Aug 12. doi: 10.1007/s10549-024-07465.
PubMed

LI Z, Ye X
Integrating social work and shared decision-making for equity in metastatic breast cancer care.
Breast Cancer Res Treat. 2024 Aug 10. doi: 10.1007/s10549-024-07463.
PubMed

ALTUNDAG K
Different distant breast cancer metastases might show discordant hormone receptor status in the same patient.
Breast Cancer Res Treat. 2024 Aug 10. doi: 10.1007/s10549-024-07464.
PubMed

ZENG F, Heng J, Guo X, Wang Y, et al
Correction: The novel TP53 3'-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection.
Breast Cancer Res Treat. 2024 Aug 8. doi: 10.1007/s10549-024-07424.
PubMed

WONG HCY, Lee SF, Caini S, Chan AW, et al
Barrier films or dressings for the prevention of acute radiation dermatitis in breast cancer: a systematic review and network meta-analysis.
Breast Cancer Res Treat. 2024 Aug 7. doi: 10.1007/s10549-024-07435.
PubMed Abstract available

WALYELDEEN AA, Sabet S, Anis SE, Stein T, et al
FBLN2 is associated with basal cell markers Krt14 and ITGB1 in mouse mammary epithelial cells and has a preferential expression in molecular subtypes of human breast cancer.
Breast Cancer Res Treat. 2024 Aug 7. doi: 10.1007/s10549-024-07447.
PubMed Abstract available

FREEMAN HD, Burke LC, Humphrey JG, Wilbers AJ, et al
Fragmentation of care in breast cancer: greater than the sum of its parts.
Breast Cancer Res Treat. 2024 Aug 3. doi: 10.1007/s10549-024-07442.
PubMed Abstract available

KINSEY-TROTMAN S, Nguyen A, Edwards S, Swalling A, et al
Influence of tumour grade on disease survival in male breast cancer patients: a systematic review.
Breast Cancer Res Treat. 2024 Aug 2. doi: 10.1007/s10549-024-07446.
PubMed Abstract available

ROCQUE GB, Eltoum N, Caston NE, Williams CP, et al
A randomized controlled trial of shared decision-making treatment planning process to enhance shared decision-making in patients with MBC.
Breast Cancer Res Treat. 2024;206:483-493.
PubMed Abstract available

SURMELI Z
Letter to the editor: "Body composition measures as a determinant of alpelisib-related toxicity".
Breast Cancer Res Treat. 2024;206:677.
PubMed

ROCA NAVARRO MJ, Oliver Goldaracena JM, Garrido Alonso D, Navarro Monforte Y, et al
Pre-surgical cryoablation in
Breast Cancer Res Treat. 2024;206:561-573.
PubMed Abstract available

STEAD TS, Lu CY, Geletzke A, Butler E, et al
Indocyanine green angiography guidance for vascular preservation in skin and nipple sparing mastectomy.
Breast Cancer Res Treat. 2024;206:575-583.
PubMed Abstract available

ANDERSON SA, Bartow BB, Harada S, Siegal GP, et al
p53 protein expression patterns associated with TP53 mutations in breast carcinoma.
Breast Cancer Res Treat. 2024;207:213-222.
PubMed Abstract available

ZENG A, Houssami N, Noguchi N, Nickel B, et al
Frequency and characteristics of errors by artificial intelligence (AI) in reading screening mammography: a systematic review.
Breast Cancer Res Treat. 2024;207:1-13.
PubMed Abstract available

PAN K, Nelson RA, Chlebowski RT, Piela R, et al
Ductal carcinoma in situ and cause-specific mortality among younger and older postmenopausal women: the Women's Health Initiative.
Breast Cancer Res Treat. 2024;207:65-79.
PubMed Abstract available

THOMPSON CN, Chandler J, Ju T, Tsai J, et al
Residual cancer burden in two-stage nipple sparing mastectomy after first stage lumpectomy and devascularization of the nipple areolar complex.
Breast Cancer Res Treat. 2024;207:143-149.
PubMed Abstract available

DOWLING GP, Keelan S, Cosgrove NS, Daly GR, et al
Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease.
Breast Cancer Res Treat. 2024 Aug 1. doi: 10.1007/s10549-024-07431.
PubMed Abstract available

July 2024

AWAN AA, Stober C, Pond GR, Machado I, et al
A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer.
Breast Cancer Res Treat. 2024 Jul 31. doi: 10.1007/s10549-024-07443.
PubMed Abstract available

IZABELA L, Rafal M, Stanislaw S, Pawel K, et al
Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status.
Breast Cancer Res Treat. 2024 Jul 30. doi: 10.1007/s10549-024-07441.
PubMed Abstract available

FANSA S, Ghusn W, Tama E, Nicolalde B, et al
Efficacy of antiobesity medications among breast cancer survivors taking aromatase inhibitors.
Breast Cancer Res Treat. 2024 Jul 30. doi: 10.1007/s10549-024-07450.
PubMed Abstract available

MOKHTARPOUR K, Razi S, Rezaei N
Correction: Ferroptosis as a promising targeted therapy for triple negative breast cancer.
Breast Cancer Res Treat. 2024 Jul 30. doi: 10.1007/s10549-024-07438.
PubMed

WANG Z, Lu Y, Han M, Li A, et al
Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer.
Breast Cancer Res Treat. 2024 Jul 24. doi: 10.1007/s10549-024-07436.
PubMed Abstract available

ZHOU K, Zhang M, Zhai D, Wang Z, et al
Genomic and transcriptomic profiling of inflammatory breast cancer reveals distinct molecular characteristics to non-inflammatory breast cancers.
Breast Cancer Res Treat. 2024 Jul 19. doi: 10.1007/s10549-024-07437.
PubMed Abstract available

SATO T, Oshi M, Huang JL, Chida K, et al
CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.
Breast Cancer Res Treat. 2024 Jul 17. doi: 10.1007/s10549-024-07434.
PubMed Abstract available

PHILLIPS SM, Starikovsky J, Solk P, Desai R, et al
Feasibility and preliminary effects of the Fit2ThriveMB pilot physical activity promotion intervention on physical activity and patient reported outcomes in individuals with metastatic breast cancer.
Breast Cancer Res Treat. 2024 Jul 16. doi: 10.1007/s10549-024-07432.
PubMed Abstract available

BHAVE MA, Quintanilha JCF, Tukachinsky H, Li G, et al
Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
Breast Cancer Res Treat. 2024 Jul 13. doi: 10.1007/s10549-024-07427.
PubMed

FOLDI J, Blenman KRM, Marczyk M, Gunasekharan V, et al
Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer.
Breast Cancer Res Treat. 2024 Jul 13. doi: 10.1007/s10549-024-07426.
PubMed Abstract available

SANJAYA A, Ratnawati H, Adhika OA, Rahmatilah FR, et al
The heterogeneity of breast cancer metastasis: a bioinformatics analysis utilizing single-cell RNA sequencing data.
Breast Cancer Res Treat. 2024 Jul 11. doi: 10.1007/s10549-024-07428.
PubMed Abstract available

DU KY, Wu S, Ma X, Liu Y, et al
Circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers combined with clinicopathological risk has potential to better predict recurrence in stage III breast cancer treated with neoadjuvant chemotherapy: a pilot s
Breast Cancer Res Treat. 2024 Jul 11. doi: 10.1007/s10549-024-07430.
PubMed Abstract available

KUMAR S, Ziegler Y, Plotner BN, Flatt KM, et al
Resistance to FOXM1 inhibitors in breast cancer is accompanied by impeding ferroptosis and apoptotic cell death.
Breast Cancer Res Treat. 2024 Jul 9. doi: 10.1007/s10549-024-07420.
PubMed Abstract available

LIANG E, Beshara M, Sheng H, Huang XW, et al
A prospective study of vitamin D, proinflammatory cytokines, and risk of fragility fractures in women on aromatase inhibitors for breast cancer.
Breast Cancer Res Treat. 2024 Jul 8. doi: 10.1007/s10549-024-07423.
PubMed Abstract available

CHIDA K, Oshi M, Roy AM, Sato T, et al
Enhanced cancer cell proliferation and aggressive phenotype counterbalance in breast cancer with high BRCA1 gene expression.
Breast Cancer Res Treat. 2024 Jul 7. doi: 10.1007/s10549-024-07421.
PubMed Abstract available

BRANTLEY KD, Tamimi RM
The association between infectious agents and breast cancer: a review of the epidemiologic evidence.
Breast Cancer Res Treat. 2024 Jul 6. doi: 10.1007/s10549-024-07388.
PubMed Abstract available

MEZZANOTTE-SHARPE J, ONeill A, Mayer IA, Arteaga CL, et al
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).
Breast Cancer Res Treat. 2024 Jul 5. doi: 10.1007/s10549-024-07417.
PubMed Abstract available

CHEN HW, Kuo WH, Lu YS, Chen IC, et al
Interaction of base excision repair gene polymorphism and estrogen-DNA adducts in breast cancer risk among East Asian women.
Breast Cancer Res Treat. 2024 Jul 5. doi: 10.1007/s10549-024-07418.
PubMed Abstract available

SIMMONS R, Kameyama H, Kubota S, Sun Y, et al
Sustained delivery of celecoxib from nanoparticles embedded in hydrogel injected into the biopsy cavity to prevent biopsy-induced breast cancer metastasis.
Breast Cancer Res Treat. 2024 Jul 5. doi: 10.1007/s10549-024-07410.
PubMed Abstract available

FEFFERMAN ML, Stump TK, Thompson D, Simovic S, et al
Patient-reported observations on medical procedure timeliness (PROMPT) in breast cancer: a qualitative study.
Breast Cancer Res Treat. 2024 Jul 4. doi: 10.1007/s10549-024-07406.
PubMed Abstract available

MAGNONI F, Bianchi B, Pagan E, Corso G, et al
Long-term outcome of invasive pure micropapillary breast cancer compared with invasive mixed micropapillary and invasive ductal breast cancer: a matched retrospective study.
Breast Cancer Res Treat. 2024 Jul 4. doi: 10.1007/s10549-024-07422.
PubMed Abstract available

MATHESON J, Elder K, Nickson C, Park A, et al
Contrast-enhanced mammography for surveillance in women with a personal history of breast cancer.
Breast Cancer Res Treat. 2024 Jul 4. doi: 10.1007/s10549-024-07419.
PubMed Abstract available

FANG T, Hu S, Song X, Wang J, et al
Combination of monensin and erlotinib synergistically inhibited the growth and cancer stem cell properties of triple-negative breast cancer by simultaneously inhibiting EGFR and PI3K signaling pathways.
Breast Cancer Res Treat. 2024 Jul 3. doi: 10.1007/s10549-024-07374.
PubMed Abstract available

OZ O, Irmak Yuzuguldu R, Yazici A, Kocatepe Cavdar D, et al
The differences between pure and mixed invasive micropapillary breast cancer: the epithelial-mesenchymal transition molecules and prognosis.
Breast Cancer Res Treat. 2024 Jul 2. doi: 10.1007/s10549-024-07384.
PubMed Abstract available

LEE M, Woo J, Peak SH, Kim HG, et al
An exploratory clinical trial of preoperative non-invasive localization before breast-conserving surgery using augmented reality technology.
Breast Cancer Res Treat. 2024;206:31-44.
PubMed Abstract available

HONG R, Cao B, Chen D, Wu W, et al
Multi-omics portrait of ductal carcinoma in situ in young women.
Breast Cancer Res Treat. 2024;206:105-118.
PubMed Abstract available

LI S, Lin Y, Liu G, Shao Z, et al
Unveiling the potential of breast MRI: a game changer for BI-RADS 4A microcalcifications.
Breast Cancer Res Treat. 2024;206:425-435.
PubMed Abstract available

HAAS CB, Chen H, Harrison T, Fan S, et al
Disentangling the relationships of body mass index and circulating sex hormone concentrations in mammographic density using Mendelian randomization.
Breast Cancer Res Treat. 2024;206:295-305.
PubMed Abstract available

ASSAD H, Levitin M, Petrucelli N, Manning M, et al
Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center.
Breast Cancer Res Treat. 2024;206:261-272.
PubMed Abstract available

SHACHAR E, Raphael A, Katz U, Kessner R, et al
Body composition measures as a determinant of Alpelisib related toxicity.
Breast Cancer Res Treat. 2024;206:369-376.
PubMed Abstract available

June 2024

LAMMERS SWM, Geurts SME, Hermans KEPE, van Hellemond IEG, et al
Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial.
Breast Cancer Res Treat. 2024 Jun 28. doi: 10.1007/s10549-024-07411.
PubMed Abstract available

SHIEN T, Tsuda H, Sasaki K, Mizusawa J, et al
Comparison of proportions and prognostic impact of pathological complete response between evaluations of representative specimen and total specimen in primary breast cancer after neoadjuvant chemoradiotherapy: an ancillary study of JCOG0306.
Breast Cancer Res Treat. 2024 Jun 27. doi: 10.1007/s10549-024-07408.
PubMed Abstract available

IWAMOTO T, Niikura N, Watanabe K, Takeshita T, et al
Prognostic value of the 21-Gene Breast Recurrence Score(R) assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial).
Breast Cancer Res Treat. 2024 Jun 26. doi: 10.1007/s10549-024-07414.
PubMed Abstract available

CRONIN M, Lowery A, McInerney V, Wijns W, et al
Understanding cardiac events in breast cancer (UCARE): pilot cardio-oncology assessment and surveillance pathway for breast cancer patients.
Breast Cancer Res Treat. 2024 Jun 26. doi: 10.1007/s10549-024-07322.
PubMed Abstract available

KIMMICK G, Pilehvari A, You W, Bonilla G, et al
First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting.
Breast Cancer Res Treat. 2024 Jun 26. doi: 10.1007/s10549-024-07415.
PubMed Abstract available

SINGAREEKA RAGHAVENDRA A, Liu D, Shen Y, Barcenas CH, et al
Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy: a single-institution experience.
Breast Cancer Res Treat. 2024 Jun 25. doi: 10.1007/s10549-024-07309.
PubMed Abstract available

MCCARTHY AM, Ehsan S, Hughes KS, Lehman CD, et al
Feasibility of risk assessment for breast cancer molecular subtypes.
Breast Cancer Res Treat. 2024 Jun 25. doi: 10.1007/s10549-024-07404.
PubMed Abstract available

SELIEM MA, Mohamadin AM, El-Sayed MIK, Ismail Y, et al
The clinical signature of genetic variants and serum levels of macrophage migration inhibitory factor in Egyptian breast cancer patients.
Breast Cancer Res Treat. 2024 Jun 25. doi: 10.1007/s10549-024-07393.
PubMed Abstract available

ZHANG D, Fang J, Shan J, Xu L, et al
SCARB2 associates with tumor-infiltrating neutrophils and predicts poor prognosis in breast cancer.
Breast Cancer Res Treat. 2024 Jun 24. doi: 10.1007/s10549-024-07401.
PubMed Abstract available

JOHNSTON E, Cowan K, MacKenzie M, Patton S, et al
Identifying research priorities for improving information and support for patients undergoing breast cancer surgery: a UK patient-centred priority setting project.
Breast Cancer Res Treat. 2024 Jun 24. doi: 10.1007/s10549-024-07413.
PubMed Abstract available

KALINSKY K, Spring L, Yam C, Bhave MA, et al
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.
Breast Cancer Res Treat. 2024 Jun 21. doi: 10.1007/s10549-024-07412.
PubMed Abstract available

WEN S, Zhang M, Chen J, Hu L, et al
Characteristics of Chinese breast cancer patients with double heterozygosity for BRCA1 and BRCA2 germline pathogenic variants.
Breast Cancer Res Treat. 2024 Jun 20. doi: 10.1007/s10549-024-07409.
PubMed Abstract available

BRAVO EI, Martinez AM, Alva HP, Sancho DR, et al
Reliability of Magseed(R) marking before neoadjuvant systemic therapy with subsequent contrast-enhanced mammography in patients with non-palpable breast cancer lesions after treatment: the MAGMA study.
Breast Cancer Res Treat. 2024 Jun 20. doi: 10.1007/s10549-024-07407.
PubMed Abstract available

TEUFELSBAUER M, Stickler S, Eggerstorfer MT, Hammond DC, et al
BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436.
Breast Cancer Res Treat. 2024 Jun 19. doi: 10.1007/s10549-024-07403.
PubMed Abstract available

RODRIGUEZ-ROJAS K, Cortes-Reynosa P, Torres-Alamilla P, Rodriguez-Ochoa N, et al
A novel role of IGFBP5 in the migration, invasion and spheroids formation induced by IGF-I and insulin in MCF-7 breast cancer cells.
Breast Cancer Res Treat. 2024 Jun 19. doi: 10.1007/s10549-024-07397.
PubMed Abstract available

LISSIDINI G, Nicosia L, Sargenti M, Cucchi MC, et al
Male breast cancer: a multicenter study to provide a guide for proper management.
Breast Cancer Res Treat. 2024 Jun 19. doi: 10.1007/s10549-024-07380.
PubMed Abstract available

NAKAMOTO S, Kajiwara Y, Taniguchi K, Hida AI, et al
Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-14.
Breast Cancer Res Treat. 2024 Jun 18. doi: 10.1007/s10549-024-07395.
PubMed Abstract available

HUPPERT LA, Fisch S, Tsopurashvili E, Somepalle SS, et al
Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study.
Breast Cancer Res Treat. 2024 Jun 18. doi: 10.1007/s10549-024-07339.
PubMed Abstract available

NEVEN P, Han S, Borremans K, Van Houdt M, et al
Re: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB).
Breast Cancer Res Treat. 2024 Jun 16. doi: 10.1007/s10549-024-07399.
PubMed

HUANG X, Chen C, Lin Y, Wang C, et al
Pedigree analysis exploring the inconsistency between diverse phenotypes and testing criteria for germline TP53 mutations in Chinese women with breast cancer.
Breast Cancer Res Treat. 2024 Jun 15. doi: 10.1007/s10549-024-07341.
PubMed Abstract available

MOKHTARPOUR K, Razi S, Rezaei N
Ferroptosis as a promising targeted therapy for triple negative breast cancer.
Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07387.
PubMed Abstract available

JACKISCH C, Anastasiadou L, Aulmann S, Argyriadis A, et al
The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score(R) assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer.
Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07390.
PubMed Abstract available

RAN X, Hu A, Kuang Y, Wang C, et al
UM171 suppresses breast cancer progression by inducing KLF2.
Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07372.
PubMed Abstract available

BIDISHA B, Sowmya M, Shalini S, Mythri C, et al
Tamoxifen modulates nutrition deprivation-induced ER stress through AMPK-mediated ER-phagy in breast cancer cells.
Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07398.
PubMed Abstract available

BHAVE MA, Quintanilha JCF, Tukachinsky H, Li G, et al
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07376.
PubMed Abstract available

ALABEDI HH, Ahmed IK, Jamil ASM
Incidence of local breast cancer recurrence with delayed radiation therapy.
Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07385.
PubMed Abstract available

GONCALVES E, Fontes F, Rodrigues JR, Calisto R, et al
The contribution of second primary cancers to the mortality of patients with a first primary breast cancer.
Breast Cancer Res Treat. 2024 Jun 13. doi: 10.1007/s10549-024-07361.
PubMed Abstract available

VAN OLMEN JP, Schrijver AM, Stokkel MPM, Loo CE, et al
Clinical implications of non-breast cancer related findings on FDG-PET/CT scan prior to neoadjuvant chemotherapy in patients with breast cancer.
Breast Cancer Res Treat. 2024 Jun 12. doi: 10.1007/s10549-024-07331.
PubMed Abstract available

ZHANG BX, Brantley KD, Rosenberg SM, Kirkner GJ, et al
Second primary non-breast cancers in young breast cancer survivors.
Breast Cancer Res Treat. 2024 Jun 10. doi: 10.1007/s10549-024-07400.
PubMed Abstract available

LI Y, Long W, Zhou H, Tan T, et al
Revolutionizing breast cancer Ki-67 diagnosis: ultrasound radiomics and fully connected neural networks (FCNN) combination method.
Breast Cancer Res Treat. 2024 Jun 9. doi: 10.1007/s10549-024-07375.
PubMed Abstract available

HOWARD EC, Murray Horwitz ME, Gunn CM, Bak S, et al
Burden and trajectory of social needs after breast cancer diagnosis at a safety-net hospital.
Breast Cancer Res Treat. 2024 Jun 8. doi: 10.1007/s10549-024-07389.
PubMed Abstract available

YIN C, Li H, Zhang B, Liu Y, et al
Expression of Concern to: RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial-mesenchymal transition.
Breast Cancer Res Treat. 2024 Jun 6. doi: 10.1007/s10549-024-07392.
PubMed

FRANCOIS C, Mailliez A, Chretien S, Leguillette C, et al
Therapeutic impact of (18)F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer.
Breast Cancer Res Treat. 2024 Jun 5. doi: 10.1007/s10549-024-07386.
PubMed Abstract available

SCOTT OW, TinTin S, Cavadino A, Elwood JM, et al
Beta-blocker use and breast cancer outcomes: a meta-analysis.
Breast Cancer Res Treat. 2024 Jun 5. doi: 10.1007/s10549-024-07263.
PubMed Abstract available

SHI W, Xu C, Lei P, Sun X, et al
A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets for breast cancer.
Breast Cancer Res Treat. 2024 Jun 4. doi: 10.1007/s10549-024-07373.
PubMed Abstract available

BOYLE L, Lawrenson R, Nosa V, Campbell I, et al
Ethnic inequities in use of breast conserving surgery and radiation therapy in Aotearoa/New Zealand: which factors contribute?
Breast Cancer Res Treat. 2024;205:641-653.
PubMed Abstract available

PERERA D, Pirikahu S, Walter J, Cadby G, et al
The distribution of breast density in women aged 18 years and older.
Breast Cancer Res Treat. 2024;205:521-531.
PubMed Abstract available

LEO CSY, Cheng LJ, Lam XR, He H, et al
Global prevalence and factors associated with preoperative depression in women undergoing breast surgery: a meta-analysis and meta-regression.
Breast Cancer Res Treat. 2024;205:425-438.
PubMed Abstract available

FRANKLIN J, Hayes J, Knippa E, Dogan B, et al
False negative breast cancers on imaging and associated risk factors: a single institution six-year analysis.
Breast Cancer Res Treat. 2024;205:507-520.
PubMed Abstract available

GINZAC A, Molnar I, Durando X, Motte Rouge T, et al
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Breast Cancer Res Treat. 2024;205:267-279.
PubMed Abstract available

SHIBAHARA Y, Delabie JMA, Kulkarni S, Grant A, et al
Primary MALT lymphoma of the breast: pathological and radiological characteristics.
Breast Cancer Res Treat. 2024;205:387-394.
PubMed Abstract available

MOKBEL K, Alamoodi M
Reassessing treatment strategies for DCIS: analysis of survival and recurrence patterns.
Breast Cancer Res Treat. 2024;205:423-424.
PubMed

WIMMER K, Hlauschek D, Balic M, Pfeiler G, et al
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
Breast Cancer Res Treat. 2024;205:227-239.
PubMed Abstract available

ELSON NC, Wernke K, Yoder LM, Fellner AN, et al
Universal genetic counseling in breast cancer patients significantly improves overall testing rates and improves completion rates in subpopulations.
Breast Cancer Res Treat. 2024 Jun 1. doi: 10.1007/s10549-024-07329.
PubMed Abstract available

May 2024

ATRE SY, Soulos PR, Kuderer NM, Gross CP, et al
Characterization of time toxicity in older patients with metastatic breast cancer.
Breast Cancer Res Treat. 2024 May 31. doi: 10.1007/s10549-024-07379.
PubMed Abstract available

VAN DER MERWE NC, Buccimazza I, Rossouw B, Araujo M, et al
Clinical relevance of double heterozygosity revealed by next-generation sequencing of homologous recombination repair pathway genes in South African breast cancer patients.
Breast Cancer Res Treat. 2024 May 30. doi: 10.1007/s10549-024-07362.
PubMed Abstract available

LUBARSKY M, Hernandez AE, Collie BL, Westrick AC, et al
Does structural racism impact receipt of NCCN guideline-concordant breast cancer treatment?
Breast Cancer Res Treat. 2024 May 29. doi: 10.1007/s10549-024-07245.
PubMed Abstract available

REWCASTLE E, Skaland I, Gudlaugsson E, Fykse SK, et al
The Ki67 dilemma: investigating prognostic cut-offs and reproducibility for automated Ki67 scoring in breast cancer.
Breast Cancer Res Treat. 2024 May 26. doi: 10.1007/s10549-024-07352.
PubMed Abstract available

ISOGAI A, Nozawa K, Nakakami A, Komaki R, et al
Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study.
Breast Cancer Res Treat. 2024 May 26. doi: 10.1007/s10549-024-07367.
PubMed Abstract available

MENES TS, Zippel D, Sklair-Levy M, Friedman E, et al
Clinical breast exam contribution to breast cancer diagnosis in BRCA mutation carriers vs. average to intermediate risk women.
Breast Cancer Res Treat. 2024 May 26. doi: 10.1007/s10549-024-07345.
PubMed Abstract available

SCHWIEGER L, Postlewait LM, Liu Y, Jou S, et al
Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival.
Breast Cancer Res Treat. 2024 May 23. doi: 10.1007/s10549-024-07368.
PubMed Abstract available

ZHUO X, Deng H, Qiu M, Qiu X, et al
Pathomic model based on histopathological features and machine learning to predict IDO1 status and its association with breast cancer prognosis.
Breast Cancer Res Treat. 2024 May 23. doi: 10.1007/s10549-024-07350.
PubMed Abstract available

PEARSON A, Chen J, Dhillon HM, Kiely BE, et al
Measuring serum oestrogen levels in breast cancer survivors using vaginal oestrogens: a systematic review.
Breast Cancer Res Treat. 2024 May 23. doi: 10.1007/s10549-024-07364.
PubMed Abstract available

WHITE O, Dent S, Westbrook K, Lee HJ, et al
Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer.
Breast Cancer Res Treat. 2024 May 21. doi: 10.1007/s10549-024-07354.
PubMed Abstract available

ZHANG Y, Wang H, Zhao H, He X, et al
Prognostic significance and value of further classification of lymphovascular invasion in invasive breast cancer: a retrospective observational study.
Breast Cancer Res Treat. 2024 May 21. doi: 10.1007/s10549-024-07318.
PubMed Abstract available

BARKUR S, Boitor RA, Mihai R, Gopal NSR, et al
Intraoperative spectroscopic evaluation of sentinel lymph nodes in breast cancer surgery.
Breast Cancer Res Treat. 2024 May 20. doi: 10.1007/s10549-024-07349.
PubMed Abstract available

GUPTA A, Roy AM, Gupta K, Attwood K, et al
Impact of environmental temperature on the survival outcomes of breast cancer: A SEER-based study.
Breast Cancer Res Treat. 2024 May 20. doi: 10.1007/s10549-024-07369.
PubMed Abstract available

TAKANO T, Masuda N, Ito M, Inoue K, et al
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
Breast Cancer Res Treat. 2024 May 20. doi: 10.1007/s10549-024-07333.
PubMed Abstract available

COLE KM, McGee S, Clemons M, Liu M, et al
Development and application of a weighted change score to evaluate interventions for vasomotor symptoms in patients with breast cancer using regression trees: a cohort study.
Breast Cancer Res Treat. 2024 May 19. doi: 10.1007/s10549-024-07360.
PubMed Abstract available

STRELL C, Smith DR, Valachis A, Woldeyesus H, et al
Use of beta-blockers in patients with ductal carcinoma in situ and risk of invasive breast cancer recurrence: a Swedish retrospective cohort study.
Breast Cancer Res Treat. 2024 May 19. doi: 10.1007/s10549-024-07358.
PubMed Abstract available

BOLDRINI L, Dinapoli L, Boccia E, Caliandro M, et al
Coping with modesty during radiotherapy for breast cancer: a multicentric study.
Breast Cancer Res Treat. 2024 May 18. doi: 10.1007/s10549-024-07365.
PubMed Abstract available

HARVIE M, Livingstone K, McMulllan D, Pegington M, et al
BE-WEL trial (breast: evaluation of weight and exercise for lymphoedema) testing weight control and exercise programmes for women with breast cancer related lymphoedema: a feasibility trial.
Breast Cancer Res Treat. 2024 May 17. doi: 10.1007/s10549-024-07356.
PubMed Abstract available

WOO JW, Han EK, Suh KJ, Kim SH, et al
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer.
Breast Cancer Res Treat. 2024 May 16. doi: 10.1007/s10549-024-07359.
PubMed Abstract available

SHI X, Sheng Y, Fei H, Wei B, et al
Combined transcriptome and proteome analysis reveals MSN and ARFIP2 as biomarkers for trastuzumab resistance of breast cancer.
Breast Cancer Res Treat. 2024 May 15. doi: 10.1007/s10549-024-07355.
PubMed Abstract available

FREEMAN JQ, Sheade JB, Zhao F, Olopade OI, et al
Racial differences in familiarity, interest, and use of integrative medicine among patients with breast cancer.
Breast Cancer Res Treat. 2024 May 15. doi: 10.1007/s10549-024-07363.
PubMed Abstract available

GIRO C, Yamada AMTD, Cruz FJSM, do R Barros LA, et al
Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients: a pilot study.
Breast Cancer Res Treat. 2024 May 14. doi: 10.1007/s10549-024-07366.
PubMed Abstract available

CORIANO M, Tommasi C, Dinh ATL, Needham J, et al
The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study.
Breast Cancer Res Treat. 2024 May 14. doi: 10.1007/s10549-024-07336.
PubMed Abstract available

YAMADA M, Jinno H, Naruse S, Isono Y, et al
Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics.
Breast Cancer Res Treat. 2024 May 13. doi: 10.1007/s10549-024-07370.
PubMed Abstract available

ROSENBERG SM, Zeng C, An A, Ssebyala SN, et al
Characterizing "collateral damage" in men and women with metastatic breast cancer (mBC) from diverse racial and ethnic backgrounds in New York City.
Breast Cancer Res Treat. 2024 May 13. doi: 10.1007/s10549-024-07347.
PubMed Abstract available

WU Y, Tran T, Dwabe S, Sarkissyan M, et al
Retraction Note: A83-01 inhibits TGF-beta-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells.
Breast Cancer Res Treat. 2024 May 10. doi: 10.1007/s10549-024-07371.
PubMed

ZHANG S, Yang H, Xu Y, Wang S, et al
Do we need reshape rTNM staging system for ipsilateral breast tumor recurrence of breast cancer? A population-based, propensity score matched cohort study.
Breast Cancer Res Treat. 2024 May 10. doi: 10.1007/s10549-024-07340.
PubMed Abstract available

FAIRHURST K, McIntosh SA, Cutress RI, Potter S, et al
Current axillary management of patients with early breast cancer and low-volume nodal disease undergoing primary surgery: results of a United Kingdom national practice survey.
Breast Cancer Res Treat. 2024 May 10. doi: 10.1007/s10549-024-07328.
PubMed Abstract available

KLEIN E, Kiechle M, Josipovic A, Anders SI, et al
Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer.
Breast Cancer Res Treat. 2024 May 9. doi: 10.1007/s10549-024-07346.
PubMed Abstract available

LIN B, LeVee A, Cao L, Basho R, et al
Left ventricular global longitudinal strain is worse in BRCA mutation positive breast cancer patients prior to cancer treatment and premature menopause.
Breast Cancer Res Treat. 2024 May 8. doi: 10.1007/s10549-024-07344.
PubMed Abstract available

SAINT K, Nemirovsky D, Lessing A, Chen Y, et al
Impact of exercise on chemotherapy-induced peripheral neuropathy in survivors with post-treatment primary breast cancer.
Breast Cancer Res Treat. 2024 May 7. doi: 10.1007/s10549-024-07342.
PubMed Abstract available

CHEN Y, Zhang R, Yan Y, Li H, et al
Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study.
Breast Cancer Res Treat. 2024 May 6. doi: 10.1007/s10549-024-07323.
PubMed Abstract available

RICHMAN J, Schuster G, Buus R, Lopez-Knowles E, et al
Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients.
Breast Cancer Res Treat. 2024 May 6. doi: 10.1007/s10549-024-07311.
PubMed Abstract available

COOMBES RC, Angelou C, Al-Khalili Z, Hart W, et al
Correction: Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study.
Breast Cancer Res Treat. 2024 May 5. doi: 10.1007/s10549-024-07276.
PubMed

KIMURA T, Takami T, Piao Y, Ntalla I, et al
Treatment patterns and clinical outcomes in patients with metastatic triple-negative breast cancer: a large-scale data analysis using the Japanese claims database.
Breast Cancer Res Treat. 2024 May 5. doi: 10.1007/s10549-024-07273.
PubMed Abstract available

SATHE C, Accordino MK, DeStephano D, Shah M, et al
Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer.
Breast Cancer Res Treat. 2024 May 4. doi: 10.1007/s10549-024-07337.
PubMed Abstract available

CHIN K, Landen AH, Kovacs A, Warnberg F, et al
Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study.
Breast Cancer Res Treat. 2024 May 4. doi: 10.1007/s10549-024-07334.
PubMed Abstract available

SANCHEZ-BAYONA R, Lopez de Sa A, Jerez Gilarranz Y, Sanchez de Torre A, et al
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.
Breast Cancer Res Treat. 2024 May 4. doi: 10.1007/s10549-024-07324.
PubMed Abstract available

BRABENDER D, Ballard A, Kim S, Hovanessian-Larsen L, et al
Use of ultrasound and MRI to stage the axilla for breast cancer before and after neoadjuvant chemotherapy prior to targeted sentinel lymphadenectomy.
Breast Cancer Res Treat. 2024 May 3. doi: 10.1007/s10549-024-07332.
PubMed Abstract available

PITTELL H, Calip GS, Pierre A, Ryals CA, et al
Racialized economic segregation and inequities in treatment initiation and survival among patients with metastatic breast cancer.
Breast Cancer Res Treat. 2024 May 3. doi: 10.1007/s10549-024-07319.
PubMed Abstract available

NASIF D, Laurito S, Real S, Branham MT, et al
Exploring the epigenetic profile of ID4 in breast cancer: bioinformatic insights into methylation patterns and chromatin accessibility dynamics.
Breast Cancer Res Treat. 2024 May 3. doi: 10.1007/s10549-024-07343.
PubMed Abstract available

TENG YT, Wang YA, Dong YH, Liu JJ, et al
Correction: Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics.
Breast Cancer Res Treat. 2024 May 2. doi: 10.1007/s10549-024-07335.
PubMed

BISSELL MB, Keshavarsi S, Fleming R, Au F, et al
MRI-visualized T2 hyperintense breast lesions: identifying clinical and imaging factors linked to malignant biopsy outcomes.
Breast Cancer Res Treat. 2024;205:159-168.
PubMed Abstract available

WUYTS K, Durston V, Morstyn L, Mills S, et al
Information needs in breast reconstruction after mastectomy: a qualitative analysis of free-text responses from 2077 women.
Breast Cancer Res Treat. 2024;205:147-157.
PubMed Abstract available

JORGENSEN SF, Sagstad S, Louro J, Roman M, et al
Comparisons of assessment pathways after abnormal mammography screening in Denmark, Norway, and Spain.
Breast Cancer Res Treat. 2024;205:135-145.
PubMed Abstract available

LUSTBERG M, Fan-Havard P, Wong FL, Hill K, et al
Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial.
Breast Cancer Res Treat. 2024;205:61-73.
PubMed Abstract available

April 2024

PIZZAMIGLIO S, Ciniselli CM, de Azambuja E, Agbor-Tarh D, et al
Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO.
Breast Cancer Res Treat. 2024 Apr 30. doi: 10.1007/s10549-024-07299.
PubMed Abstract available

MORAD A, Johnson K, Bate S, Birkby I, et al
Ten-year trend analysis of breast cancer, oncoplastic, and reconstructive breast surgery in a single institution (2010-2019), what has not changed?
Breast Cancer Res Treat. 2024 Apr 30. doi: 10.1007/s10549-024-07294.
PubMed Abstract available

SCHAFFAR R, Benhamou S, Chappuis PO, Rapiti E, et al
Risk of first recurrence after treatment in a population-based cohort of young women with breast cancer.
Breast Cancer Res Treat. 2024 Apr 30. doi: 10.1007/s10549-024-07338.
PubMed Abstract available

HIJAZI A, Mohanna M, Sabbagh S, Herran M, et al
Clinico-pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis.
Breast Cancer Res Treat. 2024 Apr 29. doi: 10.1007/s10549-024-07321.
PubMed Abstract available

ROBERTS A, Hallet J, Nguyen L, Coburn N, et al
Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care.
Breast Cancer Res Treat. 2024 Apr 27. doi: 10.1007/s10549-024-07282.
PubMed Abstract available

YADAV SK, Bharath S, Sharma D, Srivastava A, et al
A systematic review and meta-analysis of diagnostic performance of fluorescein-guided sentinel lymph node biopsy in early breast cancer.
Breast Cancer Res Treat. 2024 Apr 26. doi: 10.1007/s10549-024-07310.
PubMed Abstract available

BRADBURY M, Savard MF, Stober C, Clemons L, et al
Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey.
Breast Cancer Res Treat. 2024 Apr 25. doi: 10.1007/s10549-024-07302.
PubMed Abstract available

LEE SY, Yoo TK, Kim J, Chung IY, et al
Characteristics and risk factors of axillary lymph node metastasis of microinvasive breast cancer.
Breast Cancer Res Treat. 2024 Apr 25. doi: 10.1007/s10549-024-07305.
PubMed Abstract available

SHI Y, Lu H, Zhang Y
Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer.
Breast Cancer Res Treat. 2024 Apr 24. doi: 10.1007/s10549-024-07317.
PubMed Abstract available

CHLEBOWSKI RT, Aragaki AK, Pan K, Mortimer JE, et al
Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis.
Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07307.
PubMed Abstract available

BERTELSEN BE, Almas B, Fjermeros K, Viste K, et al
Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane.
Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07313.
PubMed Abstract available

LEONARD S, Jones AN, Newman L, Chavez-MacGregor M, et al
Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial.
Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07308.
PubMed Abstract available

DA SILVA JL, de Albuquerque LZ, Rodrigues MES, Thuler LCS, et al
Ethnic disparities in breast cancer patterns in Brazil: examining findings from population-based registries.
Breast Cancer Res Treat. 2024 Apr 21. doi: 10.1007/s10549-024-07314.
PubMed Abstract available

HSU R, Al-Zubeidy B, Flores D, Nazarian A, et al
Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast to liver metastases in breast cancer.
Breast Cancer Res Treat. 2024 Apr 20. doi: 10.1007/s10549-024-07295.
PubMed Abstract available

FERNANDEZ-GONZALEZ S, Falo C, Pla MJ, Campos M, et al
Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival-a propensity score cohort study.
Breast Cancer Res Treat. 2024 Apr 18. doi: 10.1007/s10549-024-07274.
PubMed Abstract available

BALTUSSEN JC, Mooijaart SP, Vulink AJE, Houtsma D, et al
Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer.
Breast Cancer Res Treat. 2024 Apr 16. doi: 10.1007/s10549-024-07312.
PubMed Abstract available

TAN CF, Wang J, Zhong XR, Dai ZL, et al
Is postmastectomy radiotherapy necessary for breast cancer patients with clinically node-positive downstaging to ypN0 after neoadjuvant chemotherapy?
Breast Cancer Res Treat. 2024 Apr 15. doi: 10.1007/s10549-024-07249.
PubMed Abstract available

BRANDAO M, Martins-Branco D, De Angelis C, Vuylsteke P, et al
Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07275.
PubMed

FORTNER RT, Brantley KD, Tworoger SS, Tamimi RM, et al
Recreational physical activity and breast cancer risk by menopausal status and tumor hormone receptor status: results from the Nurses' Health Studies.
Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-023-07238.
PubMed Abstract available

WANG Y, Sun W, Karlsson E, Kang Lovgren S, et al
Clinical evaluation of deep learning-based risk profiling in breast cancer histopathology and comparison to an established multigene assay.
Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07303.
PubMed Abstract available

RUKHSANA, Supty AT, Hussain M, Lee Y, et al
STK3 higher expression association with clinical characteristics in intrinsic subtypes of breast cancer invasive ductal carcinoma patients.
Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07248.
PubMed Abstract available

SULLIVAN M, Lei X, Giordano SH, Chavez-MacGregor M, et al
Breast cancer (BC) and severe COVID-19 (C-19) outcomes: a matched analysis.
Breast Cancer Res Treat. 2024 Apr 6. doi: 10.1007/s10549-024-07301.
PubMed Abstract available

ALLSOPP RC, Guo Q, Page K, Bhagani S, et al
Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study.
Breast Cancer Res Treat. 2024 Apr 6. doi: 10.1007/s10549-024-07316.
PubMed Abstract available

ALHUDIRI I, Nolan C, Ellis I, Elzagheid A, et al
Expression of Cathepsin D in early-stage breast cancer and its prognostic and predictive value.
Breast Cancer Res Treat. 2024 Apr 5. doi: 10.1007/s10549-024-07293.
PubMed Abstract available

YERUSHALMI R, Pomerantz A, Lewin R, Paluch-Shimon S, et al
BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.
Breast Cancer Res Treat. 2024 Apr 3. doi: 10.1007/s10549-024-07271.
PubMed Abstract available

KONTOS M, Kanavidis P, Kuhn T, Masannat Y, et al
Targeted axillary dissection: worldwide variations in clinical practice.
Breast Cancer Res Treat. 2024;204:389-396.
PubMed Abstract available

AI D, Turashvili G, Gjeorgjievski SG, Wang Q, et al
Subspecialized breast pathologists have suboptimal interobserver agreement in Ki-67 evaluation using 20% as the cutoff.
Breast Cancer Res Treat. 2024;204:415-422.
PubMed Abstract available

COBLEIGH MA, Layng KV, Mauer E, Mahon B, et al
Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers.
Breast Cancer Res Treat. 2024;204:407-414.
PubMed Abstract available

BAHL M, Deng B
Impact of pre-operative MRI on surgical management of screening digital breast tomosynthesis-detected invasive lobular carcinoma.
Breast Cancer Res Treat. 2024;204:397-405.
PubMed Abstract available

WALSH EA, Post K, Massad K, Horick N, et al
Identification of patient subgroups who benefit from a behavioral intervention to improve adjuvant endocrine therapy adherence: a randomized-controlled trial.
Breast Cancer Res Treat. 2024;204:547-559.
PubMed Abstract available

FLETCHER KA, Alkurashi MH, Lindsay AJ
Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies.
Breast Cancer Res Treat. 2024;204:631-642.
PubMed Abstract available

WANG H, Yee D, Potter D, Jewett P, et al
Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial.
Breast Cancer Res Treat. 2024;204:589-597.
PubMed Abstract available

VAN HEMERT A, van Loevezijn AA, Bosman A, Vlahu CA, et al
Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome.
Breast Cancer Res Treat. 2024;204:497-507.
PubMed Abstract available

HARDY-ABELOOS C, Xiao J, Oh C, Barbee D, et al
Effectiveness and toxicity of five-fraction prone accelerated partial breast irradiation.
Breast Cancer Res Treat. 2024;204:485-495.
PubMed Abstract available

BLOMQVIST C, Vehmanen L, Kellokumpu-Lehtinen PL, Huovinen R, et al
Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study.
Breast Cancer Res Treat. 2024 Apr 1. doi: 10.1007/s10549-024-07252.
PubMed Abstract available

MARTINEZ-JANEZ N, Ezquerra MB, Manso Sanchez LM, Carrasco FH, et al
First-line therapy with palbociclib in patients with advanced HR(+)/HER2(-) breast cancer: The real-life study PALBOSPAIN.
Breast Cancer Res Treat. 2024 Apr 1. doi: 10.1007/s10549-024-07287.
PubMed Abstract available

March 2024

CAMPBELL EK, Campbell TM, Culakova E, Blanchard L, et al
A whole food, plant-based randomized controlled trial in metastatic breast cancer: feasibility, nutrient, and patient-reported outcomes.
Breast Cancer Res Treat. 2024 Mar 30. doi: 10.1007/s10549-024-07284.
PubMed Abstract available

BURO AW, Nguyen T, Abaskaron M, Haver MK, et al
Lifestyle interventions with dietary strategies after breast cancer diagnosis: a systematic review.
Breast Cancer Res Treat. 2024 Mar 29. doi: 10.1007/s10549-024-07278.
PubMed Abstract available

GULIYEV M, Sen GA, Gulturk I, Majidova N, et al
The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study.
Breast Cancer Res Treat. 2024 Mar 25. doi: 10.1007/s10549-024-07291.
PubMed Abstract available

JUNG JJ, Cheun JH, Kim HK, Lee HB, et al
Comparison of long-term oncologic outcomes of central lumpectomy and conventional breast-conserving surgery for invasive breast cancer: propensity score matching analysis.
Breast Cancer Res Treat. 2024 Mar 25. doi: 10.1007/s10549-024-07297.
PubMed Abstract available

TENG YT, Wang YA, Dong YH, Liu JJ, et al
Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics.
Breast Cancer Res Treat. 2024 Mar 25. doi: 10.1007/s10549-024-07280.
PubMed Abstract available

KAPLAN HG, Dowdell AK, Berry AB, Shimol RB, et al
Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer.
Breast Cancer Res Treat. 2024 Mar 24. doi: 10.1007/s10549-024-07270.
PubMed Abstract available

GODINEZ PAREDES JM, Rodriguez I, Ren M, Orozco A, et al
Germline pathogenic variants associated with triple-negative breast cancer in US Hispanic and Guatemalan women using hospital and community-based recruitment strategies.
Breast Cancer Res Treat. 2024 Mar 23. doi: 10.1007/s10549-024-07300.
PubMed Abstract available

DOUBBLESTEIN D, Koehler L, Anderson E, Scheiman N, et al
Development of a core set of outcome measures to be applied toward breast cancer-related lymphedema core outcome domains.
Breast Cancer Res Treat. 2024 Mar 22. doi: 10.1007/s10549-024-07298.
PubMed Abstract available

COLLIN LJ, Jones J, Nash R, Switchenko JM, et al
Racial disparities in initiation of chemotherapy among breast cancer patients with discretionary treatment indication in the state of Georgia.
Breast Cancer Res Treat. 2024 Mar 22. doi: 10.1007/s10549-024-07279.
PubMed Abstract available

NASIRI N, Hu M, Hajizadeh M
Trends in socioeconomic inequalities in breast cancer mortality in Canada: 1992-2019.
Breast Cancer Res Treat. 2024 Mar 19. doi: 10.1007/s10549-024-07277.
PubMed Abstract available

AUGUSTINSSON A, Loman N, Ehrencrona H
Retrospective genetic testing (Traceback) in women with early-onset breast cancer after revised national guidelines: a clinical implementation study.
Breast Cancer Res Treat. 2024 Mar 16. doi: 10.1007/s10549-024-07288.
PubMed Abstract available

WU Q, Hatse S, Kenis C, Fernandez-Garcia J, et al
Aging-accumulated methylmalonic acid serum levels at breast cancer diagnosis are not associated with distant metastases.
Breast Cancer Res Treat. 2024 Mar 13. doi: 10.1007/s10549-024-07260.
PubMed Abstract available

CHUNG HL, Middleton LP, Sun J, Whitman GJ, et al
Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants.
Breast Cancer Res Treat. 2024 Mar 12. doi: 10.1007/s10549-024-07261.
PubMed Abstract available

FARLAND LV, Lind KE, Thomson CA, Saquib N, et al
Infertility and risk of postmenopausal breast cancer in the women's health initiative.
Breast Cancer Res Treat. 2024 Mar 9. doi: 10.1007/s10549-024-07257.
PubMed Abstract available

GION M, Garcia-Mosquera JJ, Perez-Garcia JM, Peg V, et al
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
Breast Cancer Res Treat. 2024 Mar 8. doi: 10.1007/s10549-024-07292.
PubMed Abstract available

AVILA J, Leone J, Vallejo CT, Lin NU, et al
Survival analysis of patients with brain metastases at initial breast cancer diagnosis over the last decade.
Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07290.
PubMed Abstract available

GARCIA-TORRALBA E, Perez Ramos M, Ivars Rubio A, Navarro Manzano E, et al
Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypes.
Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07286.
PubMed Abstract available

BAYRAKCEKEN E, Yarali S, Alkan O
Identify risk factors affecting participation of Turkish women in mammography screening for breast cancer prevention.
Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07296.
PubMed Abstract available

FINSTERBUSCH K, van Diest PJ, Focke CM
Intertumoral heterogeneity of bifocal breast cancer: a morphological and molecular study.
Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07281.
PubMed Abstract available

CAMPBELL TM, Campbell EK, Culakova E, Blanchard LM, et al
A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes.
Breast Cancer Res Treat. 2024 Mar 6. doi: 10.1007/s10549-024-07266.
PubMed Abstract available

SUN H, Kang EY, Chen H, Sweeney KJ, et al
Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis.
Breast Cancer Res Treat. 2024 Mar 5. doi: 10.1007/s10549-024-07256.
PubMed Abstract available

PLICHTA JK, Thomas SM, Wang X, McDuff SGR, et al
Survival among patients with untreated metastatic breast cancer: "What if I do nothing?".
Breast Cancer Res Treat. 2024 Mar 5. doi: 10.1007/s10549-024-07265.
PubMed Abstract available

KULOTHUNGAN V, Ramamoorthy T, Sathishkumar K, Mohan R, et al
Burden of female breast cancer in India: estimates of YLDs, YLLs, and DALYs at national and subnational levels based on the national cancer registry programme.
Breast Cancer Res Treat. 2024 Mar 4. doi: 10.1007/s10549-024-07264.
PubMed Abstract available

WU Y, Li Z, Lee AV, Oesterreich S, et al
Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration.
Breast Cancer Res Treat. 2024 Mar 1. doi: 10.1007/s10549-024-07255.
PubMed Abstract available

February 2024

DOUBBLESTEIN D, Koehler L, Anderson E, Scheiman N, et al
Development of a core outcome set for breast cancer-related lymphedema: a Delphi study.
Breast Cancer Res Treat. 2024 Feb 29. doi: 10.1007/s10549-024-07262.
PubMed Abstract available

HOSSEINI Y, Hadi Sichani P, Moslemi E, Nouri M, et al
Pro-vegetarian dietary pattern and risk of breast cancer: a case-control study.
Breast Cancer Res Treat. 2024 Feb 28. doi: 10.1007/s10549-024-07243.
PubMed Abstract available

VOETS MM, Hassink NS, Veltman J, Slump CH, et al
Opportunities for personalised follow-up in breast cancer: the gap between daily practice and recurrence risk.
Breast Cancer Res Treat. 2024 Feb 26. doi: 10.1007/s10549-024-07246.
PubMed Abstract available

December 2023

PACE LE, Fata AM, Cubaka VK, Nsemgiyumva T, et al
Patients' experiences undergoing breast evaluation in Rwanda's Women's Cancer Early Detection Program.
Breast Cancer Res Treat. 2023;202:541-550.
PubMed Abstract available

TURASHVILI G, Gjeorgjievski SG, Wang Q, Ewaz A, et al
Intraoperative assessment of axillary sentinel lymph nodes by telepathology.
Breast Cancer Res Treat. 2023;202:423-434.
PubMed Abstract available

PESAPANE F, Nicosia L, Tantrige P, Schiaffino S, et al
Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study.
Breast Cancer Res Treat. 2023;202:451-459.
PubMed Abstract available

BUN A, Nagahashi M, Kuroiwa M, Komatsu M, et al
Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin.
Breast Cancer Res Treat. 2023;202:575-583.
PubMed Abstract available

SHARMA R
Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990-2019: an examination using estimates from the global burden of disease 2019 study.
Breast Cancer Res Treat. 2023;202:529-540.
PubMed Abstract available

COSTEIRA B, da Silva FB, Fonseca F, Oom R, et al
Long-term locoregional recurrence in patients treated for breast cancer.
Breast Cancer Res Treat. 2023;202:551-561.
PubMed Abstract available

ZHANG X, Huang L, Sun J, Liu J, et al
Monopolar spindle 1 contributes to tamoxifen resistance in breast cancer through phosphorylation of estrogen receptor alpha.
Breast Cancer Res Treat. 2023;202:595-606.
PubMed Abstract available

SASADA S, Kondo N, Hashimoto H, Takahashi Y, et al
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer.
Breast Cancer Res Treat. 2023;202:473-483.
PubMed Abstract available

HARTMANN S, Banys-Paluchowski M, Stickeler E, de Boniface J, et al
Applicability of magnetic seeds for target lymph node biopsy after neoadjuvant chemotherapy in initially node-positive breast cancer patients: data from the AXSANA study.
Breast Cancer Res Treat. 2023;202:497-504.
PubMed Abstract available

TAKADA M, Imoto S, Ishida T, Ito Y, et al
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.
Breast Cancer Res Treat. 2023;202:485-496.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum